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Abstract 
Positron emission tomography (PET) is a non-invasive imaging technique that is 
emerging as a useful tool in the field of cancer medicine particularly in drug 
development. The purpose of this thesis has been to perform clinical studies using 
two different radiotracers, 5-[^V]fIuorouracil (5-['^F]FU) and 2-[''C]thymidine, 
to assess pharmacokinetic and pharmacodynamic parameters respectively, which 
were derived from PET imaging and to establish the contribution that PET can 
add to drug development, in vivo, in man. 
Aims: 1) Quantify the pharmacodynamic effects of cytotoxic agents in tumour 
and normal tissue using 2-["C]thymidine 2) Measure changes in tumour and 
normal tissue pharmacokinetics of 5-Fluorouracil in response to the modulating 
agents carbogen and nicotinamide or interferon 3) Assessment of blood flow 
change in tumour and normal tissue to carbogen and nicotinamide or interferon 4) 
Interpretation of PET data using novel analysis methods with modified Patlak and 
spectral analysis 
Methods: In the 5-['^]FU study, patients with metastatic gastrointestinal cancer 
underwent PET scanning at the start of 2 separate chemotherapy cycles. The 2"'' 
scan was performed after the administration of carbogen and nicotinamide or 
interferon. In the 2-["C]thymidine study patients receiving chemotherapy were 
scanned before commencing chemotherapy, and 1 week after the 3''' cycle of 
chemotherapy. Patients also had conventional imaging before the start of and after 
3 cycles of treatment. 
Findings: After carbogen and nicotinamide administration, 5-['^]FU uptake was 
increased in tumour, but not in normal tissue. Regional perfusion was elevated in 
tumours but decreased in kidneys after carbogen and nicotinamide. After 
interferon administration, there was an increase in 5-['^]FU retention in tumours, 
but no increase in uptake. Regional perfusion in tumour and normal tissue was 
unaltered by interferon. Retention of 2-["C]thymidine decreased in tumour in 
keeping with the results of conventional radiology, suggesting a pathological 
response, assessed in vivo, to chemotherapy. 
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Chapter 1 Introduction 
The widespread nature of cancer represents a major worldwide issue responsible 
for a third of all deaths in the developed world with an increasing number in the 
developing world, despite a massive investment of time and money by 
governments, charities, scientists, healthcare professionals and drug industries. 
Recent advances in molecular science have led to an increase in the understanding 
and elucidation of tumour biology, particularly with regard to the molecular basis 
of cell cycle control and proliferation, with cancer now viewed as a series of 
biological processes rather than a single disease entity. New insights into the 
genetic and molecular basis of cancer development have resulted in a fundamental 
re-ordering of drug development and therapeutic approaches from empirical drug 
observations, towards rational drug discovery based on molecular sites of action. 
Treatment strategies have therefore altered to assimilate the evolving 
identification of abnormal pathways in cancer biology. This has required a 
paradigm shift in the demands on imaging, moving from solely providing rigid 
structural and anatomical details, to providing in vivo methods to detect and 
characterise cellular and biochemical changes in the cancer cell itself 
Just as molecular science has advanced, simultaneous progress has been made in 
nuclear imaging technology, particularly in positron emission tomography and 
magnetic resonance imaging and spectroscopy. This has been based upon 
improved electronics, greater computing powers, better sensitivity resolution and 
new tracers for key molecules that facilitate cancer growth and development. 
These imaging technologies now allow real-time, non-invasive assessment of 
physiological, biochemical, biological, pathological and pharmacological 
processes in vivo, in man, which was not previously available. 
1.1 Positron Emission Tomography 
Positron emission tomography (PET) is a quantitative and dynamic imaging 
technique with high spatial (clinical scanners of 4-7mm; animal scanners of 1 mm) 
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and temporal (5-10 s) resolution. PET has unrivalled sensitivity and is able to 
provide information down the sub-picomolar level and it is therefore possible to 
measure the distribution of tracer amounts of a radiolabeled compound in a 
subject, without perturbing the biological or physiological process under 
examination. Furthermore, there are many naturally occurring positron emitting 
isotopes for elements which are found in a large number of compounds, so there 
are an infinite number of radiolabelled tracers that are potentially available 
providing radiochemical synthesis and the other pre-requisites for a clinical PET 
radiotracer are achievable. Developments in instrumentation, analysis and 
methodology have enabled PET to be used increasingly for quantitative 
measurements. 
PET encompasses complex technology and requires an expert multi-disciplinary 
approach involving experts from the fields of chemistry, pharmacology, physics, 
computer science, radiology, oncology and molecular biology to operate 
successfully. However, for the reasons described above, PET provides an ideal 
imaging technique in oncology. 
A major area that can benefit from PET imaging is that of drug development. At 
the present time this is an extremely slow process taking many years to progress 
from drug conception to clinical trials and costing several millions of pounds. In 
addition, of the thousands of promising new drugs discovered, only a few 
eventually enter routine clinical practice. PET can facilitate drug development by 
identification of relevant avenues for targeted drug treatment in conjunction with 
molecular and genetic findings. PET can also aid the elucidation of the 
pharmacokinetic profile of a novel or modulated therapy using not only plasma 
samples, but by direct tissue analysis and with PET animal studies to facilitate this 
process. Finally, the pharmacodynamic endpoint to assess drug effect can 
potentially be measured in tumour and also normal tissue and at an earlier time 
point than with conventional practices. 
Apart from FDG-PET, the use of other radiotracers in PET has predominantly 
been as research tools. The purpose of this thesis has been to perform clinical 
studies using two different radiotracers, 5-['^F]fluorouracil and 2-["C]thymidine, 
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to assess PET derived pharmacokinetic and pharmacodynamic parameters 
respectively, and to establish the contribution that PET can add to drug 
development. 
1.2 Outline of Thesis 
In this thesis, the pharmacokinetics of the commonly used anti-metabolite drug, 5-
Fluororacil, will be studied alone and in combination with biomodulating agents. 
The pharmacodynamic endpoint of anti-cancer drugs will be examined using 2-
['^CJthymidine, in tumour and normal tissue. 
The thesis begins with a chapter (Chapter 2) outlining PET and looks in detail at 
image acquisition and processing and the methods of semi-quantitative and 
quantitative analysis of data. The next chapter (Chapter 3) reviews the potential 
role of PET in molecular imaging in oncology with particular emphasis on the use 
of newer, investigational, radiotracers in preliminary studies in man and animals. 
Subsequent chapters (Chapters 4, 5 and 8) provide information on the 
methodology of the studies undertaken in this thesis and on the current methods 
and limitations of pharmacokinetic and pharmacodynamic assessment in man, 
with the potential of radiolabelled 5-FU (5-['^F]FU) and radiolabelled thymidine 
(2-["C]thymidine) explored in each field respectively. 
In Chapters 6 and 7 the effect of modulation of 5-['^F]FU with carbogen and 
nicotinamide, and interferon, will be reported respectively, and in Chapter 8 the 
use of 2-['^C]thymidine in PET scanning to measure disease response to 
chemotherapy in comparison to conventional imaging will be assessed. 
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Chapter 2 Principles of PET Scanning and Data Modelling 
2.1 Introduction 
PET scanning falls within a specialised category of nuclear imaging. Nuclear 
imaging methods are based on the external detection of nuclear radiation emitted 
from a radiolabelled compound introduced into the body either intravenously or 
via inhalation. The isotopes used to label these compounds are unstable and decay 
by emitting radiation to achieve a stable non-radioactive state. The radiolabelled 
compound is an analogue of a biochemical of interest that behaves identically in 
vivo to its counterpart without perturbing the pharmaceutical, biological or 
physiological properties of the system under observation, allowing imaging of the 
underlying process. It is the type of radiation emission that characterises PET 
imaging namely, positrons, and this is dependent on the configuration of the 
nucleus of the radiotracer used in PET scanning, which must disintegrate by the 
production of positrons. 
PET imaging is a complex, multidisciplinary technique. In this chapter the 
fundamental requirements of PET scanning, radiotracer production, image 
acquisition and processing will be discussed. The derivation of quantitative data to 
describe the fate of radiolabelled compounds in tissue is one of the most important 
aspects of PET and the models utilised in this process will be fully outlined as 
well. 
2.2 PET Image Acquisition 
2.2.1 Basic Physics 
P.Dirac, a theoretical physicist, first postulated the existence of positive electrons 
(positrons) on the basis of the equations of quantum mechanics and Einstein's 
theory of relativity (Dirac, 1930). CD Anderson, a couple of years later, proved 
their existence by observing experimentally that cosmic rays include particles 
with the mass of electrons but which move along a magnetic path indicating that 
they have a positive charge (Anderson, 1932). He called these particles positrons, 
or positive electrons. 
The PET scanner does not detect positrons directly, but uses the important feature 
of positron annihilation to determine their spatial location. Proton rich isotopes 
reduce the excessive positive charge of their nucleus by either electron capture, or 
positron emission. In positron emission, the extra proton (p) is converted to a 
neutron (n), with the release of a positron (p+) and neutrino (v), leaving a stable 
daughter nuclide that has the same atomic number as the parent (A) but with a 
reduction in proton number (Z) by one. 
The emitted positron has an initial kinetic energy characteristic of the 
radioisotope, with the remaining energy removed by the neutrino. The positron 
travels a few mms in tissue before losing its kinetic energy through collisions with 
neighbouring electrons in surrounding tissue (see Table 2.1). 
Table 2.1: Characteristics of Positron Emitters Used in this MD 
Positron 
Emitter 
Maximum 
positron energy 
(MeV) 
Half-life 
(min) 
Maximum range 
in soft tissue 
(mm) 
Mean range in 
soft tissue 
(mm) 
18p 0.63 109.8 2.6 0.6 
" C 0.96 2&3 4.2 1.2 
liQ 1.74 2.04 8.4 2.9 
When the positron loses all or most of its energy it combines with an electron to 
form a positronium. A positronium has a short half-life, resulting in the 
annihilation of the positron/electron pair, with all the mass being converted into 
electromagnetic radiation. In order to conserve energy and linear momentum, the 
electromagnetic radiation appears in the form of two photons of equal energy of 
511 keV (equal to the resting energy of the electron and positron) and which are 
always in opposite directions at 180° (see Figure 1). The emitted photons can be 
recorded by two opposing coincidence detectors, which transmit a signal if, within 
a narrow time frame of nanoseconds, both are stimulated simultaneously. Such 
detection of photons enables localisation of the source of radiation without the 
need for physical collimation, and is called 'electronic collimation'. Electronic 
collimation is more efficient than absorption collimation used for gamma ray 
photons in single photon emission computerised tomography (SPECT), another 
form of nuclear imaging, as the latter relies on exclusion, with many photons 
emitted by the patient absorbed and not contributing to the final image. Electronic 
collimation can utilize potentially all of the photons emitted by the radiotracer 
provided that the source of the photons is completely surrounded by detectors. 
This forms the basis of PET imaging and confers one advantage of it over other 
forms of nuclear imaging. Furthermore, the sensitivity of the coincidence counting 
system within the volume subtended by the two detectors varies only slightly, 
with a region between the two detectors where the sensitivity is almost uniform. 
In contrast, absorption collimators exhibit greatly varying sensitivity. 
II Q : Radiotracer 
with unstable nucleus 
(neutrino) 
3^ (positron) 
p (electrons) 
Y ray 
511 keV 
-• ^ ( 2 ) positronmm 
511 keV 
II B5: Radionuclide y 
with stable nucleus 
Figure 1: An example of radioactive decay using 
Carbon-11 
Carbon-11 (["CJehas an unstable nucleus with an excess of protons (green) of which there are 6 in 
total. The unstable nucleus decays naturally by emitting a positron (blue) and neutrino (v), which 
has negligible energy and mass, to leave the stable nucleus, boron ("B5). The asterix *, denotes the 
proton which has changed into a neutron. The positron travels a short distance in tissue before 
colliding with a surrounding electron (yellow) and forms a positronium. Almost instantaneously, 
the positronium disintegrates, forming two gamma rays (y) that are simultaneously emitted at 
approximately 180® to one another. 
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2.2.2. PET Scan Detectors 
The detection apparatus in a typical PET scanner consists of multiple rings of 
scintillation detector blocks that are composed of inorganic crystals such as 
bismuth germinate (Bi4Ge30i2 or BGO) which are arranged around the area to be 
imaged in the patient. Each block is divided into arrays of detector elements 
(usually 8 X 8 or 8 X 4) with detector elements having a specific size according to 
the PET scanner type. The detector blocks are in contact with a number of 
photomultiplier tubes (PMT), typically four per detector. Measurement of 
annihilation radiation is based on the fact that the photon to be detected transfers 
its energy by accelerating electrons within the BGO detector block. As BGO has a 
high density and atomic number, this ensures with a high probability that such an 
exchange of energy takes place. The photons thus absorbed by the BGO crystal 
converts the energy into flashes of light or scintillations, which, after 
amplification are then converted into a measurable electrical signal by the PM'f, 
and are then processed by the computer system. BGO generates approximately 2 
500 light photons per 511 keV, and has a short decay time of around 300 
nanoseconds so that high counting rates can be counted. The detector block is 
fabricated in such a way that the amount of light collected by each PMT varies 
uniquely depending on the crystal in which the scintillation occurred (Dahlbom el 
al, 1988). Identification of the detector element where the photon interacted is 
achieved by decoding integrals of the PMT outputs to yield the exact position of 
every scinfillation. The sum of the integrated PMT outputs is proportional to the 
energy deposited in the crystal. 
The signals from the individual detectors on opposite sides of a ring are fed into 
separate amplifier and energy discrimination circuits. If both these circuits 
produce a signal within a very short (around 10 nanoseconds) timing window (the 
coincidence timing window) a 'coincidence event" is recorded. As the annihilation 
photons are propagated in opposite directions, the origin of the annihilation event 
is assumed to have occurred along the line between detectors known as the line of 
response (LOR). The intersecting coincidence lines formed between the detectors 
facilitate electronic collimation by dual photon coincidence counting. 
During a PET scan several million coincidence events are recorded. Each detector 
is in a circular array and can form a fan of coincidences with any number of 
detectors. The location and direction of any given coincidence event is unique and 
all the coincidence lines form the data set for the final PET image. Acquired 
coincidences are stored as two-dimensional matrices, in which the horizontal 
direction describes the offset (p) from the centre of the field of view (FOV), and 
the vertical direction describes the projection angle. This two dimensional matrix 
is called a sinogram, and is a convenient way of storing the data prior to 
reconstruction (see Fig 2). 
Before reconstruction of the image can occur, corrections must be made for 
detector inefficiency of response and attenuation of the photons in the body. Not 
all coincidence events are true or valid such as random coincidences, and not all 
coincidences are detected due to scatter and must be taken into consideration. This 
is outlined in the next section. 
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Figure 2: Coincidence Event Detection and Sinogram Formation Coincidence Event 
Detection and Sinogram Formation. 
a) A detector can be in coincidence witii any number of opposing detectors, each of which has (b) 
a unique offset p, and angle 9, from the centre of the scanner, c) Parallel coincidence lines can be 
separated into a set, (d) and re-arranged into a 2-dimensional sinogram. 
2.2.3 Image Data Correction 
2.2.3.1 Normalisation 
Numerous coincidence events are detected during the course of a PET scan. 
However, due to geometrical arrangements of the detectors and differences in 
energy discrimination there may be significant variation in the efficiency of 
detector elements in the system, for example, the detectors at the edge of the BGO 
block may be less effective than those at the centre. If this is not corrected for, 
artefacts may be present in the final image. A correction factor is therefore applied 
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to normalise the data. This is achieved by exposing all detectors to a uniform flux 
of photons to measure the inherent variations. The data is subsequently adjusted to 
account for this. 
2.2.3.2 Dead Time Correction 
The time required to process a single event limits the counting rate of a PET 
scanner. Dead time refers to the period of time in which the detector or electronic 
circuitry are unable to recognize an incoming event as the apparatus is still 
processing the previous one, and is therefore proportional to the incoming photons 
approaching the detector. Dead time is the dominant effect that limits the dose of 
injected activity (Ollinger et al, 1997). For scanners in which the number of 
photomultiplier tubes is greater than one, electronic circuitry is needed to 
determine which crystal detected the photon, and this processing circuitry can 
contribute a major source of dead time. With high count rates, mispositioning of 
individual events can occur with more events assigned to detector elements near 
the centre of the crystal array rather than at the periphery. This can result in loss of 
in-plane resolution by 1 - 2 mm. 
Quantification of the PET image without correction for dead time would 
underestimate actual activity. Correction of dead time can be obtained by 
scanning a phantom containing short-lived positron emitter e.g. ["C] at serial 
times as the activity decays. Dead time loss is extrapolated from low activity 
measurements to estimate the true plus scatter (see next section) that would have 
been obtained without the losses. The activity level where the percent dead time 
loss is 50% is calculated from the extrapolated and measured counts. Most 
commercial scanners provide automatic dead time correction. 
2.2.3.3 Non-Valid Coincidence Correction 
A true coincidence event is one where the detectors record an event from a unique 
positron annihilation that occurred along the line between two activated detectors. 
However, PET scanners also detect other types of coincidences that arise from 
unrelated annihilation photons, which degrade the quality of the 'true' image 
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(Figure 3 a). Non-valid coincidences fall into three categories and require different 
correction strategies: 
(i) Multiple coincidences 
This occurs if two or more photons are recorded during the coincidence window 
resulting from more than one positron annihilation. It therefore becomes 
ambiguous where the line of response should be positioned (Figure 3b). Multiple 
coincidences, which are easily distinguished from unique coincidences, are 
usually discarded even though two may have represented a valid coincidence. 
(ii) Random coincidences 
As there are a large number of scattered photons and a relatively small angle 
subtended by the detector ring, it is apparent that only one photon will be detected 
for some annihilation events, which are known as singles. Random or accidental 
coincidences arise when two, unrelated single events from separate annihilations 
are detected within the same coincidence timing window and registered as a 
coincidence (Figure 3c). A coincidence window is necessary because even though 
two detectors should be stimulated simultaneously by a true annihilation event, 
limitations of the scintillation detectors and processing circuitry requires that 
coincidence events have to be accepted within a certain finite time interval, as 
mentioned. Random coincidences do not contain any spatial information about 
activity distribution and contribute to a smooth 'background' in the image, and 
therefore need to be corrected for. 
Random coincidences can be corrected for by two methods. In the first way, direct 
measurement is made by delayed coincidence. This employs a second coincidence 
circuit where one circuit is delayed by several times the length of the coincidence 
window so that only random coincidences are measured. The second method 
makes use of the relationship that exists between the random coincidence rate (R) 
and is expressed by: 
R = 271X (Si X S2) 
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where Si and S2 are the single counting rates for each detector, and 71 is the 
coincidence window. In both methods, the random counting is subtracted from the 
measured coincidence data prior to image reconstruction. 
As can be seen from the equation, random coincidences can be reduced by 
decreasing the coincidence window interval if faster detectors and electronics are 
used, though this still results in a sufficient number of random counts to warrant 
correction. However, BGO detectors require at least a 10-15 ns timing window 
due to variations in the rise-time of the crystal light output. 
As the incident counting rate for singles is proportional to the amount of injected 
isotope, the random coincidence rate increases as the square of the amount of 
isotope in the field of view (when the detectors are not saturated ). This, and 
detector dead time, imposes an upper limit on injected dose activity in some 
studies. 
(iii) Scattered Coincidence Events 
Compton interaction describes the predominant exchange between photons and 
matter. If an annihilation photon interacts with an electron in the surrounding 
tissue, the photon will not only incur some energy loss, but will also be deflected 
from their original path. When both photons are eventually detected, the LOR 
assigned to it will not represent the true LOR that would have occurred if the 
photon had not been diverted, and the coincidence event is said to be 
'mispositioned'. Scatter coincidences originate from activity both inside and 
outside the coincidence FOV and contributes around 15% to the measured 
coincidences. The inclusion of scattered events in the projection data does not 
significantly affect the spatial resolution of the reconstructed image but lessens 
the contrast by adding a structureless background to the image and causes 
inaccuracies in quantification. Theoretically, as these scattered photons lose 
energy after their collisions, they should be distinct from unscattered photons by 
energy discrimination. However, the PET detectors actually have poor energy 
resolution and can only distinguish photons having undergone appreciable energy 
loss after large-angle scatter events. 
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Key: Photon Emission from Source 
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Figure 3: Coincidence Events Detected During PET Scanning 
(a) True coincidence (b) Multiple coincidence (c) Random or accidental coincidence (d) Scattered 
coincidence 
Scattered events can be reduced by the inclusion of septa between the ring 
detectors and by using shields at the end of the scanner to impede scattered 
coincidences from other parts of the body. Another strategy to diminish scattered 
events is to decrease the solid angle for detection of coincidence events as the 
number of scattered events produced is related to this angle. However, this 
method will make the sensitivity of the scanner worse. 
Scatter events must be removed in order to derive quantitative data from the PET 
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scan. Several methods are available to correct for scatter. One method employs a 
dual-energy window correction where two energy windows are defined: 200-380 
keV (lower) and 380-850 keV (upper). Data are simultaneously acquired in both 
energy windows, with the upper window comprising true coincidences and the 
lower window containing predominantly scatter events. Line source 
measurements in air and phantom are used to estimate the amount of scatter in the 
photo peak and scaling factors are calculated from this. These are used to 
calculate a scatter sinogram, which is subtracted from the photo peak sinogram to 
obtain a scatter corrected sonogram (Grootoonk et al, 1992). With this method 
scatter events are reduced to within 6% of true values. 
Whilst the dual-window method produces better out of field scatter correction, it 
is sensitive to temperature fiuctuations which can affect crystal efficiency. 
2.2.3.4 Attenuation 
Attenuation occurs when the photon emitted from the radioisotope interacts with 
the object by photoelectric absorption or are scattered out of the field of view by 
Compton scatter. Whilst attenuation is less for PET than SPECT, PET requires the 
detection of two photons emerging from the object without attenuation for 
imaging purposes. In the brain, only 20% of coincident photons emitted along a 
line through the centre reach the PET detector and in the chest around 80 to 90% 
of photons are scattered or absorbed by the object (Daube-Witherspoon, 1995). 
A unique feature of PET is that for a given coincidence line, the probability of 
photon attenuation is the same from any source, independent of its location along 
the line joining the two detectors. This is true even when the source lies outside 
the object which facilitates attenuation correction using an external transmission 
source. This concept can be explained by considering a point source situated at x 
cm, within the boundary of a cylinder with diameter, D and |i representing the 
linear attenuation coefficient of the material of the cylinder (Figure 4). The 
proportion of emitted photons that reach the detector closest to the source at point 
a, is e'^^and those reaching the detector furthest away, is e ' ^ ( F i g u r e 4a). If the 
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number of detected coincidences is N (without an object in the field of view), and 
the initial count rate is No, then: 
N = No[e'^''xe-^' 
= No e-^ "* 
This demonstrates that the probability of coincidence detection is independent of 
the source depth, x cm. If the source is external to the object at point b, then the 
probability terms for the nearest and furthest detectors are e° and e'^^, respectively 
(Figure 4 b). In this situation, the number of detected coincidences is given by: 
N = No[e° 
= Noe-^^ 
This is the same as that obtained for the internal source, as shown in the equation 
above. 
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Figure 4: Diagram Showing Attenuation 
Probabilities used in PET Scanning a) 
Attenuation for an internal source b) Attenuation 
for an external source 
Attenuation correction is therefore relatively straightforward. A scan using an 
external source is obtained with the patient in the scanner (attenuated transmission 
scan) and another, unattenuated scan using the same external source is taken when 
the scanner is empty (blank scan). The count rate from the attenuated transmission 
scan is compared to the blank scan to give a measure of attenuation which is used 
to correct the PET data. A transmission scan is usually performed prior to the PET 
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tracer scan. The transmission source contains a long-lived positron emitter such as 
germanium-68 (^^Ge) which has a half-life of 275 days. ^^Ge is housed in one or 
more retractable rods that rotate around the patient to measure the transmission 
count rate from all possible lines of response. 
2.2.4 Three-Dimensional PET 
Most modem PET scanners have the capability of providing information about the 
3-D distribution of radioactivity in an object. The difference between 2D and 3D 
images lies in data acquisition and reconstruction. In 2D scans, lead or tungsten 
septa are normally used to separate adjacent imaging planes. These inter-ring 
septa were originally designed to reduce the registration of unwanted random and 
scatter coincidences. In 2-D mode, data are acquired as a number of contiguous 
slices, with contributions for each slice arising from within an individual or 
closely associated ring. However, whilst diminishing the number of invalid 
coincidences, this method also removes many true coincidences and increases 
statistical noise (see next section). In 3D PET, the septa are retracted allowing 
coincidences between all possible pairs of detectors and increasing the effective 
sensitivity by a factor of eight (Spinks et al., 1992). This increased efficiency can 
be used to improve the image quality in low count studies, reduce the radiation 
dose administered and reduce scan times (Ollinger et al., 1997). The development 
and availability of image algorithms to reconstruct the data into a 3D image has 
allowed exploitation of the 3D acquisition mode, which is now frequently 
employed particularly in neuro-imaging. 
One disadvantage of 3D imaging is the significant increase in scatter coincidences 
recorded. Of all coincidences measured approximately 45% are due to scatter in 
the 3-D mode compared to 15% in 2-D. Despite this, 3-D PET offers great 
potential in nuclear imaging. 
2.2.5 PET Image Reconstruction 
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The goal of image reconstruction is to recover the regional tissue concentrations 
of radiotracer measured during the PET scan. Raw PET data consists of a number 
of views (or projections) obtained from around the patient which consists of the 
sum of activity along a LOR but gives no information about the actual distribution 
and depth in the patient. There are many methods of image reconstruction with all 
of them involving back projection of the views across the FOV (Kak et al, 1988), 
a technique utilised routinely in CT and SPECT scans as well. The image 
formation process conventionally divides the 'image space' into a matrix of 
square boxes called pixels, and puts counts in each pixel that are proportional to 
the counts from a particular LOR and places them in an area of overlap of the 
LOR and pixel. The data is back projected equally across the image grid for all 
angles subtended by each detector. The back-projected profiles will intersect for 
each projection at the position of the source of activity, but the image will be of a 
poor representation of the original because of the background generated by this 
procedure. Furthermore, back projection has the effect of amplifying the intensity 
of signal in large structures with low spatial frequencies. 
This can be improved by the use of spatial filters which aims to suppress these 
amplifications and restore the true distribution. The Fournier transform is one 
such technique which subjects the data profile and data to a filter to weight each 
component in proportion to its own frequency so that increased weight is given to 
small structures that have high frequency. Problems associated with this technique 
include an increase in statistical uncertainty and noise in the projection data 
(Ollinger et al., 1997). Filtering causes each pixel in the image to be associated 
with every other pixel, resulting in correlafion of noise between pixels (Alpert el 
al., 1982). After data filtering, an inverse transform is performed to produce a 
quantitative image. An alternative method of reconstruction so called iterative, 
enables a more superior form of image reconstruction in which the image data is 
successively reconstructed with different algorithms to be consistent with the 
projection data. 
2.2.6 PET Performance Characteristics 
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2.2.6.1 Spatial Resolution 
There are several main characteristics that determine the spatial resolution of PET 
images which include the physical size and shape of the detector element, positron 
movement in the tissue before annihilation and deviation from the strict collinear 
pathway that affect some emitted photons. 
Detector dimension is fundamental in determining the spatial resolution of the 
PET image. In-plane spatial (transverse) resolution is characterised by two values 
of the spread of a point source in the image; radial (width) resolution, a line of 
spread from a point source in the directions along a line from the centre of the 
gantry to the source position, and tangential resolution, which is perpendicular to 
that line. Both these resolutions give a count profile curve that is approximately 
Gaussian in shape (see Figure 5). The width of this curve at one-half maximum 
value (the full width at half-maximum [FWHM]) is the most commonly used 
parameter to describe spatial resolution. FWHM is the minimum separation 
required for two points to be resolved and is primarily limited by individual 
detector size. The major advances in spatial resolution in the last few years have 
been due to the reduction in detector size. 
Radial Profile 
Radial Resolution 
Tangential Profile 
Tangential Resolution 
Figure 5: Parameters of Transverse Resolution 
Transverse resolution is characterised by two values of the spread of a point or line source in the 
image. The radial resolution is the width of a profile from the centre of the gantry to the source 
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position at distance, R. The tangential resolution is the width of the profile perpendicular to the 
radial direction (Daube-Witherspoon, 1995). 
Positron energy imposes another restriction on spatial resolution. When a positron 
is emitted from the radioisotope, it has a range of energies and travels a finite 
distance before combining with an electron. A positron released form '^F isotope 
may travel 2-3mm prior to annihilation (Cho et al, 1975). If the positron travels 
in the direction of the coincidence detector no error is introduced. However, the 
error is maximised when the positron travels in a direction orthogonal to a line 
joining the two detectors. On average, the error introduced is 0.2mm for '^F, for 
example (Phelps et al., 1975) (Table 2.1). 
Another factor that limits spatial resolution is non-colinearity of annihilation 
photons. This refers to a property of the positron- electron pair which does not 
come to complete rest before annihilation. In this situation the positron-electron 
particle still has residual momentum when it annihilates. As momentum has to be 
conserved the emitted annihilation photons deviate from the 180° degree pathway. 
This introduces a small error (< 0.5%) in positioning of the annihilation event. 
The impact of this error is dependent on the diameter of the detector ring and not 
on photon energy. For a detector ring diameter of 80cm, the limit imposed by 
theses effects is less than 2mm, and for a diameter of 20cm, is less than 1mm. 
2.2.6.2 Counting Efficiency 
This refers to the proportion of emitted photons that are detected and contribute to 
the final image. The higher the counting efficiency the lower the noise level in the 
images. The counting efficiency of a 3-D mode PET scanner is higher than for 2-
D PET mode. However, both compare favourably to a single head SPECT scanner 
with PET conferring a 30-fold advantage in efficiency over SPECT. 
2.2.6.3 Count Rate Performance 
33 
This describes the response of the detector apparatus to increasing levels of 
radioactivity within the field of view. In an ideal situation, the count rate would 
increase linearly in response to increased activity. However, as discussed, a point 
is reached where the detector system is unable to process all events due to the 
rapidity of incoming events. As a result, the count rate response becomes non-
linear. Corrections are available in commercial scaimers to account for dead-time 
loss. 
2.2.6.4 Statistical Noise 
Statistical noise in PET scans is a result of the limited number of counts in each 
pixel and the random nature of radioactive decay. In general, the greater the 
number of image counts acquired, the better the quality and quantitative precision 
of the data. The radioactive decay process obeys the Poisson probability of 
distribution, where the standard deviation (SD) is defined as the square root of the 
mean number of counts (N); 
SD = VN 
Mean number of counts represents signal and SD is used as a measure of noise. 
For total counts of 10 000, 1 000 and 100, noise is 1%, 3% and 10% respectively, 
thereby demonstrating that noise increases as the number of counts decreases. 
Statistical noise is also affected by the reconstruction process, which correlates 
noise between pixels (Alpert et al, 1982) and corrections made for random, 
multiple and scatter coincidences, attenuation and detector non-uniformities and 
the size and location of the region of interest (Carson et al., 1993). 
The number of image counts detected is dependent on injected radiotracer 
activity, camera sensitivity and scan duration. The amount of radioactivity 
injected in clinical studies is limited by the requirement to limit radioactive 
exposure to the patient and by the characteristics of the scanner. Increasing 
injected radioactive dose results in more dead-time losses and random 
coincidences and camera sensitivity is influenced by detector counting efficiency 
as discussed. Scan duration takes into account the biological and physical half 
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lives of the radiotracer and consideration must be made of patient discomfort and 
potential motion errors with longer scanning schedules. 
2.2,6.5 Noise Equivalent Count Rate 
The noise equivalent rate (NEC) is a parameter calculated to determine the effect 
of combining the degrading effects of dead-time loss, random and scatter 
coincidences on image quality: 
NEC = 
, S kR 
1 + — + — 
T T 
where T, S and R are true, scattered and random coincidence rates respectively, 
and k is a factor of 1 or 2 depending on the method used to estimate random 
coincidences (Strother et al, 1990). NEC is the count rate that would have 
resulted in the same signal-to-noise ratio in the data in the absence of scatter and 
random events and is always less than the observed count rate. NEC provides an 
overall factor to examine statistical quality and noise in the reconstructed image. 
2.3 PET Calibration 
PET systems detect only a fraction of the photons emitted from the radiotracers, 
and therefore the efficiency of the PET must be assessed and calibrated. This is 
usually achieved by first measuring the activity of a source of positron emission in 
the scanner followed by measurement of an aliquot from that source with a 
calibrated radiation detector such as a well counter. The well counter is calibrated 
in the UK by measurement of a standard source from the National Physical 
Laboratory, Teddington. As the measurements will be made at different times, a 
decay correction factor is applied to data sets from the scanner and well counter. If 
arterial blood samples are taken during the duration of the PET scan, the on-line 
detectors are calibrated in a similar fashion. A relationship is therefore established 
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between the radioactive concentrations in the tissue, derived from the PET image, 
and blood. This is important in modelling PET data to derive quantitative 
parameters. 
2.4 Radioisotope Production 
Positron emitting radionuclides are not usually present in nature and must be 
produced artificially, which most often occurs in a cyclotron. The production of 
radioactive atoms was first demonstrated in 1934 by Curie and Joliot after 
bombarding magnesium and aluminium with alpha particles from radium or 
polonium. They observed that positron emission from the target continued after 
the bombardment had stopped. In 1930, E. Lawrence conceived the idea of 
accelerating particles between two D-shaped magnets, called a cyclotron, in order 
to produce progressively higher energy particles for bombarding atoms. 
Cyclotrons in use today harness powerful and electric magnetic fields to 
accelerate charged particles such as protons, deutrons or alpha particles, which are 
created by the ionisation of the gases hydrogen, deuterium and helium, 
respectively. These particles are accelerated to such high speeds (2-5% of the 
speed of light) that they overcome the forces of repulsion from a positively 
charged nucleus and bombard a target containing stable atoms, to give rise to 
radionuclides. The radioisotopes generated have an excessive positive charge and 
decay by positron emission as previously described. 
A limited number of radioisotopes with short half-lives are not produced in a 
cyclotron and can be formed in an on-site generator. Gallium-68 (^^Ga) and 
rubidium-82 (^^Rb) are extracted as decay products from their parents, 
germanium-68 (half-life = 275 days) and strontium-82 (half-life = 25 days), 
respectively. 
2.5 Radiochemistry of Radioactive Tracers 
This describes the process of labelling the compound of interest or radiotracer to 
be studied using PET with the radioisotope after it has been produced in the 
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cyclotron. An advantage of PET is that positron emitting radioisotopes are 
available for commonly occurring elements such as carbon ("C), oxygen ('^O), 
nitrogen (^^N) and fluorine (^^F) which are used as substitution of an element in 
the compound to be radiolabeled. Fluorine-18 is commonly used to replace 
fluorine present in 5-fluorouracil for PET imaging studies (Brown G. et ai, 1993), 
though '^F can also be used to replace hydrogen atoms with which it is isoteric, or 
hydroxyl groups with which it is isoelectronic (Brooks et al., 1992; Inoue et al, 
1997). 
Many of the radioisotopes have a short half-life (Table 2.2), requiring rapid 
methods of radiochemical synthesis and necessitating the need for an on-site 
cyclotron. Difficulties will also be encountered when longer studies need to be 
performed. Radioisotopes with longer half-lives can be transported from their site 
of production to the administration site. 
The aim of radiochemistry is the simple and fast production of radiotracers to 
ensure sufficient quantities of radiotracer with high specific activity. Radiotracers 
with a very high specific activity of the order 150-600 GBq/mmol are required to 
ensure that concentrations of the non-radioactive part of the compound are low so 
as not to interfere pharmacologically with the in vivo measurement of the kinetics 
of the radiotracer. In general, radiotracer production should be quick enough to 
allow the radiolabelled target drug/compound to be isolated, purified and 
formulated as a pyrogen-free, sterile isotonic solution within 2 to 3 half-lives of 
the radionuclide. 
High levels of radioactivity have to be handled in the production of radiotracers, 
particularly those utilising short-lived radioisotopes. To limit the exposure of 
personnel to this high radioactivity, single-step synthesis methods have been 
developed. In addition, radiochemistry now incorporates remote controlled and 
robotic-based chemistry techniques, though this necessitates complicated 
machinery and expertise to be on site. 
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Table 2.2: A list of positron emitters and their half-lives 
Radioisotope Half-life Positron decay 
(%) 
Bromine-75 98 min 76 
Bromine-76 16.1 hrs 57 
Carbon-11 20.4 min 99.8 
Cobalt-55 17.5 hrs 77 
Copper-62 9.7 min 97.8 
Copper-64 12.7 hrs 19.3 
Fluorine-18 109.8 min 96.9 
Gallium-68 68.1 min 90 
Iodine-124 4.2 days 25 
Iron-52 8.3 hrs 57 
Nitrogen-13 10 min 100 
Oxygen-15 2.03 min 99.9 
Rubidium-82 1.25 min 96 
Technetium-94m 53 min 72 
Yttrium-86 14.7 min 34 
Zirconium-89 78.4 min 25 
2.6 PET Modelling Techniques 
The aim of modelling the behaviour of radiotracers in PET studies is to interpret 
kinetic data in terms of standard physiological, biological and pharmacological 
parameters. PET modelling allows the response of tissue and subsequent dynamic 
changes in radiotracer concentration to an injected dose of radioactivity to be 
observed and analysed to derive a parameter to describe the tissue kinetic of the 
radiotracer. Temporal resolution of tissue radioactivity is high and is determined 
by the frame durations of the dynamic scans which are shorter early on in the 
scan, to ensure the inclusion of rapidly changing radiotracer kinetics in the 
measurement. Mathematical modelling of tissue radioactivity alone is known as 
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semi-quantitative analysis, as the input of the radiotracer is not accounted for in 
this methodology. An example of this is integral analysis, which is discussed later 
in this chapter. 
In other PET models, arterial blood radiotracer concentrations are recorded and 
are related to the radioactivity concentrations in tissue via an appropriate model. 
This enables the determination of plasma and tissue rates of exchange and 
provides an in vivo method of calculating quantitative regional tissue radiotracer 
kinetics. Arterial blood sampling in dynamic PET scans is derived from a 
combination of continuous on-line monitoring (second by second measurements) 
of whole blood radioactivity and discrete blood samples (5-10 samples per PET 
scan). From these measurements, a plasma input function for the radiotracer can 
be acquired from blood/plasma radioactivity portioning and plasma metabolite 
analysis. Blood data acquisition is sufficiently rapid to ensure that the fast kinetic 
profile of the radiotracer can be detected, as with radiotracer tissue data. The 
convolution operator is used to enable time-dependent changes in arterial 
radioactivity (input) and tissue radioactivity (output) to be assessed together and 
thereby generate a quantitative parameter of interest. 
Modelling, when using both arterial and tissue radioactivity inputs, requires that 
two factors, delay and dispersion, be considered. Delay is the result of the 
temporal lag (~ 10 s) between injection time into a vein in the arm or hand, and 
time to reach the target organ such as tumour or liver. Dispersion occurs as a 
result of spreading of the bolus after injection in the BGO detectors and is 
corrected for by modelling measured and actual arterial concentration time 
courses. 
Quantitative PET analysis can be divided into two categories: model led or data 
led analysis. Model led techniques themselves form a broad spectrum of methods 
ranging from a rigid compartmental model to more flexible approaches such as 
spectral analysis. In compartmental modelling, the potential distribution of the 
radiotracer is assigned to a limited number of discrete compartments, within 
which it can be free, specifically or non-specifically bound. This method requires 
a priori knowledge of the radiotracer. Spectral analysis on the other hand requires 
few a priori assumptions. An alternative technique is graphical analysis which lies 
between compartmental and spectral analysis. Data led methods include principle 
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component analysis which employs orthonoimal transformation of standard 
coordinate axes to obtain key temporal components from dynamic data. Another 
technique is cluster analysis which allows natural groupings in data to be 
uncovered and provides estimates of association in PET data (Gunn et al., 1998). 
In this thesis, the principal analyses used are integral, compartmental, graphical 
and spectral methods, which are discussed below. 
2.6.1 Semi-Quantitative Modelling Methods 
2.6.1.1 Integral Methods 
Two important parameters, standardised uptake value and area under the curve, 
are obtained relatively simply from the injected radioactivity dose, tissue 
radioactivity data and patient weight, using integral methodology. The 
radioactivity must be decay corrected (described below) to take into account the 
decay of the radioisotopes over the duration of the scan. 
2.6.1.2 Decay Correction 
Although the amount of radioactive material decreases with time the rate of 
radioactive decay remains the same. Different radioisotopes decay at different 
rates, but they all follow the exponential law of decay for radioactivity which 
depends on the initial radioactive count. The equation for exponential decay is: 
N = Noe-^, 
Where, N and No are the number of radioactive nuclei present initially and after 
time t, respectively. X (lambda) is the disintegration constant and is the probability 
that an atom will decay in a second. X is characteristic for each radioisotope, and 
for the isotopes used in this thesis are shown in Table 2.3. 
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Table 2.3: Radio isotopes and their X constants 
Radioisotope 1 constant 
["F] 1.053 X lO"' 
["q 5.663 X 10-4 
["()]) 5.6896 X 10-' 
2,6.1.3 Standardised Uptake Value 
Standardise uptake value (SUV) is a relatively simple mathematical model in PET 
and therefore one of the most frequently employed. SUV is defined as the decay 
corrected tissue activity as measured by PET divided by the radioactivity injected 
divided by body weight (Zasadny et al, 1993). Variability of SUV has been 
reduced by normalisation with body surface area (BSA) rather than body weight. 
SUV(t) [m^/ml] = Measured activity at time rkBa/ml] x 
Injected dose [kBq] / BSA 
In oncology studies SUV is used to compare normal and malignant tissue tracer 
pharmacokinetics. In dynamic PET scans, the SUV is the integral over a time 
frame of decay corrected tissue radioactivity normalised to injected activity and 
BSA. When the SUV for each time frame is plotted against mid-frame times 
(MFT, see Chapter 4), the so called time versus radioactivity curve (TAG) is 
generated. SUVs can be calculated at various time points during the scan. Early 
time points such as at 3 minutes (SUVa.ysmins), before metabolism of parent 
radiotracer, can give a measure of delivery of radiotracer e.g. of 5-
['^F]fluorouracil to tissue. For radiotracers that are 'trapped' in tissue, e.g. 2-floro-
2-deoxy-glucose (['^F]-FDG, see chapter 3) a later time point of SUV gives an 
indication of retention of radiotracer by tissue. 
2.6.1.4 Area under the Radioactivity Curve 
Area under the radioactivity curve (AUG) is another commonly used parameter 
which describes exposure of tissue to the radiotracer (parent and radiolabeled 
metabolite). It is calculated from the TAG, by integrating the activity in all time 
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frames for the frill duration of the dynamic scan. AUC is expressed as m^/ml x 
sec, after correction for radioactive decay and normalisation for body surface area. 
2.6.2 Quantitative Modelling Methods 
2.6.2.1 Compartmental Modelling 
Compartmental analysis, as mentioned, requires some a priori knowledge of the 
behaviour of the radiotracer in tissue. A system is then constructed using a single 
or a series of interacting compartments between blood and tissue which are 
representative, although a simplification, of the underlying 
biological/physiological/pharmacological process. The compartments may either 
define physical distinct parts if the 'system' or the behaviour of chemical species 
within it. If there is direct proportionality between the model variable and the 
predicted response, the optimal set of variables can be computed directly using 
linear regression. The transfer of radiotracer between compartments is 
proportional to the amount of material within each compartment and is described 
by rate constants. 
A number of assumptions are imposed when using a linear compartmental model: 
i) The tracer must mix instantaneously within the compartment and be of uniform 
concentration. 
ii) The quantity of tracer must be small compared to the 'system' being measured. 
iii) The rate constants between the compartments do not change. 
In oncology, a smgle tissue compartment model is used in radiolabelled water 
(H2 ['^O]) blood flow modelling (see below). 
2.6.2.2 Blood Flow Modelling 
2.6.2.2.1 Fick Principle 
Blood flow modellmg is based on the Fick principle, originally described for the 
mdicator dilution method to assess cardiac output. This postulates that the 
quantity of any tracer taken up by an organ from blood that perfuses it in a given 
period of time is equal to the amount of tracer carried to the organ by the arterial 
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in-flow minus the quantity removed from by venous drainage, during the same 
time interval. The basic equation expressing this is: 
~ = ^ c - ^ c dt 
Where, 0 is the blood flow of the organ (ml/min), dQ is the amount of the 
radiotracer in the organ of interest (mol), and Ca and Cy the concentrations of 
tracer in arterial blood and in venous blood respectively. 
2.6.2.2.2 Non-Dynamic Methods 
Methods for measuring regional blood flow with PET are based on a model 
originally developed by Landau et al. (Landau et ai, 1955), and Kety (Kety, 
1965), who measured regional cerebral blood flow with diffusible radiotracers 
(nitrous oxide) and tissue autoradiography. 
The first quantitative PET techniques used were developed by Raichle and his 
group in St. Louis (Herscovitch et al., 1983; Raichle et al., 1983) and Frackowiak 
and co-workers at the Hammersmith Hospital (Frackowiak et al., 1980). Raichle 
used '^0-labelled water which was injected intravenously as a bolus and the PET 
image acquired over 40 seconds. Frackowiak et al. developed the steady-state 
inhalation method to estimate blood flow, oxygen extraction, oxygen utilisation 
and blood volume in the brain. In this method the patient inhales '^0-labelled CO2 
which is converted rapidly in the lung by carbonic anhydrase to radiolabelled 
water. After an mhalation of several minutes equilibrium is reached between 
radiotracer concentration in blood and tissue. Tissue perfusion can then be 
calculated from two measurements: tissue concentration, determined from the 
PET signal and arterial concentration, measured by arterial sampling using a cross 
calibrated well counter. In addition, radiolabelled water (H2['^0]) has several 
useful characteristics as a flow tracer as it is biologically inert as well as 
chemically stable with no physiological effects, and has a short half-life allowing 
rapid and repeatable studies to be performed. However, several assumptions are 
made to calculate blood flow using this model. First, it assumes that water is a 
completely and freely diffusible substance and that extraction of water from the 
circulation at different flow rates is always 100% (Frackowiak et al., 1980). It also 
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makes assumptions about partition co-efficient. Partition co-efficient (or volume 
of distribution as it is called in PET) is the fraction of the volume of tumour in 
which the radiolabeled water is distributed at equilibrium. In this model, it is 
assumed that the partition co-efficient of water in healthy and diseased tissue is 
the same and that the volume of distribution of radiolabeled water is 1. 
Subsequent analyses (Herscovitch et al, 1983; Lammertsma et al, 1992; 
Lammertsma et al., 1981) found that these assumptions led to underestimation of 
blood flow in heterogeneous tissue and in homogeneous tissue with volume of 
distribution less than 1. This is particularly important in tumours where the tissue 
is frequently heterogeneous. 
2.6.2.2.3 Dynamic Methods 
As a consequence of these limitations of perfusion estimation and coinciding with 
the development of faster scanners, these methods were modified and adopted for 
use in a dynamic procedure which employed kinetic information from the arterial 
input curve and tissue radioactivity. This method was initially developed for 
measuring blood flow and oxygen utilization in the brain and heart (Frackowiak e( 
al., 1980). It has subsequently been modified and used to measure blood flow and 
exchanging water space in breast tumours (Wilson et al, 1992). In this technique, 
the behaviour of '^0-labelled water, which is metabolically inert and freely 
diffusible, can be described by the following differential equation for a single-
compartment model (Fig. 6). 
dCt(t)/dt = F.Ca(t)- (F/Vd + %).C.(t) 
Where, Ct(t) is the regional tissue concentration ofHzL'^O] (kBq/ml of tissue) as a 
function of time and Ca(t) is the arterial whole blood concentration of H2['^0] 
(kBq/ml of blood). F is the regional blood flow (perfusion) in ml (blood)/min/ml 
(tissue), Vd is the volume of distribution of water (mlbiood/mltissue) and X is the 
decay constant of '^O. 
The solution to this differential equation is given by: 
C,(t) = F. Ca(t)(g)exp -[''^'' + ' ]' 
44 
Where (g) is the convolution operator and Ct(t) represents the tissue response to an 
arterial input function Ca(t). As Ca(t) and Ct(t) are measured over time with 
dynamic PET, best estimates of both F and Vd can be obtained using non-linear 
regression analysis (Wilson et al, 1992). 
Artery 
Ca (kBq/ml blood) 
PET Region of 
Interest e.g. tumour 
Ct (kBq/ml blood) 
F/Vd 
Vein 
Figure 6: One-tissue compartment blood flow model. 
Amongst the advantages to the dynamic model are that the acquisition of data is 
quicker and can be repeated easily. The faster acquisition with a shorter build up 
means a lower effective dose is delivered to the patient in addition to the lower 
total dose of radioactivity needed to acquire the data. In addition, Vd can be 
derived from the dynamic model, which may be a useful parameter particularly 
when measuring heterogeneous tissues such as tumours. One of the major 
disadvantages of the O blood flow model is that it becomes unreliable at high 
flow rates. This is because the model depends on a difference between the arterial 
and tissue time activity curves. At high flow rates the arterial curves approaches 
the tissue curve and the data cannot be modelled. This is usually not a problem 
when measuring tumours as perfusion in such tissues is characteristically low. 
Apart from measuring blood flow in breast cancer, PET has also been used to 
measure regional perfusion in primary and secondary brain tumours, pancreatic 
and hepatic malignancies including hepatocellular cancer and metastases 
(Anderson et al., 2002). 
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2.6.2.3 Graphical Analysis 
This method of analysis was largely developed by Patlak and his associates, based 
on mathematical principles exploited earlier by Patlak and Rutland, who used it in 
nuclear imaging (Patlak CS. et ai, 1983). The purpose of graphical analysis is to 
derive the unidirectional and irreversible uptake of tracer from plasma into tissue 
and was originally utilised to study solute exchange across the blood-brain barrier. 
The general theoretical model behind graphical analysis describes tracer exchange 
between a plasma compartment, a reversible tissue region with an arbitrary 
number of compartments, and one or more tissue compartments in which the 
uptake of tracer is irreversible. A number of assumptions are required in this 
analysis: 
i) There is a single point source, the plasma, for the radiotracer in the 
system. 
ii) The concentration of the radiotracer in plasma may vary with time. 
iii) Relatively rapid exchange occurs between the radiotracer in plasma 
and the tissue region which is made up of n number of compartments, 
where radiotracer exchange among plasma and this first region of 
tissue compartments is reversible. 
iv) The radiotracer can enter a second tissue or compartment distribution 
region from the plasma or first region compartments. However, after 
entering the second region, the radiotracer cannot leave, and the 
radiotracer uptake is irreversible. The irreversible region may consist 
of more than one compartment, but these are mathematically lumped 
together to form a single compartment. 
v) The radiotracer does not alter the system and the exchange of 
radiotracer within the system obeys first-order kinetics. 
vi) If there is any metabolism of the parent in the plasma or exchangeable 
regions, the metabolites must behave in the same pattern as the parent. 
vii) Generation of metabolites within the irreversible region must not leave 
this tissue compartment and must be measurable. 
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viii) The radiotracer is not initially present in either the exchangeable or 
irreversibly bound compartments. 
In Patlak analysis, the data are first transformed and can then be depicted 
graphically. Data on the y-axis represents tissue concentration divided by plasma 
concentration for that time point. The normalisation of data on the x-axis 
effectively transforms the bolus input function into an infusion function of the 
arterial plasma activity. This is achieved by taking the integral of the plasma 
signal up to each measured time point and dividing by the actual plasma 
concentration at that time point. This normalised time is known as 'stretched 
time'. 
In a typical Patlak plot using a two-tissue compartment model (Fig 7), the initial 
slope is curved upwards and is attributed to the radiotracer reaching equilibrium 
between plasma and reversible compartments while continuing to be taken up by 
the irreversible compartment. The gradient of the final linear upslope of the curve 
is proportional to the irreversible tissue uptake of radiotracer from plasma and 
reversible tissue regions and is known as Kj, the net clearance of radiotracer from 
plasma into tissue. If there is no trapping of radiotracer by the tissue, tissue levels 
follow plasma levels and the tissue over plasma curve bends and becomes 
horizontal. After transformation of the data, the Patlak model equation is defined 
as: 
t 
A l , s s ( t ) / C x ( t ) = K , J C x ( t ) d r / C x ( t ) + (Vox + V b ) 
0 
Where Au^Ct) and Cx(t) are the time concentrations of radiotracer in tissue and 
plasma respectively, Vox is the volume of the exchangeable regions, and Vb is the 
blood volume within the tissue. K, is net unidirectional influx constant or net 
irreversible uptake constant as described. 
47 
I Cp ( r ) d r / Cp (normalised time ) 
Figure 7: Craplucal Representation of Radiotracer Transfer and Typical Patlak 
a) Transfer of radiotracer from plasma (compartment 1) and exchangeable regions (compartment 
2) and unidirectionally into tissue (compartment 3). 
b) Patlak plot showing the initial upslope gradient Z,, proportional to the clearance of radiotracer 
from plasma to exchangeable regions and K,, proportional to the net unidirectional clearance from 
plasma and exchangeable compartments into tissue 
The origmal Patlak model described above has been modified to allow analysis of 
radiotracer which has labelled metabolites that do not behave in an identical 
manner to the parent. In modified Patlak (Mankoff e/ ai, 1996), the following 
additional assumptions are made: 
i).The blood concentrations of tracer and its metabolites are known over time. In 
tissue, only the sum of the concentration of tracer and metabolites is known. 
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ii).The blood is the only source of metabolites i.e. a tissue other than the tissue of 
interest is principally responsible for the generation of metabolites. 
iii) The metabolites are fully reversible between blood and tissue and are not 
taken up irreversibly by the tissue of interest. 
In this extended Patlak, the equation is modified to the following: 
t 
Anss{t) / Cwt{t ) = Kl\ Cx(t) dx I + Vox[Cx{t) / C,o,{t)\ + ^ Von,{Cm{t) / C,o,{t)\ + Vb 
0 
Where, Atiss(t) and Ctot(t) are the time concentrations of total radiotracer (parent 
and metabolite) in tissue and plasma respectively, Cx(t) and Cm(t) are the time 
concentration of parent radiotracer and metabolite respectively in plasma, Vox and 
Vom are the distribution volumes of parent and metabolite respectively and Vy is 
the blood volume within the tissue. From this, the parameter K, can be calculated. 
2.6.2.4 Spectral Analysis 
Spectral analysis is a general modelling technique that enables the determination 
of pharmacokinetic and pharmacodynamic parameters, with relatively few 
modelling assumptions (Cunningham VJ. et al, 1993). This technique is based on 
identifying a spectrum of kinetic components within a given data set which are 
involved in the regional uptake and portioning of radiotracer from blood to the 
tissue, rather than being restricted to a predefined compartment model. No a 
priori assumptions are required and the technique allows the distinction between 
transient components, associated with tracer in the tissue vasculature, and 
reversible and irreversible components comprising the tissue response to the 
administered radiotracer. 
The fundamental process of spectral analysis is the method by which it relates the 
tissue radioactivity-time curve and arterial plasma input function. It does this by 
modelling the tissue data as a positive linear combination of basis functions, each 
of which IS a single exponential in time convolved with the arterial input function. 
_ i=i 
Cuss{ti) = Cm(t)0 e x p ( - y 0 , • t) 
Where, Ctjss(t) and Cm(t) are radioactracer concentrations in tissue and arterial 
blood or plasma respectively at time (tj), <S) denotes convolution operator, k is the 
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upper limit of the number of non-negative functions allowed in the model 
(typically 100). a and P parameters may be positive or zero, due to the constraint 
of the assumptions of first order tracer kinetics. 
P values are predetermined, and are selected to cover the spectrum of expected 
kinetic behaviour. For short-lived radioisotopes, the range incorporates the 
slowest possible loss of radioactivity (indicative of the radioactive half-life of the 
radioisotope) up to the fastest measurable dynamic (e.g. the transient passage of 
activity through the vasculature). The use of PET data which are not decay 
corrected provides a natural constraint on the values for p. For example, for 
studies using ['^F] with a decay constant of 0.000105s'', a suitable range is 10"^  to 
I s " ' . Kinetic componenets may take any value between 0 to I . Therefore, a p 
value of I s ' i s associated with the fastest component and is usually due to blood 
volume effects whilst a value closer to X reflects retention of radiotracer in the 
tissue. 
a indicates the relative contribution and intensity of each of the the components. 
Values for a may be obtained from a fit of the model to the measured time-
activity data from the tissue being analysed using the non-negative least-squares 
algorithm (Meikle SR. et al, 1998). 
The fitted values of a and the corresponding pre-chosen values of p define the 
tissue unit impulse response function (IRF). The IRF describes the time course of 
the radiotracer that would be expected if it were possible to deliver the tracer 
instantaneously to tissue, and is represented by the following equation: 
i=k 
= YJ GXp(-(/?' - X)t) 
/ = ! 
An alternative way of displaying the data is as a log frequency of P values, which 
shows the spectrum of individual kinetic components that adequately describe the 
tissue response and their amplitude. From this, the three parameters that are listed 
below, can be identified and calculated: 
1) Ki, which is the clearance of radiotracer from plasma to tissue and is 
represented by: 
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i=k 
K\ = h(0) = ^ at 
i=l 
ii) The fractional volume of distribution (VD) of the radiotracer (i.e. the 
steady state ratio of concentration of tracer in tissue and plasma) is 
given as: 
aj 
Pi — X 
iii) The mean residence time (MKT) of radiotracer in the sampled tissue, 
and is obtained by: 
MRT = — 
Ki 
2.6.2.4.1 Permeability and Surface Area Product 
Transport across the capillary endothelial cell is known as the permeability 
and surface area product (PS), and is a product of the capillary surface area 
and permeability (Cunningham VJ. et al, 1994). According to the Renkin-
Cronin model, K, incorporates PS and two other related components (i) the 
rate of plasma flow through capillaries and (ii) the change in concentration of 
the radiotracer as it passes across the capillary bed from artery to vein. The 
Renkm-Cronin model was originally formulated to describe the unidirectional 
uptake of tracer from the capillary in terms of properties of an ideal unit 
capillary in the brain (Crone, 1963). Furthermore, certain assumptions are 
imposed on the model such as assuming that the capillary transit time is 
negligible and ignoring the exchange of label between red blood cells and 
plasma which can occur during transit through the capillaries. However, this 
model can be extended to other tissue systems to derive PS product if K, and 
regional blood flow are known. If extravascular concentration of the 
radiotracer is negligible and influx of the tracer from plasma to tissue is 
greater than efflux, then: 
E = (Ca-Cy)/Ca 
Where C, and Cy are the concentrations of the radiotracer in the arterial and 
venous ends of the capillary respectively and E denotes extraction. 
Ki = FxE Equation 1 
Where F is the regional blood flow and calculated using a one-compartment 
model and modified Kety-Schmidt equation (Kety et al, 1948). If there is 
exponential decline of radiotracer concentration between Ca and Cy, then the 
following equation applies; 
E = 1-e Equation 2 
Therefore PS product can be calculated if K| and regional blood flow values are 
known, using Equations 1 and 2 as follows: 
Ki/F = 
e-^^^=l-Ki /F 
-PS/F = In(l-Ki/F) 
PS = -Fx In(l-Ki/F) 
2.7 Summary 
PET is a complex, multi-step technique requiring contributions from experts in a 
wide range of specialties. Advances have been made in PET scanners, detectors 
and software involved in image reconstruction which has improved the quality of 
PET scans. 
Clinically, PET can give non-invasive information on the temporal and spatial 
distribution of radiotracers. Various models have been formulated to help interpret 
these data making it a valuable technique in clinical medicine. 
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Chapter 3 Molecular Imaging in Oncology 
3.1 Introduction 
The term molecular imaging can be broadly defined as the 'in vivo characterisation 
and measurement of biological processes at the cellular and molecular level' 
(Weissleder et al., 2001). PET is an ideal tool with which to explore biochemical, 
physiological, pharmacological and genetic pathways that are altered in the 
development of cancer or can be manipulated in its treatment. 
PET imaging with ['^F]fluoro-2-deoxy-D-glucose (['^F]FDG) has dominated the 
field of oncology for the last two decades. An observation by Warburg (Warburg, 
1956) in the 1930's that malignant tumours have increased gylcolytic rate 
compared to normal tissue was followed in the 1980's with studies by Di Chiro, 
who showed that the degree of malignancy of cerebral tumours was correlated 
with their FDG uptake (Di Chiro, 1985; Di Chiro et al., 1982). After systemic 
delivery, [^®F]FDG initially follows the same metabolic pathway as glucose, and 
is transferred into cells by specific glucose transporters (GLUT-1) and is then 
phosphorylated into ['V]FDG-6-phosphate by hexokinase. Unlike glucose, 
[ ^F]FDG-6-phosphate is trapped and accumulates within the cell as it lacks a 
hydroxyl group and cannot act as a substrate for further glycolysis (Nelson et al., 
1996). Although FDG uptake is not specific to neoplastic cells, the role of 
['^F]FDG in current clinical applications in oncology is diverse and includes: pre-
operative detection and staging of disease, detection of recurrence, differentiation 
between recurrence and scarring post treatment, evaluating response to treatment 
(Young et al., 1999) and determination of biopsy site. 
Despite the fact that 95% of all clinical PET scans use ['^F]FDG (Gambhir, 2002), 
the future challenge for PET imaging lies in the development of novel PET 
radiotracers (or molecular PET probes) to fulfil its expectation in the arena of 
molecular imaging and cancer treatment. 
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This chapter will give an overview of new advances in various molecular 
processes in oncology such as angiogenesis, gene expression, hypoxia, apoptosis, 
and receptor interactions that have been identified as important determinants of 
cancer prognosis and treatment, and the utilisation of novel, investigative PET 
radiotracers with which to image them. The pharmacological processes of 
pharmacokinetics and pharmacodynamic endpoint assessment using 5-
[ FJfluorouracil and 2-["C]thymidine PET will be discussed in subsequent 
chapters. 
3.2 Angiogenesis 
Tumours do not grow beyond l-2mm^ in size without the development of new 
blood vessels (Folkman, 1971). Angiogenesis, which is the growth of blood 
vessels either from existing vasculature or from de novo generation of blood 
vessels, is imperative to allow tumour cells to increase their nutrient supply, 
proliferate and survive even though the new vessels often have structural and 
functional abnormalities compared to normal tissue. Numerous experimental 
animal models have demonstrated that angiogenesis is one of the most critical 
steps for progression of the primary tumour, as well as metastatic dissemination 
(Folkman, 1990). Though angiogenesis remains a complex, multistep process, 
great strides have been made in the last few years to elucidate its molecular 
mechanism in much greater detail. Many cytokines implicated in this pathway 
have been discovered including vascular endothelial growth factor (VEGF), 
whose levels are upregulated in several cancers such as breast, colon, ovarian and 
lung, and which may have prognostic significance (Miller et ai, 2001). There are 
two evolving categories of treatment that interfere with tumour vasculature for 
therapeutic benefit: 
i) Antiangiogenic agents that inhibit new endothelial cell development and 
subsequent formation of capillary networks. 
ii) Antivascular drugs that disrupt existing endothelial cells leading to 
destruction of the tumour blood vessel architecture. 
54 
Both treatment strategies have proved attractive with the development of 
numerous therapeutic agents with antiangiogenic or antivascular activity. 
3.2.1 Antiangiogenesis 
The mam restriction in the increasing number of new antiangiogenic drugs is the 
hmited availabihty of surrogate markers of therapeutic efficacy. The outcome of 
antiangiogenic drugs is difficult to determine as there is a wide range of 
mechanisms by which they can prevent neogenesis or neovacularisation. Effective 
therapy may not lead to any substantial reduction in tumour size, rendering 
conventional imaging modalities unable to determine response. PET methods are 
being developed to measure parameters related to the angiogenic phenotype. 
VEGF is one of the most potent cytokines mediating angiogenesis (Ferrara, 2002), 
and is secreted in response to hypoxia by tumour cells (Shweiki et al, 1992). One 
study has demonstrated the feasibility of imaging VEGF using an anti-VEGF 
antibody labelled with iodine 124 ('^'^I-VG76e) in mice bearing human 
xenografts. Ex vivo biodistribution confirmed antibody localisation within tumour 
(Collingridge et al., 2002). Such PET imaging may help identify patients with 
high tumoural expression of VEGF allowing appropriate selection for treatment 
with antiangiogenic drugs and provide an accurate marker of treatment response. 
Recent effort has concentrated on developing radiolabelled antagonists to the 
integrin avp3- "vPs is highly expressed on activated endothelial cells and plays a 
crucial part in new vessel formation (Stromblad et al., 1996). It binds to the 
tripeptide sequence arginine-glycine-aspartic acid (RGD) of various extracellular 
matrix proteins and by blocking these interactions can result in inhibition of 
tumour-induced angiogenesis (Brooks et al., 1995; Westlin, 2001). A 
radiolabelled glycopeptide of RGD, ['¥]Galacto-RGD, showed accumulation in 
ttvPa receptor positive tumours in mice using small animal PET scanning 
(Haubner et al., 2001). Further studies need to be undertaken to determine the 
clinical potential of ['^F]Galacto-RGD PET imaging in patients undergoing 
antiangiogenic treatment. 
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3.2.2 Antivascular 
The endpoint of antivascular activity is easier to define as the direct consequence 
of destruction of tumour vasculature is a reduction in tumour perfusion. Therefore 
the effect of newer antivascular agents may be monitored by changes in blood 
flow. [ O]-labelled water (H2['^0]) has been utilised extensively and with good 
reproducibility in dynamic PET studies to quantify normal tissue and tumour 
blood flow in vivo using an input function derived from continuous arterial 
sampling over the period of imaging (Anderson et al, 2002; Beaney et al, 1984; 
Ijammertsrna, 1987; Wilson 19()2). PISTT bloocl Gow scans have contrilbuted 
to the clinical evaluation of a novel antivascular agent, Combretastatin A4 
Phosphate (CA4P), a tubulin binding agent, which induces rapid and selective 
blood flow reductions in experimental tumour systems by possible cytotoxic 
effects on proliferating endothelial cells (Chaplin et al., 2002; Dark et al., 1997; 
Prise et al., 2002; Tozer et al., 1999). 8 patients treated with CA4P in a phase 1 
trial had PET scanning before, 30 minutes and 24 hours after the first 
infusion of CA4P. Results showed a 30-60% temporary reduction in tumour blood 
flow at the higher dose level of CA4P, corroborating data obtained in animal 
studies (Anderson et al, 2003; Griggs et al, 2001). 
3.3 Gene Expression 
Remarkable progress in genetic engineering has been made to develop and clarify 
knowledge about cascades of gene expression and interaction between gene and 
gene products. This has been accompanied by the exciting prospect of gene 
manipulation in cancer treatment by either transferring appropriate genes into 
abnormal cells or by detection of endogenous gene expression for clinical 
translation and diagnosis (Gillies, 2002). However, without improving the ability 
to monitor and quantitate the degree of gene expression, which can currently only 
be achieved with biopsy specimens, the field of gene therapy would continue to 
face significant obstacles for routine use. Imaging gene expression is important 
for monitoring the location(s), magnitude and time variation of gene expression 
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from gene-therapy vectors, and can be important to measure efficacy of treatment 
and to answer questions pertaining to optimisation of treatment (Blasberg, 2002): 
1. Has gene transfer been successful? 
2. Is gene expression localised to the target tissue or organ, and is this 
optimal? 
3. Is there sufficient transgene expression to obtain a therapeutic effect? 
4. Are there any unwanted toxicities resulting from gene expression? 
5. When pro-drug treatment is to be initiated, when is the most effective time 
to commence it? 
6. How long does the gene expression persist in the target or any other 
tissues? 
Two major approaches have been developed for monitoring gene expression using 
PET methodology; 
(i) Direct imaging of endogenous genes or molecules 
(ii) Indirect imaging, where there is 'linking' of the expressed therapeutic 
gene to a 'PET reporter gene' which 'reports' back on the status of 
expression of the gene of interest when properly linked. 
3.3.1 Direct Imaging 
Direct imaging of gene expression can be accomplished by developing 
radiolabeled probes that bind selectively to highly specific regions of the product 
of the expressed gene (e.g. protein, mRNA, or DNA) (Tavitian, 2000; Tavitian et 
a l , 1998). However, the advancement of this method of gene expression imaging 
IS limited by the lack of specific and suitably labelled PET probes currently 
available (Younes et al, 2002). 
3.3.2 Indirect Imaging 
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More progress has been made with indirect imaging of gene expression utilising 
reporter genes despite its greater complexity (Tjuvajev et al, 1995). Indirect 
imaging falls into two distinct categories; enzyme-based or receptor-based. In 
both cases, indirect imaging involves simultaneous expression between both the 
reporter gene and therapeutic gene product after construction of a cassette linking 
these genes that can be transacted into specific cells using a vector. This can be 
achieved in several ways: 
• A single vector encoding for both transcribed genes in one mRNA, which is 
then translated into 2 proteins, labelled via an internal ribosome entry site 
(IRES) sequence (Pelletier et al, 1988). 
An inducible bi-directional vector can be used which initiates the transcription 
of both the therapeutic and the reporter gene. 
• The reporter and therapeutic gene can be delivered using 2 separate vectors. 
• A ftision protein containing both the therapeutic and reporter protein can be 
used. 
All of these approaches are dependent on having a useful PET reporter gene and 
radiolabelled probe (Gambhir, 2002). The paradigm for enzyme-based gene 
expression is the herpes simplex virus type 1 thymidine kinase gene (HSVl-tk), 
and is illustrated in Fig 8. The HSVl-tk gene encodes for the enzyme, HSVl-TK 
that can phosphorylate radiolabelled derivatives of thymidine (e.g. iodinated 2'-
fluoro-2'-deoxy-l-p-D-arabinofuranosyl-5-iodo-uracil or ['^'^I]-F1AU) which acts 
as the PET probe after transportation into cells. In cells where HSVl-TK has 
been expressed, the radiolabelled phosphorylated probe (i.e. ['^''l]-FIAU (PO4)) is 
effectively 'trapped' (as it does not readily cross the cell membrane), and so 
accumulates within the cell, emitting a radioactive signal that reflects level of 
HSVl-TK enzyme activity and HSVl-tk gene expression (Tjuvajev et al., 1995). 
The HSVl-tk gene vector with ['^^I]-FIAU as the tracer has imaged gene 
expression in the liver and in transfected tumour cells (Gambhir et al., 2000). 
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1. Gene delivery of 
2. Reporter gene HSVl-tk transfected into 
target cell by vector 
mRNA HSV-tk 
4. Radiolabelled 
probe, [• IJ-FIAU, 
enters cell 
3. Translation of mRNA 
HSV-tk at ribosome 124 
HSVl-TK 
N HSVl-TK enzyme 
124 
[ I]-FIAU (PO4) 
5. Phosphorylation of [' I]-F1AU 
by HSVl-TK to [* I]-F1AU (PO4) 
Figure 8: Diagram illustrating the paradigm of imaging gene expression with 
the PET reporter gene, HSVl-tk 
Where gene expression uses the model of receptor imaging, the reporter gene is a 
cell surface receptor that 'binds' (and may internalise) the complimentary 
radiolabelled PET probe in the transduced cell. An example of a receptor PET 
reporter gene is the dopamine type 2 receptor (DR2) (MacLaren et al, 1999) 
which has been validated in animals. Other reporter genes including those that 
encode stomatostatin receptor (Rogers et al., 1999) and Na/I symporter (NIS 
gene) (Groot-Wassink et al., 2002) have been examined in preliminary studies. 
All of these PET reporter genes work on the premise of binding to a suitable 
radiotracer producing sufficient, proportional accumulation of PET signal within 
the region for further analysis. 
Studies in imaging reporter-gene expression in human subjects have only recently 
started. The HSV-1 tk gene vector can also be used as a therapeutic 'suicide' gene 
in combination with the pro-drug, ganciclovir. In this scenario, a cell expressing 
HSV-1 TK enzyme will commit suicide on exposure to ganciclovir under 
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appropriate conditions (Moolten, 1994). To assess the extent of gene expression 
and predict therapeutic potency, intratumoural liposomal HSV-1 tk gene vector 
was infused into recurrent glioblastomas of 5 patients (Jacobs et al, 2001). 
Dynamic PET scannmg with ['^'^IJ-FIAU was performed at baseline and after 
gene vector application and ganciclovir treatment commenced 4 days after vector 
infusion. Results showed that in 1 in 5 of patients there was accumulation of 
IJ-FIAU activity within the observed tumour after HSV-1 tk inftision, and this 
corresponded to an area of intratumoural necrosis on an FDG-PET scan 
performed after ganciclovir treatment. These preliminary findings show that non-
invasive FIAU-PET imaging of HSV-1 tk expression is feasible in patients and 
that vector-mediated gene expression may predict therapeutic effect. 
3.4 Markers of Hypoxia 
Tumour hypoxia, resulting from inadequate and chaotic blood supply to 
neoplastic tissue, is an important prognostic indicator and a crucial factor in 
cancer therapy outcome to radiotherapy and some chemotherapy treatments. 
Oxygen mediates the biological effects of ionizing radiation and the response of 
cells to radiation depends strongly on the availability of oxygen. This 'oxygen 
effect' was first recognized by Mottram (Mottram, 1936) in 1936. Gray (Gray et 
a l , 1953) studied the influence of oxygen in mammalian tissue in detail and 
discovered that typically, hypoxic cells were 2.5-3 times more radioresistant than 
well-oxygenated cells. Assessment of tumour hypoxia prior to radiation therapy 
would provide a rational means to identify the outcome of radiation therapy in 
patients and to offer alternative radiotherapy strategies that may be more effective. 
Preliminary clinical studies with Eppendorf p02 histographs have shown 
significant correlation between median pO: of tumours and their response to 
therapy (Brizel et al, 1999; Brizel et al., 1995; Hockel et al., 1996). However, 
limitations of microelectrode probes to measure tumour hypoxia are that it is 
invasive, has poor reproducibility, can only access superficial tumours and may 
overestimate degree of hypoxia in necrotic tissue (Khali 1 et al., 1995). 
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PET imaging bU m ^ 2 aa%pnes: 2-
nitroimidazole analogues and non-nitroimidazole agents. 2-nitroimidazole 
analogues contain a nitro group that can bind covalently to cellular molecules 
upon reduction in hypoxic cells e.g. ''fluorine-labelled misonidazole 
([ ^FJFMISO). Non-nitroimidazole markers such as Cu(II)-diacetyl-bis(7V^-
nwd^^aiosemicambamK) (Cu-ATSMD, zms a ccrnqdec of copper 
bis(thiosemicarbazones) that rely on the reduction of chelated metal for their 
selective deposition in hypoxic tissue (Lewis et al, 1999). 
In PET, the most experimental and clinical experience of hypoxic imaging has 
been gained by studying ['^FJFMISO (see Fig 9a). 
NH 
Figure 9: (a): ['*F]MISO; (b): ['TIFETA 
[ F]MISO has been shown to accumulate in hypoxic tissue in an inverse 
proportion to tissue oxygenation (Yeh et al., 1996). Under hypoxic conditions the 
rate of ['^FJMISO binding can be up to 28 times than in normoxic cells (Rasey et 
al, 1989). Subsequent biodistribution studies defined hypoxia as tissue-to-blood 
[ ' 'F]MIS0 ratio of 1.4, 2 hours after radiotracer administration (Rasey et al, 
1989). In a study of 37 patients with lung, head and neck and prostate cancer, 
hypoxia was present in 97% of the tumours studied and the extent of hypoxia 
varied markedly between tumours in the same site or of the same histology. 
Hypoxia was also distributed heterogeneously between regions within a single 
tumour. The intra- and intertumour variability indicate the importance of making 
oxygenation measures in individual tumours and the necessity to sample as much 
of the tumour volume as possible (Rasey et al., 1996). However, there are 3 main 
problems with imaging with ['^FJMISO: 
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(i) There is lack of contrast between tumour and normal tissue uptake of 
[•^F]MISO due to poor cellular uptake of ['^FJMISO in vivo (Lewis et 
a/., 2001b). 
(ii) [ FJMISO is cleared from normal tissue over a 2 hour period. These 
slow kmetics delay imaging and result in low count rate studies with 
images of reduced quality (Lewis et al, 2001b). 
(lii) High rates of metabolism of ['^FJMISO limit its use to permit 
quantitative analysis (Varagnolo et al, 2000). 
Current research has reported on the synthesis of a new 2-nitroimidazole 
Guometamdamk (['^^FETA) (Fig 6b), a rnmwGuonmmd 
congener of etanicbzole. ['SFjFET/Ldernondraks mcygen-depemde^ binding and 
retention in tumours that are very similar to that for [ 'V]MISO in vitro, and may 
offer the advantage in imaging hypoxic tumours because it is less rapidly 
metabolised in vivo and has had validation studies recently performed in mice 
(Barthel et al, 2004). In addition brain-to-blood ratios indicate that ['^FJFETA 
readily crosses the blood-brain barrier and may have a role in assessment of 
gliomas (Rasey etal.,\999). 
The latest development in nitroimidazole imaging of hypoxia with PET is fluorine 
-labelled 2-(2-nitro-l[H]-imidazol-l-yl) - N-(2,2,3,3,3-pentafluoropropyl)-
acetamide (['^F]-EF5). In rat tumour models, ['^F]-EF5 distributed evenly in 
normal tissues with higher uptake in tumours visualized. Again, activity was 
located in the brain, and plans are underway to initiate a research project to 
determine the safety and preliminary evidence for the efficacy of this preparation 
in patients with brain tumours (Ziemer et al., 2003). 
Several recent studies have concentrated on the use of Cu-ATSM as a hypoxic 
marker. Cu-ATSM is retained in ischaemic tissue but rapidly diffuses out of 
normoxic tissue and uptake has been correlated with tumour pO; in small animal 
models (Lewis et al, 2001a). Compared with ['^FJMISO, Cu-ATSM exhibits 
more efficient uptake and superior washout kinetics in hypoxic and normoxic 
cells with higher contrast levels obtained 10-15 minutes post injection. The 
positron emitting isotope ^^CU-ATSM has been used to predict response in 
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patients with NSCLC with encouraging results (Dehdashti et al, 2003). Systems 
aretKA%,ck%%dopedtoint%pMA:ChtVlTSA4ckliiK:ata 
and dehvermg higher doses of radiotherapy to these smaller subvolumes using 
intensity modulated radiotherapy (IMRT) (Chao et al, 2001). 
3.5 Receptor Detection and Drug Interactions 
Advances in tumour biology characteristics have revealed that many cell-surface 
and intracellular receptors are upregulated in cancer cells. The detection of these 
receptors can provide important information that can aid diagnosis and prognosis. 
As they are often the targets of inhibitory effects of hormones and growth factors 
that exert their therapeutic effect by interacting with these receptors, identification 
might help in selection of patients suitable for hormonal therapy and in assessing 
response. PET can be used to image relevant receptors and study drug-receptor 
interactions in vivo with either appropriately radiolabeled receptor binding 
hormones or antibodies, avoiding the necessity of recurrent invasive tumour 
biopsies which may also be prone to errors of tumour sampling. Receptor studies 
can either be direct (labelling the molecule of interest) or indirect (displacement of 
radioligand by the molecule of interest). The regional kinetics of radioligands can 
be used to derive values for receptor number (B^ax), affinity (Kd) and binding 
potential (B^ax/Kd) (Cunningham VJ. et al, 1994). With the production and 
availability of radioligands of different receptors in various types of cancers, (e.g. 
breast, prostate, and neuroendocrine), receptor studies are now being performed in 
oncology. 
3.5.1 Oestrogen 
The most extensively studied receptor is the intracellular steroid oestrogen 
receptor (ER). 16a-['®F] fluoro-17p-oestradiol (FES), an oestrogen analogue has 
been widely used to assess ER status in breast tumours in vivo (Figs 10a and b). 
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HO 
Figure 10 (a): Oestrogen 
OH 
HO 
(b): 16a-[ F] fluoro-17P-oestradiol (FES) 
(}o()d overall a;sreeinent between ejc IiR assziys arid FE!S upkike lias led to liie 
conclusion that FES-PET provides direct information on ER status (Dehdashti et 
(zA, 1()95). clecresise in the uptzUce ofl^IiS in inetastatic breast (larwiers alter the 
administration of tamoxifen has been visualised, demonstrating the presence of 
functional oestrogen receptors in the tumour (McGuire et al, 1991). The 
reduction in FES uptake after tamoxifen was significantly greater in patients who 
responded to hormonal therapy (Dehdashti et al, 1995). A ftirther study 
correlating ER status with treatment response observed a group of patients with 
IiR. p()sid\re l)iopsies biit FE!S riegative PET scans whc) had ]po()r resjporise tc) 
hormone therapy, suggesting identification of a subset of patients with hormone 
refractory disease despite ER positive biopsies (Mortimer et al., 1996). FES-PET 
imaging has therefore opened up an intriguing new way to monitor receptor 
fimction and response to hormonal therapy in patients with breast cancer at a 
cellular level (Flanagan et al, 1998). In addition, FES has also been utilised in 
meningiomas where FES uptake correlated with in immunohistochemichal 
measurement of ER status from biopsies (Moresco et al., 1997). 
3.5.2 Androgen 
The androgen receptor (AR) is a key biomolecule in the biology of prostate cancer 
and has been targeted by PET for radiolabelling and subsequent imaging to aid 
diagnosis and therapeutic planning. '^F has been used to label several hormone 
analogues including 16p-['^F]fluoro-5a-dihydrotestosterone (FDHT), 16p-['^F]-
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substituted testosterone, 16a- and 16p-['«F]7a-methyl-nortestosterone, 20-
[' 'F]fluoro-R1881 (metribolone) and 20-['«F]fluoromiboloerone (Bonasera et al, 
1996; Liu et al., 1992). In man, AR expression has been studied with PET using 
FDHT. In a group of patients with progressive androgen independent prostate 
cancer, the majority of active lesions were visualised with FDHT using PET 
imagmg. The impact of the expression of the AR on response of individual lesions 
to AR targeted anti-cancer drug therapies is being explored (Larson, 2002). 
3.5.3 Neuroendocrine 
Neuroendocrine tumours expressing stomatostatin receptors have been imaged 
using PET with radiolabelled ocreotide, a stomatostatin analogue. ®'*Cu-labelled 
octreotide PET scanning has shown promising results in patients with carcinoid 
and islet cell tumours (Anderson et al., 2001). Ga l l ium- and '^Gallium-labelled 
octreotide analogues are currently undergoing imaging trials in patients and 
ZLoimajs, respecth/ely (Heiize ef (dL, 2()01; IJ&jr ef a/., 20()2). ['*F]fluor()-ethyl_ 
siperone, a PET tracer with a high affinity for D: dopamine receptors has been 
used to image non-fUnctioning pituitary adenomas to distinguish them from 
craniopharyngiomas and meningiomas, in vivo, which do not possess these 
receptors (Lucignani et al, 1997). 
3.5.4 Epidermal Growth Factor 
Epidermal growth factor receptor (EFGR) is frequently overexpressed in 
malignancies. Strategies to target EGFR include monoclonal antibodies to prevent 
hgand binding and small molecule inhibitors of the tyrosine kinase activity to stop 
autophosphorylation and downstream intracellular signalling e.g. gefitinib. (Van 
de Wiele et al., 2003a). A preliminary in vitro study has successfully prepared 
[ C]-6-acrylomido-4-(3,4-dichloro-6-fluoroa-nilino)quinazoline (ML03) as a 
potential PET biomarker for EGFR (Ben-David et al, 2003). In vivo visualisation 
of EGFR expressing tumours could allow for non-invasive patient selection and 
response assessment for those undergoing such treatment. 
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3.5.5 Antibodies 
Antibodies are also a potential tracer for targeting cell-surface receptors. Although 
primarily explored for imaging with gamma cameras and SPECT, newer small-
animal studies and clinical trials are starting using positron-labelled antibody 
fragments. Monoclonal antibodies developed against specific antigen targets are 
problematic because their relatively slow clearance from blood leads to images 
with very high background signals, even up to one week after injection. 
S;yskmiadc(xms&waon a ^ i m e n d a^Aody fngnxmb b r &g. C E A h ^ 
dkvebfXKLTniou^i they have lass afGnity to CEVlantgen, they are rnom n%,idly 
cleared m blood because of their smaller size. Humanised versions of these 
aiginesfedaKdbodies have been bbeUedwith7*bmrnkie and and mouse 
tumour xenografts imaging has been performed with micro PET (Lovqvist et al, 
1995; Lovqvist er a/., 1997; Wu g/ a/., 2000). 
Radiolabeled antibody fragments have also been developed to identify the cell 
surface antigen receptor to C-erb2, a proto-oncogene product, that has prognostic 
and therapeutic implications in breast cancer, with '^'^iodine for PET imaging 
(Bakir et al, 1992). Again, this may assist in targeting appropriate patient therapy. 
3.6 Apoptosis 
Deregulation of cellular proliferation and suppression of mechanisms controlling 
programmed cell death (apoptosis) are believed to be important preliminary 
molecular events in the development of cancer (Evan et al, 2001). Therapeutic 
strategies in cancer treatment are commonly mediated by initiation of apoptotic 
pathways, and apoptosis is thought to be the likely mechanism behind the 
cytoreductive effects of standard chemotherapy and radiotherapy regimes. A 
measure of apoptosis is desirable to predict and monitor tumour response to 
therapy. An early occurrence in the apoptotic cascade is the selective exposure of 
phosphatidylserine (PS) on the external surface of the cell; PS is a membrane 
associated intracellular phospholipid normally expressed internally on the plasma 
bilayer membrane (Blankenberg et al, 2000; Verhoven et al, 1999). 
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ReKxmnbmamthiKnan/lnnexm V O-h-Aimexin)/), m endogenous protein, has been 
shown % binderncUyto nK%nbran&.tKnmd])S (vanBkxxde 1995) and was 
kibdlai^nkiaUy wiA fliKwescem for«, g* Wvo apoptotic assays, butthe^ 
with "^Technetium ( ' '"Tc-Annexin V) to permit imaging of apoptosis in vivo 
usmg single photon emission tomography (SPECT) (Blankenberg et al, 1998; 
Blankenberg et al., 1999). A recent study in 15 patients (with lung, lymphoma and 
breast cancer) evaluating early response following 1 cycle of chemotherapy by 
'""Tc-Annexin V imaging found no uptake of "^Tc-Annexin V in tumour pre-
chjmotherapy. However, 1-3 days post-treatment, 7 patients showed uptake of 
**"Tc.Aanexin at tumoiw shes, mvyhom4 had compJek re%)om;eand 3 had 
ixirdatreisponse aaiciorrelated wilii FI)(3_])ET acid (yi irnaiges. C^oiiversely, 6 oiit()f 
8 patients with no significant post-chemotherapy uptake of ^"^""Tc-Annexin V had 
progressive disease. The 2 breast cancer patients demonstrated poor tracer uptake 
but actually had partial response suggesting selective use of ^"^'"Tc-Annexin V 
apoptotic imaging in lymphoma and lung follow-up only (Belhocine et al, 2002). 
tlowever, ^"Tc.^^Kiexin SPECTT zmalysis relies on visual hiterpretadon ()f 
static and planar images, resulting in qualitative or semi-quantitative data. Current 
developments are emerging to radiolabel Annexin V with iodine 124 (Glaser et 
a/., 2()03) arid fluorine 18 (Zijlstra ef a/., :20()3) f()r use as potential a]]opt()tic 
probes in PET studies. This will have the added advantage of not only allowing 
quantitative analysis but also producing dynamic, 3-D images. These radiotracers 
are being validated in pre-clinical studies, and will be of greater benefit in 
assessing the efficacy of treatment options at an early time point. 
3.7 Other Applications of PET Imaging 
3.7.1 Choline 
Alteration of choline metabolism, a constituent of the phospholipid bilayer cell 
membrane, has recently been evaluated as a marker of malignant transformation 
(Aboagye et al, 1999). Extracellular choline is phosphorylated to phosphocholine 
by choline kinase after it is transported into cells. This commits choline to 
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growth and essentially 'traps' the extracellular choline within the cell, hence its 
attraction for PET imaging. Whilst little is known of the mechanisms that regulate 
chohne kinase activity or phosphocholine production, choline kinase 
dysregualtion is frequently found in a variety of human tumours such as lung, 
colorectal and prostate tumours and increased activity of choline kinase is found 
in panels of human cancer-derived cell lines compared to non-malignant cells 
(Ramirez de Molina et ai, 2002). This has supported the role of PET imaging 
with radiolabelled choline as a tumour marker. 
Clinical studies have been conducted with methyl-"carbon (methyl-["C]) labelled 
choline. It appears to be of particular interest in urological tumours where methyl-
[ C]-choline has higher uptake in bladder and prostate cancer than ['^F]FDG (de 
Jong et al, 2002a; de Jong et al, 2002b; Picchio et al, 2002). In addition, better 
visualisation is obtained of urinary tract malignancies as there is minimal renal 
excretion of the tracer (de Jong et al, 2002b). 
Another study has compared methyl-"C-choline uptake with histopathological 
specimens and gadolinium enhanced MRI, in 22 patients with brain tumours. The 
niethyl-"C-choline PET scans differentiated between high and low grade gliomas, 
and areas of methyl-"C-choline accumulation were larger than areas enhanced 
with MR in some patients. However, methyl-"C-choline was unable to 
distinguish low grade gliomas from benign lesions (Ohtani et al, 2001). This 
suggests that a combination of methyl-"C-choline PET scanning and MRI will 
allow more accurate diagnosis of high grade gliomas. 
3.7.2 Multi-Drug Resistance 
Acquired multi-drug resistance (MDR) represents a major cause of chemotherapy 
failure in cancer treatment with certain classes of drugs, in particular, compounds 
such as anthracyclines, vinca alkaloids and taxanes (Bellamy et al., 1990; Zijlstra 
et al., 1987). The molecular mechanism for this resistance has been identified as 
overexpression of the P-glycoprotein (Pgp), a plasma membrane transporter. 
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encoded for by the MDR gene (Germann et al, 1993; Gottesman et al, 1993). 
These proteins reduce intracellular accumulation of cytotoxic agents and diminish 
further using radiolabeled pharmaceuticals, in conjunction with strategies to 
decrease the activity of Pgp. Technetium-99m Sestamibi (^^"'Tc-Sestamibi), a 
substrate for P-gp, hais been utilised in SHPIBCT stuciies to iniage tlie blo(:kade of the 
Pgp-mediated transport after suppression of the Pgp pump (Hendrikse et al, 
1999). In vivo PET studies involved in evaluation of MDR have been confined to 
eiqpenirientidicMi in aiiinials. ' 'cait)ori([''(]]_) labeUed ckiigs siich aus' '(Z-T/erapwarnil 
aiid ''(ZHckwumorulbicin (Elshiga ef <,/., 19!)6) awid ''(Z-cokhicine (lLe\rchenlco ef a/., 
2000) have been investigated and are additional tools for the quantification of 
Pgp-mediated transport with PET. A potential use of such agents would be to 
select patients who could benefit from the addition of Pgp modulators which are 
being designed (Brady et al., 2001). 
3.8 Summary 
Huge advances have been made in molecular science to determine the complex 
processes underlying tumour biology with abnormal cellular and molecular 
pathways are being targeted to provide a novel and rational basis for cancer 
treatment. A fundamental change in the requirements of imaging is required to 
meet the current challenges posed by these new treatment strategies in cancer 
medicine and molecular imaging with PET is a valuable technique that can 
address many questions related to this emerging field. 
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Chapter 4 Methodology 
4.1 Introduction 
This chapter will describe the steps involved in the production of radionuclides, 
the scanning procedure and data acquisition that were required for the studies in 
this thesis. The methodology presented here is common to all studies but any 
deviations from the protocol will be outlined in the relevant chapters. 
PET requires an expert, multi-disciplinary team and contributions made by other 
clinicians, chemists, physicists and technicians to the study are credited in the 
'Acknowledgements' section. 
All PET scans were performed in IMANET (formerly MRC) Cyclotron Building, 
Hammersmith Hospital, London, UK. 
The projects reported in this thesis and radiotracers required for each are listed 
below: 
1. Carbogen and nicotinamide modulation of 5-FU Pharmacokinetics and 
Perfusion. 
• 5-['^F]FU and H2[ ' '0] 
2. Interferon-a modulation of 5-FU Pharmacokinetics and Perfusion. 
• 5-['^F]FU and C['^0]2 
3. Thymidine to Assess the Pharmacodynamic End-Point of Anti-Cancer 
Drugs. 
• 2-["C]thymidine, H2['^0] and H["C]03 
4.2 Ethics and ARSAC Approval 
All study proposals were approved by the Hammersmith and Riverside Hospitals 
NHS Trust Research and Ethics Committee by for careful consideration and 
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alteration if necessary, before obtaining approval to commence the project and 
recruit patients. Permission was also granted from the Administration of 
Radioactive Substances Advisory Committee (ARSAC, UK) for the 
administration of radionuclides to ensure that the biological effective dose (BED) 
of radioactivity in the study was appropriate and relevant to the hypotheses being 
pursued in the studies. 
4.3 Production of Radionuclides 
The positron-emitting radionuclides required for PET imaging are produced by 
bombarding stable elements with high-energy beams of ionic particles accelerated 
by a cyclotron. Proton (p) bombardment of a nitrogen target results in the 
production of carbon-11 (["C] for thymidine studies) and an alpha (a) particle. 
Oxygen-15 (perfusion studies) results from deutron bombardment of a nitrogen 
target and fluorine-18 (for pharmacokinetic modulation studies) from proton 
bombardment of an oxygen target. Both reactions produce neutrons (n) in addition 
to the radionuclide. The nuclear reactions are summarised in Table 4.1. 
Table 4.1: Summary of Nuclear Reactions for Production of Radionuclides 
used in the Studies 
Nuclear Reaction Radiolabelled Compound Produced 
' 'N(p,n)"C ["C] bicarbonate 
["C] thymidine 
'^N (d,n) " 0 ['^0] water 
['^0] carbon dioxide 
'"0 (p,n) ["^F] 5-fluoruracil 
The Imanet Cyclotron Unit has two cyclotrons in use. The Scaditronix MC40 MK 
II cyclotron has a variable particle and energy machine capable of accelerating 
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helium-4 and helium-3 nuclei, protons and deutrons to produce several 
ra&onudides("c, "p, "N, T^ is hw now k:en replaced by Ae GE 
system. The second cyclotron is the smaller Cyclone 3D IBA cyclotron that is 
used only for the production of on-line '^0-labelled compounds (carbon dioxide, 
C[*^0]2 and water, H2['^0]). 
4.4 Radiopharmaceutical Production 
All radiopharmaceuticals in this study were produced on site using remote 
handling apparatus or automated synthesis techniques to ensure operator safety, as 
starting activities were high, at > lOOGBq. 
4.4.1 5-[ FJFluorouracil 
In both 5-FU modulation studies, [ 'Vjfluorine produced in the cyclotron was 
passed through a suspension of the precursor, uracil (in acetic acid), which after 
rotatory evaporation (to remove acetic acid), was washed with ethanol (which was 
then evaporated). After the addition of KH2PO4 the mixture was heated and 
mjected onto a high performance liquid chromatography (HPLC), from which the 
5-['^F]fluorouracil peak was eluted and filtered using Millipore® (see Figure II 
below). 
This method, developed in the Cyclotron Unit by Dr Gavin Brown (Brown G. et 
a l , 1993) gave reliable yields of 5-['^F]fluorouracil with high radiochemical 
purity and specific activity. 
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5-['^F]fluorouracil 5-fluorouracil 
Figure 11: Radiosynthesis of 5-['*F] 
fluorouracil 
4.4.2 H2['®0] and C['^0]2 
Radiolabelled water (H2['^0]) was produced in a lead-shielded bed side unit by 
mixing [^^O] from the cyclotron with hydrogen over a palladium catalyst in an 
oven at 150° C. The gaseous output is led through a semi-permeable membrane on 
the other side of which is sterile saline which leads to the production of aqueous 
O], which can then be given as an intravenous infusion. 
For C[ 0]2 production the ['^O] is exposed to a mixture of nitrogen and 1% CO2 
to produce radiolabelled carbon dioxide (C['^02]). 
4.4.3 2-[ CJthymidine 
Cyclotron produced ["C] was exposed to a mixture of nitrogen and 5% hydrogen, 
to form [''C]methane. From this, dry urea (the precursor of thymidine), is made 
by a number of steps via the production of phosphogene. 2-["C]thymine is 
converted to 2-[''C]thymidine by a process of simple acid neutralisation, which is 
performed at room temperature (Steel et al, 1999). 
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4.4.4 ["CJHCOa 
Carbon dioxide (["CjOz) was produced after bombardment of nitrogen containing 
1% O2 with protons. ["CjOz from the cyclotron was then bubbled through an 
aqueous mixture of sodium bicarbonate for injection (8.4% BP) diluted with 
isotonic solution for approximately 2 minutes. The resulting solution was 
radiolabeled sodium bicarbonate (["C] sodium bicarbonate). 
4.5 Quality Control 
Radiotracers were transferred directly to the Quality Control (QC) laboratory after 
production to ensure the radiotracer fulfilled all the predetermined specifications 
required for injection or inhalation by the patient. Initially the radiotracer (5-
[^^FJfluorouracil or 2-["C]thymidine) was analysed by HPLC and spectrometry to 
check for radiochemical purity. Any stable (i.e. non-radioactive) compounds were 
noted as well as the presence of other known or unknown impurities. 
Radioactivity was measured using a calibrated ionisation chamber. The 
radiotracer was then injected through a disposable filter in an exclusion chamber 
to obtain a sterile injectate. The pH of the radiotracer was quantified using pH 
indicator strips. Pyrogen assessments were performed after every 10 
radiopharmaceuticals productions retrospectively using the Limulus amoebocyte 
lysate (LAL) pyrogen test. 
["CJHCOa and C['^0]2 were tested for radiochemical purity and [ "c jHCOs and 
H2['^0] were tested for pH. 
Only if the radiotracers met all the stringent requirements were they released for 
clinical injection or inhalation. 
4.6 Quality Assurance 
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Each radiotracer had a detailed sheet listing every chemical necessary for its 
production and the conditions required to ensure stability (e.g. temperature, pH, 
during every run of radiotracer production. 
Patient Recruitment and Preparation 
Patients were recruited from Oncology out-patient clinics or wards at Charing 
Cross or Hammersmith Hospitals after permission from the Consultant Oncologist 
supenismg die patients' treatment. Chtheinkid meeting vwththe pnwpecdve 
patient details of the study and procedures were discussed and an information 
sheet given to them with a contact number for the investigators in case of ftirther 
queries. At least 24 hours were given to allow for a decision to be made regarding 
participation. A similar procedure was undertaken for the study not conducted by 
the author. A consent form was signed by each patient for participation in the 
study with the understanding that the patient was free to withdraw from the trial at 
any time. All scans were performed as an out-patient at the Cyclotron Unit, 
Hammersmith Hospital, London, UK. 
Each patient had a recent, diagnostic imaging scan (either CT or MRI) at the time 
of recruitment and this was used to locate the selected area to be scanned by PET. 
The central plane of this region was identified by x-ray simulation and was 
marked by a skin tattoo. The patients lay supine on the PET couch and were 
positioned by matching the skin tattoo to laser beams in the scanner. Patients were 
made comfortable on the scanning table with bolsters for knee supports and had 
the choice of listening to music or lying quietly. Patients were advised to keep still 
for the duration of the scan and were monitored by close circuit cameras to 
monitor any movement, which was documented as necessary. Before the 
radiotracer scan, a 20 minute transmission scan was performed for correction of 
tissue attenuation. 
Prior to the scan patients had a 21 gauge Venflon inserted into their radial artery 
after performing the Allen's test to ensure patency of the ipsi-lateral artery and 
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infiltration of the skin with 1% bupivocaine for local analgesia. In the contra-
lateral arm, a venous Venflon was inserted for radiotracer administration. 
or in combination with unlabelled drug. 
4.8 PET scanners 
Studies were performed on two PET scan machines. Both 5-['^F]FU modulation 
studies were carried out on the ECAT 931 scanner and the 2-["C]thymidine study 
on the ECAT 962 HR+ scanner. 
4.8.1 ECAT 931 Scanner 
The ECAT 931-08/12 PET scanner (CTI/Siemens , Knoxville, TN, USA) obtains 
images in a 2 dimensional (2D) mode and consists of eight rings of bismuth 
germanate (BGO) detectors which allow simultaneous acquisition from fifteen 
planes of data, eight from coincidences in the same plane (direct) and seven from 
coincidences in adjacent planes (cross). Each ring contains 512 BGO detector 
(4 096 m k)td), of the bUowing dimenwom;: 5.6nnn Ommsadal), 
12.9mm (axial) and 30mm (depth) and is separated from its neighbour by annular 
lead-tungsten septum with a retractable transmission source. Though the septa 
result in reduced camera sensitivity, they reduce registration of random and scatter 
coincidences and detector dead time. The axial field of view (FOV) is 10.8cm. 
4.8.2 ECAT HR 962 Scanner 
The ECAT EXACT HR+ 962 (CTI/Siemens, Knoxville, TN, USA) can acquire 
images in either 2D or 3D modes, but in the thymidine study only the 2D mode 
was utilised. The ECAT HR+ has 4 rings of detector blocks, with 8 rings of 
detector blocks each i.e. 32, with arrays of 8 x 8 elements each. Each ring block 
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has 72 blocks, composed of 576 elements, giving a total of 18 432 elements in all. 
Each element has dimensions of: 4.05mm (transaxial), 4.39mm (axial) and 30mm 
(depth). Again, each element is separated from its neighbour by annular lead-
tungsten septum with a retractable transmission source. Furthermore, when the 
HR scarmer is operated in a 3D mode, the septa can also be removed. Images are 
simultaneously acquired in 63 planes, with an axial total detector length (FOV) is 
15.5 cm. The transaxial FOV is 58.3 cm, with each detector element in 
coincidence with 288 elements i.e. half a ring. 
4.9 Tissue Acquisition Protocols 
Data from the dynamic PET scans were collected into specific time frame 
protocols for each radiotracer for the duration of the scan. At the beginning of the 
scan, time frames were short to permit sufficient temporal resolution of the early 
and rapid tissue activity. In the latter stages of the scan, time frames were longer 
to allow adequate and reliable counting from the detector system to maximise 
spatial resolution. This was because decay of the isotope contributes to poor 
counting statistics that occur particularly at the end of the study, and in order to 
reduce this effect, longer time frames are required at later time points. 
Patients had the 10 minute perfusion scans (H2['^0] or C['^02]) first, followed by 
the 5-['^F]FU, with a predetermined delay of 10 minutes between them, to ensure 
maximum decay of any residual H2['^0] (ti/2 = 2.03 minutes) radioactivity. 
Scanning protocols for radiotracer in each study is outlined below. 
4.9.1 Carbogen and Nicotinamide Modulation Study 
The perfusion study used H2['^0] which was produced by a bed-side water 
generator and injected as a 20 second automated infiision followed by a 2 minute 
flush. The infusion was preceded by a 30 second background acquisition frame 
(see Table 4.3) and the scan lasted 10 minutes. 
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Table 4.3: Hif O] Scan Frame Protocol 
Frame number Frame duration 
(seconds) 
1 30 
2-18 5 
19-21 10 
22-26 30 
27-32 60 
5-[ F]FU was combined with unlabelled 5-FU producing approximately lOmls of 
mixture which was injected over 30 seconds. Again, this was preceded by a 30 
second background frame with shorter frames initially followed by frames of 
longer duration. The 5-['^F]FU scan lasted 90 minutes. 
Table 4.4: 5-['^F]FU Scan Frame Protocol 
Frame number Frame duration 
(seconds) 
1 30 
2-10 30 
11-15 60 
16-20 120 
21-25 180 
26-31 600 
4.9.2 Interferon-a Modulation Study 
This study was performed in 1991 to 1992 by Dr Robert Harte and differs from the 
current protocols used in the other two studies. 
Perfusion was measured using €[ '^0]] (subsequently replaced by H2['^0] since 
1997 for ease of administration) and delivered via a light face mask (MC™ 
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oxygen mask, Henley's medical, Welwyn, UK) at an activity of 4MBq/ml and a 
constant flow rate of 500 ml/min for 5 minutes. The scan lasted 10 minutes and 
time frames are shown below. 
C[ ' '02] is rapidly converted to H2[' '0] after inhalation by the action of carbonic 
anhydrase present in red blood cells making it a suitable radiotracer for measuring 
perfusion. 
Table 4.5: C[^^02] Scan Time Frames 
Frame number Frame duration 
(seconds) 
1 30 
2-7 5 
8-13 10 
14-19 20 
20-21 10 
22-23 20 
24-27 30 
28-30 60 
5-[ F]FU was administered as a 30 second bolus either alone or in conjunction 
with unlabelled 5-FU. The scan lasted 60 minutes and time frames are given 
below. The fi-ame timings are slightly different from those in the carbogen and 
nicotinamide modulation study above. In the latter study, there is better temporal 
resolution of earlier data and a longer acquisition time as the 5-['^F]FU scanning 
protocol was refined. 
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Table 4.6: 5-[ F]FU Scan Frame Protocol 
4.9.3 2-["C]thyinidine Study 
Frame number Frame duration 
(seconds) 
1-10 30 
11-15 60 
16-20 120 
21-25 180 
26-30 300 
2-["C]thymidine was injected as a bolus over 30 sec after a 30 sec background 
scan. The scan lasted 60 min and the frames and durations are shown below. 
Table 4.7: 2-[''C]thyinidine Scan Frame Protocol 
Frame number Frame duration 
(seconds) 
1 30 
2-10 30 
11-15 60 
16-20 120 
21-25 180 
26-30 300 
After a 20 minute delay to allow for radioactive decay of 2-[' 'CJthymidine (ti/2 = 
20.4 min) the 2nd radiotracer, ["CJHCOs, was injected as a 30 second bolus. 
Frame details are given in Table 4.8 and were designed to detect early rapid 
delivery of tracer to tissue followed by a plateau phase. Total scanning time was 
62 minutes. 
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Table 4.8: [ CJHCOs Scan Frame Protocol 
Frame number Frame duration 
(seconds) 
1 30 
2-7 30 
8-13 10 
14-19 20 
20-25 30 
26-29 300 
30-33 600 
4.10 Tissue Data Calibration and Reconstruction 
Acquired coincidences described above were stored as two-dimensional matrices 
referred to as a sinogram. However, before reconstruction the sinogram data had 
to be corrected to take into account factors such as detector non-uniformity of 
response, scatter and attenuation of photons within the body, random counts and 
dead time correction and calibration. 
4.10.1 ECAT 931 PET scanner 
On this scarmer normalisation factors were calculated on a daily basis after the 
acquisition of a 'blank' scan and used to correct for detector non-uniformity. The 
20 minute transmission scan performed with the patient in position on the scanner 
before radiotracer administration was used as a ratio with the 'blank' scan to 
provide a factor for tissue attenuation. Both transmission and 'blank' scan were 
performed using eight retractable ^^Ge sources encased in steel rings. No scatter 
correction was applied to images acquired on the ECAT 931 machine. 
Sinograms were reconstructed into tomographic images using a filtered back 
projection technique after transfer to Sun SPARC^ Workstations (Sun 
Microsystems, Mountain View, CA, USA). A Hann filter with 0.5 of the Nyquist 
frequency was used as cut-off for reconstruction of the images. After 
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reconstruction each frame was presented as a 128 x 128 pixel image, with a voxel 
dimension of 2.1 mm x 2.1 mm. Spatial resolution of the final reconstructed 
image was 8 mm (FWHM) at the centre of the FOV with slice thickness of 
6.4mm. 
Tissue data was calibrated to obtain quantitative data. Calibration was checked 
every 3 months by scanning a ^^Ge containing phantom over a weekend and 
comparing radioactivity concentration obtained from the tomograph with that 
measured in a cross calibrated well counter. 
4.10.2 ECAT HR+ 962 PET scanner 
Again, normalisation factors were calculated on a daily basis after the acquisition 
of a 'blank' scan and used to correct for detector non-uniformity. The 20 minute 
transmission scan performed as on the ECAT 931 scanner. 
As described above, sinograms were reconstructed into tomographic images using 
a filtered back projection technique after transfer to Sun SPARC® Workstations 
(Sun Microsystems, Mountain View, CA, USA) using a ramp filter. After 
reconstruction each frame was presented as a 128 x 128 pixel image, and using a 
zoom factor of 2, the in plane voxel size is 2.62 mm x 2.62 mm. Spatial resolution 
is 8 mm at the centre of the FOV. Slice thickness is 4.2 mm (FWHM) at the centre 
of the FOV and 5.2 mm at a 10 cm radius. 
4.11 Blood Data Acquisition 
Arterial blood samples were obtained from the indwelling radial catheter. Arterial 
blood sampling gives the closest approximation of the delivered concentration of 
radiotracer and metabolites to the capillaries in tissue. 
Continuous blood sampling was performed for the duration of the scan using a 
peristaltic IVAC® pump which drew blood from the patient via a short length of 
plastic tubing (PTFE) to a calibrated BGO scintillation detector, to obtain a 
continuous measure of whole blood radioactivity (Ranicar ASO. et ai, 1991). The 
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pump was set at different rates according to the radiotracer injected (see Table 4.9 
below). 
Table 4.9: Pump Settings for Radiotracers Used in the Studies 
Radiotracer Pump Velocity and Duration 
H2['^0] • 5 ml/min for 10 min 
C['-'02] • 5ml/min for 10 min 
5-['''F]FU (Carbogen and Nicotinamide 
study) 
• 5 ml/min for first 10 min 
• 2.5ml/min for last 80 min 
5-[^''F]FU (Interferon-a study) • 5 ml/min for first 10 min 
• 2.5ml/min for last 50 min 
2-["C]thymidine • 5 ml/min for first 10 min 
• 2.5ml/min for last 50 min 
["CJHCOs • 5 ml/min for first 10:30 min 
• 2.5ml/min for last 51:30 min 
The continuous blood sampling was interrupted at specific times to collect 
discrete blood samples of approximately 5 ml each down stream from the BGO 
counter through a 3-way tap, according to the radiotracer injected. 
83 
Table 4.10: Pump Settings for Radiotracers Used in the Studies 
Radiotracer Time of Discrete Sample(s) After Scan 
Start 
H2['^0] 6 min 
C[^'02] 6 min 
5-["'F]FU (Carbogen and 
Nicotinamide study) 
5, 10, 15, 30, 45, 60, and 90 min 
5-['^F]FU (Interferon-a study) 5, 10, 20, 30 40 and 60 min 
2-[''C]thymidine 1.30, 2.30, 3, 6, 7.30, 9, 15, 30 and 60 min 
["C]HC03 1.30,5, 10:30,15,30 and 60 min 
The discrete blood samples were collected for several purposes; (1), to determine 
the partitioning of radioactivity between whole blood and plasma, (2), to analyse 
the percentage of radiolabeled parent and metabolite in the plasma (where 
necessary) and (3), to calibrate the radioactive counts of the continual on-line 
system. In addition, in the 5-['^F]FU (carbogen and nicotinamide study), each 
discrete blood sample was analysed for haematocrit, p02 (mmHg), pC02 
(mmHg), glucose (mmol/1) and pH using an AVL electrolyte analyser (AVL 
Medical Instruments UK Ltd). In the 5-[ 'V]FU studies, the initial discrete 
samples were obtained as drip samples to prevent disruption of the rapidly 
altering early continuous radioactive counts. 
The start and finish of collection of the discrete blood samples was documented 
by the press of a foot switch attached to a computer, which recorded times from 
scan start. The mid-withdrawal time was single point taken to represent sampling 
time. All samples were corrected for radioactive decay, counter dead time, 
background activity, sample volume and density. 
To preserve the patency of the arterial cannula during the scan, 10 ml of 
heparinised saline was periodically used to flush the indwelling Venflon. This 
involved suspending the on-line radioactivity counts for approximately 15-30 
second whilst injecting the flush. 
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Regular calibrations were performed on the well counters, BGO detectors and 
PET cameras to produce quantitative blood data. 
4.11.1 Metabolite Analysis of Discrete Blood Samples 
Metabolite analysis was necessary immediately after collection due to the short 
ti/2 of the radiotracer employing on-site technicians and facilities. After 
centrifugation of discrete samples, metabolite analysis was performed on the 
plasma samples obtained using HPLC, and was monitored by ultraviolet (UV) 
absorbance and radioactivity detection. The UV and radioactivity detectors were 
connected to a PC-based integrator (Labchrome software; Lablogic), which 
enables correction for background activity, radioactive decay and can calculate 
peak area for both radiolabelled parent and metabolites. 
4.11.2 5-['®F]FU analysis 
5-[ F]FU is metabolised to various cytotoxic anabolites and catabolised 
principally to the inactive a-fluoro-P-alanine or FBAL (see Chapter 5). To 
measure the contribution of parent 5-['^F]FU radioactivity alone, the plasma samples 
were processed and analysed. Each plasma sample was deproteinised with ice 
cold methanol and then centriftiged again. The supernatant was concentrated by 
rotatory evaporation and the residue dissolved in HPLC mobile phase and filtered. 
The filtrate was analysed on a reverse-phase Ci8|J.-Bondapak column (300 x 7.8 
mm; 10 ^m), using a mobile phase comprising 5mM octane sulphonic acid and 
phosphoric acid (pH = 3.0), delivered at a flow rate of 3ml/min, to identify and 
quantify parent 5-['^F]FU. 
4.11.3 2-["C]thymidine metabolite analysis 
2-["C]thymidine is rapidly degraded to four main metabolites: thymine, 
dihydrothymine (DHT), P aminobutyric acid and finally, carbon dioxide 
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([ C]02). The main metabolite is [''C]02, which accumulates in blood and 
expired air and is the major labelled metabolite signal in tissue. Its contribution to 
the blood signal was measured in discrete samples using Shields' method (Shields 
AF. et al, 1998b). An aliquot of blood is taken from the discrete sample and 
mixed with sodium hydroxide, which traps the ["CJOa, such that all the 
radioactivity is attributable to ["C] (Ctotai). A second aliquot of blood is taken 
from the same sample to which isopropanol is added, following which the mixture 
is acidified with hydrochloric acid and nitrogen bubbled through it to release the 
available [ C]02 (Crem)- From this, the percentage of [' 'CJOi (Ccoz) in the sample 
can be given as: 
Cc02 ~ Ctotai " Crem/ Cjotal 
Parent radiotracer and remaining radioactive metabolites were quantified in a third 
aliquot of blood by removing plasma proteins by mixing with methanol, which 
extracts 98% of the radioactivity into the methanol supernatant. This supernatant 
was then concentrated and the residue containing 2-["C]thymidine and 
radioactive metabolites was injected onto a HPLC column, analysed and 
quantified. 
4.11.4 Processing Blood Data 
From the arterial blood data, the following measurements were made: 
• a continuous measure of total blood radioactivity collected on-line from 
the patient for the entire scan 
• a measure of the portioning of radioactive counts between plasma and 
whole blood at certain time points, which does not remain constant 
through the study, but is dependent on the radiotracer 
• a measure of the plasma parent and metabolite radioactivity at certain time 
points 
From these measurements it is possible to derive plasma activity of (?) from 
whole blood at time (t) by the following equation; 
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P( t ) = PBR,ounts(t) X W B ( t ) 
Where, PBRcounts(t) — ratio of radioactivity in plasma/ radioactivity in whole 
blood, at time (t) and WB (t) = radioactivity in whole blood from on-line counter, 
at time (t). 
A continuous plasma input function could then be generated. This first required 
the continuous radioactivity count to be modified to remove the discontinuations 
incurred from flushing the catheter, as described previously. This was corrected 
for by linear interpolation between the gaps where radioactivity count recording 
were interrupted. The plasma input function was generated with in-house software 
GENIF (Version 3, MRC UK) using the continuous radioactivity curve and 
plasma/blood radioactivity ratio. A continuous parent plasma input function could 
then be produced using the parent (and metabolite fractions if required) analysed 
also from discrete samples, with GENIF 3. 
4.12 Analysis of PET Tissue Data 
4.12.1 Tissue sampling and analysis 
Tumour and normal tissue were sampled using a 'Region of Interest' (ROI) 
technique on a Sun Solaris workstation (Sun Microsystems, Mountain View, CA, 
USA). To define a ROI on the PET image, a recent CT or MRI scan was used to 
assist delineation of tumour and normal tissue areas. The ROIs were drawn 
manually on composite PET images (or 'add' image) which were created from the 
summation of individual PET time frames for each plane. This produced less 
noise and gave better anatomical detail than separate frames from the dynamic 
scan. 
The ROIs defined on the composite image, the 'object map' was then applied to 
the dynamic scan for sampling, and the mean pixel radioactivity count from 
individual time frames was calculated, at the mid-frame time point. 
ROIs were analysed using Analyze® (Biomedical Imaging Resource, Mayo 
Foundation, Rochester, MN, USA). Statistics generated from this were used to 
produce independent dependent weight code (.idwc) for every ROI using 
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Interactive Data Language (ILL, Research Systems Inc) on which PET analysis 
could be performed. 
4.12.2 ROIs 
Accurate ROI definition is essential to avoid errors in sampling or blurring of 
edges due to partial volume effect. Manually drawn ROIs are prone to operator 
subjectivity though Harte et al (Harte R. et al., 1998) showed that inter-observer 
variations were small compared to actual differences between studies. 
To minimise sampling variability, certain principles were implemented when 
defining a ROI: 
• the top and bottom plane of the scan were not used for sampling 
• the same person drew all ROIs in the studies (i.e. the author) 
a ROI was defined according to anatomical information and not on 'hot' or # 
'cold' spots on the PET image. 
4.13 Modelling Of Tissue Data 
Analysis of tissue data alone is called semi-quantitative analysis and gives rise to 
standardised uptake value (SUV) and area under the curve (AUG) as described in 
chapter 3 and were obtained for both 5-['^F]FU and 2-["C]thyniidine. To derive 
these parameters, first a tissue radioactivity curve (TAG) was generated by 
plotting the mean tissue radioactivity versus mid-frame time (MFT) for each ROI, 
using Microsoft Excel software (Microsoft Corporation, USA). The TAG was 
corrected for radioisotope decay, injected dose and body surface area (BSA) for 
each patient. From this, an early time point of 3.75 min i.e. SUVg ygmin (m^/ml) 
was calculated to give a measure of delivery of radiotracer to tissue. AUG 
(m^/ml/sec) was determined by summating the mean radioactivity at all MFTs for 
the duration of the scan, to give a measure of tissue exposure to the radiotracer. 
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4.14 Modelling of Tissue and Blood Data 
4.14.1 Tissue Perfusion 
Tissue perfusion was quantified from the H2[0'^] and ["C]02 scans combining 
tissue and blood data by the dynamic flow method (see Chapter 3 for details) using 
GENIF3, an in-house software. Two parameters were obtained: flow, a measure 
of tissue perfusion (mlbiood/min/mltissue) and volume of distribution (Va; 
mlbiood/rnltissue); for tumour, spleen and kidney where possible. These parameters 
were also calculated for the liver, but give only an index of perfusion and V j as 
the liver has a dual blood supply (see Chapter 6). 
4.14.2 S-f'^FlFU Studies 
4.14.2.1 Patlak Analysis 
This graphical, non-compartmental modelling approach is discussed in detail in 
Chapter 2. As 5-['^F]FU is metabolised, the modified version of Patlak (Mankoff 
et al, 1996) was performed after generating a Patlak plasma input fimction 
(comprising cumulative parent 5 - [ '¥ ]FU and total 5-['^F]FU in plasma over time) 
and utilising tissue ROIs already obtained using in-house software. Kj 
(mlbiood/min/mltissue) was derived from this analysis and represents the net 
irreversible clearance of radiotracer form plasma into tissue and represents 
retention of radiotracer in tissue. 
4.14.2.2SpectraI Analysis 
This data-led modelling technique requiring few a priori assumptions is fully 
outlined in Chapter 2 and was performed using in house soft-ware. Spectral 
analysis was used to determine Ki (mlbiood/min/mltissue), which is the unidirectional 
clearance of radiotracer form plasma to tissue i.e. delivery of radiotracer to tissue. 
Ki was analysed using ROI data and two input functions: parent plasma and total 
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plasma, and is discussed in chapters 6 and 7. Fractional retention of 5-['^F]FU 
(FRF) was calculated from spectral analysis by dividing an early impulse response 
function (i.e. IRFimin) by a late IRF according to scan duration (i.e. IRFgomin or 
I R P e o m i n ) to exclude the influence of delivery of the radiotracer on retention. The 
permeability and surface area product (PS) a combination of two variables: 
capillary surface area and capillary permeability, was calculated from Ki and 
tissue perfusion. 
4.14.3 2-["C]thyinidine Study 
4.14.3.1SpectraI Analysis 
As mentioned previously, 2-[''C]thymidine is rapidly catabolised via a series of 
intermediate metabolites to ["C]02,the main metabolite. Whilst blood data can be 
corrected for the contribution of [''C]02, PET tissue data carmot distinguish 
radiolabelled parent from radiolabelled metabolites. This necessitates a tissue 
metabolite scan to provide information on tissue handling of and hence 
the [''CJHCOs was performed as a metabolite correction scan. Injected ["CJHCOs 
rapidly equilibrates with [ ' 'C]02 by the action of carbonic anhydrase (present in 
red blood cells) in the following equation: 
carbonic anhydrase 
["CJHCOa ^ • H20 + ["C]02 
Analysis of the 2-["C]thymidine is complex and will be discussed in depth in 
chapter 8. Briefly however, an IRF for the ["CjHCOg scan is derived as above, 
from which the metabolite contribution of ["CJHCOs is convolved using the IRF 
from the ["CJHCOs scan and the metabolite input function from the 2-
["CJthymidine scan. Subtraction of the tissue ["CJHCOs activity from the total 
tissue activity in the 2-["C]thymidine leaves tissue thymidine activity (and 
intermediate catabolites) only. From this, Ki and fractional retention of thymidine 
(FRT) using IRFimin/IRFeomin is calculated again on in-house software. 
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4.15 Statistical Analysis 
Statistical analysis was performed using STATA® version 5.0 software (Stata 
Corporation, College Station, TX, USA). In the 5-['^F]FU biomodulation studies 
data is presented as mean and standard error of the mean (SEM) and 95% 
confidence limits ([95%CI]). The null hypothesis of no difference between the 
paired studies after modulation was tested using the Wilcoxon matched pairs 
signed rank test. A probability of a p value < 0.05 was considered significant. The 
mean percentage difference was also calculated for paired data pre and post 
modulation. Within the same data sets, two different input functions were used to 
calculate parameters derived from spectral analysis. This was analysed using the 
Marm Whitney U test, a non-parametric test for unpaired data. 
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Chapter 5 PET Pharmacokinetics and 5-[^^F]fluorouracil 
5.1 Introduction 
Pharmacokinetics is the study of absorption, distribution, metabolism and 
excretion (ADME), processes that are responsible for the fate of the drug in the 
body. Drug studies to obtain tissue pharmacokinetics are conventionally acquired 
from serial plasma samples or urine collection which are analysed using sensitive 
and specific techniques such as high performance liquid chromatography (HPLC) 
and gas- or liquid spectrometry, from which tissue kinetics can be inferred. 
Alternatively, tissue biopsies can be performed to directly measure tissue 
pharmacokinetics. However, this is associated with several difficulties. Tissue 
biopsies, whether single or multiple, are not practical for clinical studies and may 
not even be possible in certain tumour sites, with the inherent problem of tissue 
heterogeneity present. Problems also exist in analysing multiple sites of disease 
and normal tissue such as kidney and liver. 
Radiolabelled 5-fluorouracil (5-FU) in the form 5-['¥]fluorouracil (5-['®F]FU) 
has been extensively studied in some centres using PET to derive tissue 
pharmacokinetics in tumour and normal tissues. This chapter will discuss 5-FU, 
its modes of action, metabolism, clinical results and need for manipulation to 
improve effectiveness. The background of 5-['^F]FU will also be discussed with 
particular relevance to its role in assessing the modification of 5-FU which will be 
discussed in subsequent chapters. 
5.2 5-Fluorouracil 
5.2.1 Mechanism of Action 
5-Fluorouracil (5-FU) is a cytotoxic chemotherapeutic agent that has been in use 
in clinical oncology for over 40 years (Schilsky RL. et ai, 2002). 5-FU has been 
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employed in the treatment of a wide range of cancers, including gastrointestinal, 
breast and most frequently, in colorectal cancer for which it is the single most 
important drug. 5-FU is a fluorinated pyrimidine that was developed following the 
observation that in rat hepatomas, the pyrimidine uracil was utilised more rapidly 
than in normal tissue, indicating that uracil metabolism was a potential source for 
antineoplastic chemotherapy (Rutman et al, 1954). 5-FU is classified as an anti-
metabolite due to its ability to inhibit biosynthetic processes and/or by its 
incorporation into DNA and RNA with disruption of their normal function. 
5-FU requires conversion to a number of nucleotides to exert its effect on DNA or 
RNA. After entering a cell using the same facilitated transport mechanism as 
uracil, 5-FU undergoes anabolism via a number of pathways (see Fig 12). 5-
fluorouridine-5'-triphosphate (FUTP) formed directly or indirectly is 
misincorporated into different RNA fractions (Shani et ai, 1984) causing 
impaired synthesis of RNA at several levels including errors of base pairing 
during RNA transcription. 
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FUR FUMP F U D P — • FUTP-
7 
RNA 
FUdR — • FdUMP - 4 — • F d U D P — • FdUTP 
4 \ 6 
DNA 
dUMP dTMP 
CHz-THF DHF 
dTDP dTTP 
Figure 12: Anabolism of 5-FU 
Enzymes: 1. Uridine Piiosphorylase; 2. Orotate phosphoribosyltransferase; 3.Thymidine 
Phosphorylase; 4. Thymidine kinase; 5. Thymidyiate synthase; 6. DNA polymerase; 7. 
Ribonucleotide reductase 
Co-factors: a. Phosphoribosyl pyrophosphate; b. ribose-1-phosphate; c. deoxyribose-1-phosphate; 
DHF: dihydrofolate; CH2-THF: 5,10-methylenetetrahydrfolate 
Abbreviations: FUR: 5-fluorouridine; FUMP: 5-fluorouridine-5'-monophosphate; FUDP: 5-
fluorouridine-5'-diphosphate; FUTP: 5-fluorouridine-5'-triphosphate; FUdR: 5-fluoro-2'-
deoxyuridine; FdUMP: 5-fluoro-2'-deoxyuridine-5'-monophosphate; FdUTP: 5-fluoro-2'-
deoxyuridine-5'-diphosphate; FdUTP: 5-fluoro-2'-deoxyuridine-5'-triphosphate; dUMP: 2'-
deoxyuridine-5'-monophosphate; dTDP: 2'-deoxythymidine-5'-diphosphate; dTTP: 2'-
deoxythymidine-5' -triphosphate 
It has long been recognized that inhibition of thymidyiate synthase (TS) by 
FdUMP is the principle mechanism of cytotoxicity of 5-FU (Danenberg, 1977). 
TS catalyses the reductive methylation of deoxyuridine monophosphate (dUMP) 
to deoxythymidine monophosphate (dTMP), with the reduced folate 5,10-
methylenetetrahydrfolate (CH2-THF) as the methyl donor and, as can be seen 
from Figure 12, this is a pivotal step in the synthesis of thymidine and eventually 
DNA. FdUMP forms a stable ternary complex with TS and CH2-THF thus 
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preventing the normal substrate dUMP, from binding to it (Santi et al, 1974). The 
exact molecular mechanisms that mediate events downstream of TS inhibition are 
not fully understood. Reduced levels of dTMP and subsequently dTTP induce 
imbalances in the pool of other deoxynucleotides (dATP, dGTP, dTTP). This 
disturbance is thought to disrupt DNA synthesis and repair leading to lethal DNA 
damage (Houghton et al., 1995). Furthermore, elevated levels of dUMP may 
result in an increase in deoxyuridine triphospahte (dUTP). Both dTTP and FdUTP 
can be incorrectly incorporated into DNA and if not successfully repaired, 
ultimately results in DNA strand breaks and cell death (Longley et al., 2003). 
5.2.2 Plasma Pharmacokinetics 
The plasma half-life of 5-FU is approximately 6 to 20 minutes though this varies 
between patients. After 6 hours of administration, plasma concentrations fall to 
below 1 nM, which is below the threshold for in vitro cytotoxicity (Abernethy et 
al., 1989) and can be detected for several days (Peters et al., 1993). Increasing the 
dose of 5-FU leads to a non-linear increase in plasma half-life probably as a result 
of saturation of metabolic or transport mechanisms. 5-FU clearance rates vary 
reflecting administration by intravenous bolus or as a continuous infusion. A 
linear increase in steady state concentration (C^) with dose is seen with protracted 
continuous infusions (Erlichman etal., 1986). 
5.2.3 Catabolism and Excretion 
Up to 80% of systemic 5-FU is primarily catabolised by dihydropyrimidine 
dehydrogenase (DPD) to a-fluoro-p-alanine (FBAL), urea and CO2 via 5-
fluorodihydrouracil (F-DHU). DPD is a NADPH-dependent, rate limiting enzyme 
and is involved in the degradation of other pyrimidine bases including 5-FU 
(Pinedo, 1988). The highest levels of DPD are found in liver (which contributes to 
the majority of 5-FU metabolism) and peripheral blood lymphocytes as well as in 
the kidney, intestine and lung with small amounts present in tumours (Naguib et 
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al, 1985). Variable levels of DPD are found in gastrointestinal mucosa which is 
likely to contribute to the high variability in bioavailabilty of oral 5-FU. In 
addition, DPD exhibits a circadian cycle and may be responsible for the 
differences in 5-FU clearance in 5-FU infusions. A small percentage of the 
population have a profound deficiency of DPD and experience severe toxicity 
with standard doses of 5-FU (Milano et al, 1994). FBAL is excreted in urine and 
has a plasma half-life of approximately 33 hours. 20% of 5-FU is excreted 
unchanged in urine and this is increased to 90% in those patients with DPD 
deficiency. 
5.2.4 5-FU and Use in Oncology 
5-FU has been used in the treatment of many tumour types including breast and 
gastrointestinal tumours. Although it dominates the treatment of colorectal cancer, 
the response rates when 5-FU is given as a single agent in advanced disease 
remains poor, at 15% (Cancer et al., 1992; Meta-analysis et al., 1998). This poor 
response rate has initiated research into approaches to increase therapeutic index. 
Increasing the plasma levels of 5-FU can improve response and survival in 
patients (Milano et al., 1994). However, additional improvements in 5-FU 
efficacy by increasing plasma drug levels further are limited by dose-limiting 
normal tissue toxicity, and other approaches for enhancing the efficacy of 5-FU 
are required. Strategies were therefore developed to address and attempt to 
overcome the pharmacokinetic restrictions of systemic 5-FU, namely short 
biological half-life and S-phase dependency, which limit the drugs exposure and 
tumour cell kill (Leichman, 1999; Lokich et al, 1989). Schedule alteration was 
one strategy employed to overcome this comparing intravenous bolus 
administration to continuous infusions of 5-FU. A meta-analysis examining this 
found response rates of 14% for bolus compared to 22% continuous infusion 
which also produced less toxicity, but overall survival rates were similar in both 
groups (Meta-analysis et al, 1998). Other tactics have explored chronomodulation 
(Levi et al, 1995) to coincide chemotherapy delivery with circadian variation in 
drug metabolism and cell cycle metabolism, but even though this approach has 
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produced superior results, the complexity of this technique has impeded clinical 
use. Another meta-analysis looking at biochemical modulation of 5-FU found that 
the addition of leucovorin or folinic acid, (which potentiates the inhibition of 
thymidylate synthase), doubled tumour response rates but without any substantial 
improvement in survival. This combination is now widely used as first line 
treatment in the adjuvant and metastatic setting (Cancer et al, 1992). Recent data 
suggest that combining 5-FU and folinic acid with irinotecan and oxaliplatin, two 
relatively new chemotherapy agents, lead to an increase in response rates with a 
modest but significant improvement in survival compared to 5-FU and folinic acid 
alone (de Gramont et al., 2000; Douillard et al, 2000; Saltz et al., 2000). 
There is still a continuing clinical need to develop strategies to enhance 5-FU 
efficacy. The following section will discuss the development of PET imaging of 
5-['^F]FU and the contribution it has made to understanding 5-FU 
pharmacokinetics. 
5.3 [ F] Radiolabelled 5-FU and PET Imaging 
5-[^^F]FU has been the most studied anti-cancer drug by PET in animals and man. 
One reason is that the chemical synthesis of 5-['^F]FU is fully automated, leading 
to rapid and efficient production of 5-[ ^F]FU with high specific activity and 
radiochemical purity (Brown G. et al., 1993). 5-['^F]FU has a favourable half-life 
of 110 minutes allowing kinetic studies to be performed. 
5-['^F]FU biodistribution was first measured in mice (Shani J. et al., 1977) with 
subsequent studies to establish 5-['^F]FU dosimetry and pharmacokinetics in 
humans (Shani J. et al., 1982). Harte et al has produced good reproducibility data 
for 5-['^F]FU kinetic studies (Harte R. et al., 1998), confirming that PET imaging 
could be used to monitor in vivo, 5-['^F]FU pharmacokinetics in tumour and 
normal tissue. 
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Pharmacokinetic studies with 5-[^^F]FU have shown a high signal intensity in 
normal liver which has been attributed to formation and retention of ['^FJFBAL 
from 5-[ F]FU metabolism in the liver . Analysis of arterial plasma confirmed the 
presence of 5-['«F]FU and high levels of [ 'VjFBAL in the circulation (Kissel et 
al., 1997). This is consistent with data obtained with 19F-magnetic resonance 
spectroscopy (19F-MRS) which detected high levels of FBAL in the liver (Brix 
G. et al., 1998). 5-['^F]FU PET scans have shown increased uptake in the kidney 
with time (Saleem A. et al., 2000), reflecting the established route of elimination 
of 5-FU and associated metabolites (Heggie G. et al, 1987). Dimitrakopoulou et 
al evaluated 50 patients with colorectal cancer and hepatic metastasis using PET 
scanning after infusion of 5-['^F]FU in which they demonstrated a low but highly 
variable uptake of 5-['^F]FU in the liver metastases (Dimitrakopoulou et al., 
1993). In addition they found a correlation between SUV at 20 minutes (reflecting 
5-FU transport or influx of drug) and SUV at 120 minutes (representing trapped 
5-FU). This was also significantly correlated with regional blood flow measured 
with '^0-water in a subgroup of patients. 
Similar results were found in a study using 5-['^F]FU PET scanning to assess the 
biomodulation of 5-FU pharmacokinetics by N-phosphonoacetyl-L-aspartate 
(PALA), folinic acid and a-interferon in tumour and normal tissue in patients with 
gastrointestinal malignancy. In this study by Harte et al, pooled data demonstrated 
a significant correlation between tumour blood flow, early tissue exposure 
(AUCgmin) and late tissue exposure (AUCeomins) of 5-['¥]FU, suggesting the 
importance of drug delivery in initial drug uptake and its intratumoural retention 
up to 1 hour after administration (Harte R. et al., 1999). 
A pharmacodynamic relationship between tumour uptake of 5-FU and response 
first seen in mice (Shani J. et al., 1977) has been reproduced in man using PET 
methodology. A group in Heidelberg found that colorectal liver metastasis with a 
high uptake of 5-['^F]FU at 2 hours, as indicated by a standardised uptake value 
(SUV) of more than 3, had a negative growth rate, whereas those with an SUV of 
less than 2, had tumour progression (Dimitrakopoulo-Strauss A. et al, 1998). This 
was further supported by work from Kissel et al who first demonstrated the ability 
to perform complex mathematical modelling on clinical oncology PET data to 
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obtain tumour and normal tissue pharmacokinetic parameters using a six-
compartment model to quantify intracellular 5-[' 'F]FU concentrations in hepatic 
rnelzLstases adReir 5.['8F]]FU PET scanruiig. TThis gproup foiincl die rate corustants for 
transport into (kin) and out (kout) of the intracellular compartment were the most 
sensitive parameters to describe tumour response. The criteria for 'trapping' of 5-
FU in tumours (kin > kout) was met in 6/27 metastases in patients receiving 5-FU 
and in 5/6 metastases showing 'trapping' of 5-FU, were in patients receiving 5-FU 
and folinic acid (Kissel et al, 1997). '^F MRS studies have validated the PET 
association of 5-FU trapping and tumour response by showing that an increase in 
mtra-tumoural half-life of 5-FU was correlated with clinical response in man 
(Presant C. et al, 1990; Presant C. et al, 1994). 
Saleem et al investigated the mechanism of action of eniluracil, a known 
mactivator of the proximal and rate limiting enzyme, dihydropyrimidine 
dehydrogenase (responsible for the degradation of 5-FU) using 5-['®F]FU PET 
scans (Saleem A. et al, 2000). In eniluracil-naiVe patients, there was strong 
localisation of 5-['^F]FU derived radioactivity in the liver as expected due to rapid 
formation and retention of ['^F]FBAL. Following eniluracil administration, there 
was a marked reduction in radiotracer uptake in the liver and kidney suggesting a 
decrease in production of FBAL due to eniluracil activity, which was corroborated 
by a corresponding increase in plasma uracil and unmetabolised 5-['^F]FU. In 
tumour, the half-life of 5-['^F]FU increased from 2.3 to over 4 hours after 
eniluracil administration. Following metabolite correction, the levels of 5-['^F] 
FU and anabolites in plasma were found to be higher after eniluracil treatment. 
This study provided proof of principle of the mechanism of action of eniluracil. 
The data was analysed further using spectral and Patlak models, which have less 
inherent assumptions than a compartmental approach, to calculate other 
pharmacokinetic parameters of 5-FU. Aboagye et al found that net clearance of 
5FU from plasma to tumour was 0.0033 ± 0.0005 mlp^ma/ min/ml,issue and was 
200-fold less than the initial (10 min) clearance through catabolism by the liver. 
This study has shown that the cytotoxicity of 5-FU in patients with gastro-
intestinal cancer could be compromised by its intrinsically low uptake by tumours, 
as well as decreased systemic availability from hepatic clearance (Aboagye EO. et 
a/., 2001). 
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In this thesis, PET imaging using 5-['^F]FU has been used to measure the effect of 
physiological (with carbogen and nicotinamide) and biochemical (with a-
mterferon) modulation on 5-FU pharmacokinetic parameters and will be discussed 
in the following two chapters. 
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Chapter 6 Carbogen and Nicotinamide Modulation of 5-FU 
6.1 Introduction 
Solid tumour masses typically exhibit abnormal blood vessel networks. The blood 
flow associated with this heterogeneous vasculature is often disordered compared 
with normal tissues because of a variety of functional and structural irregularities 
created in the malignant tissue by new vessel formation (Vaupel P. et al, 1989). 
This can substantially reduce perfusion in tumours which results in restricted and 
impaired drug delivery, and has been postulated as one reason for poor response 
rates of solid tumours to systemic chemotherapy (Siemann, 1998). Previous work 
by the MRC Hammersmith has underlined the importance of blood flow in 
determining initial 5-['^F]FU uptake and retention in tumour at 1 hour (Harte R. et 
al., 1999). Strategies to investigate improvements in drug delivery to tumours by 
altering tumour blood flow, without affecting systemic exposure to the drug, are 
being explored. 
Carbogen, a gas comprising either 95% oxygen and 5% carbon dioxide or 98% 
oxygen and 2% carbon dioxide, in combination with nicotinamide, the amide 
derivative of vitamin B3, have generated interest in this area. Carbogen and 
nicotinamide have so far primarily been used in conjunction with radiotherapy as 
an approach to reducing tumour hypoxia (Rojas A. et al., 1996), an important 
factor in cancer treatment resistance (Gray et al., 1953; Mottram, 1936), and for 
improving radiotherapy response (Bemier et al., 2000; Hoskin et al., 1999; Rubin 
et al, 1979). Whilst the use of carbogen and nicotinamide in radiotherapy stems 
fi-om their independent ability to increase blood oxygenation in tumours by a 
variety of pathways, using this combination as an adjunct to improving drug 
delivery lies in their probable inherently related mechanisms of action on blood 
vessels and tissue perfusion. 
Carbogen has been documented to have an influence on blood flow since 1967 
(Kruuv et al, 1967), and is generally considered to inhibit hyperoxia induced 
vasoconstriction by the action of the carbon dioxide component (Kety S. et al., 
1948) and to facilitate capillary recruitment (Chen J. et al., 1994) as a way of 
altering blood vasculature dynamics in normal tissues. There have been 
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conflicting reports on the outcome of carbogen breathing on blood flow in 
tumours. An overall increase in perfusion in implanted rat prolactinomas 
(Robinson et al, 1995; Robinson et al, 1997), chemically induced mammary 
cancer in rats (Robinson et al., 1997) and murine RlF-1 tumours (Honess et al., 
1995) has been observed. However, no changes in perfusion were documented 
using carbogen alone in other tumour models (Durm et al., 1999; Grau et al., 
1992; Hirst et al., 1994), or on microregional blood flow in advanced cancer in 
man (Powell MEB. et al., 1996). This infers that amongst other factors, tumour 
type dependence on carbogen may be relevant (Dunn et al., 1999) and also within 
the same tumour heterogeneity exists, with increases and decreases in blood flow 
observed in response to carbogen in the same tumour (Powell MEB. et al., 1996). 
Nicotinamide is thought to act by eliminating transient closure of vessels in the 
microvasculature thereby stabilising blood flow (Chaplin D. et ai, 1990; Hirst et 
al., 1994) and by decreasing interstitial fluid pressure (Peters CE. et al., 1997). 
Other theories have suggested that nicotinamide is implicated in modulating 
tumour metabolism following its conversion to nicotinamide adenine dinucleotide 
(NAD"^). NAD^ is a co-enzyme for over a 100 different dehydrogenases, which are 
responsible for many processes including oxidative metabolism and glycolysis. 
An increase in NAD^ could have secondary effects on tumour blood flow and 
oxygenation (Kaanders et al., 2002; Robinson et al., 2000). Again, there have 
been contradictory reports of the effect of nicotinamide alone on tumour 
perfusion. An improvement in blood flow was seen in murine squamous cell 
tumours (Chaplin D. et al., 1990). However, in radiation-induced fibrosarcomas 
(RlF-1) there was no change in blood flow with nicotinamide (Honess et al., 
1995) or in human tumours (Powell MEB. et al., 1997), though this may reflect 
the lower dose of nicotinamide that was used. Alternatively, nicotinamide may 
affect only small blood vessels that are too small to be visualised by these imaging 
techniques. Intermittent hypoxia only occurs in blood vessels < 0.1 mm (Kimura 
et al., 1996) and contribution to actual tissue perfusion may only be marginal, and 
hence unquantifiable, (Robinson et al., 2000), and may be complementary to other 
agents influencing blood flow. 
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As carbogen and nicotinamide appear to act independently of one another in 
manipulating blood flow, studies have focused on the combination of carbogen 
and nicotinamide to assess blood flow response. In superficial human tumours, 
carbogen and nicotinamide together increased blood flow by 20% compared with 
baseline values, as measured using Laser doppler probes (Powell MEB. et al, 
1997). This increase in blood flow suggests that carbogen and nicotinamide can 
act synergistically. 
In order to assess the effects of altering tumour blood flow on systemically 
administered chemotherapy, carbogen was administered to mice bearing 
subcutaneous RIF-1 tumours whilst receiving 5-FU chemotherapy (McSheehy et 
a l , 1998). The study found an increase in 5-FU uptake attributed not only to 
changes in tumour perfusion, but also to pH differences, resulting in an increased 
formation of anabolites detected by MRS and enhanced cytotoxicity in the larger 
tumours. 
To address the question whether a similar relationship exists in man, this study 
was conducted to investigate the effects of carbogen and nicotinamide modulation 
on 5-FU pharmacokinetics in patients with metastatic colorectal cancer. 
6.2 Study Aims 
The study aims were as follows: 
1) To investigate whether the combination of carbogen and nicotinamide 
modulated tissue perfusion in normal tissue and tumour in vivo. 
2) To establish if other physiological factors measurable in blood or by PET are 
altered in response to carbogen and nicotinamide. 
3). To investigate change in tumour and normal tissue handling of 5-['®F]FU 
when carbogen and nicotinamide are co-administered. 
6.3 Methods 
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6.3.1 Patient Selection 
Patients with metastatic colorectal cancer due to undergo first line palliative 
treatment with 5-FU/folinic acid chemotherapy attending the Department of 
Oncology at either Charing Cross or Hammersmith hospitals, were entered into 
this study. Patients all had imageable metastases > 2 cm in size in at least 1 axis of 
dimension, as measured on CT scan. 
Patients were excluded if they had a history of chronic obstructive pulmonary 
disease (COPD). These patients would not tolerate the high O2 content of 
carbogen as it would impair their hypoxic respiratory drive. Patients unable to 
consume oral medication were also ineligible as they would have been incapable 
of swallowing nicotinamide tablets. 
Eligibility criteria included a life expectancy of > 3 months, performance status > 
2 (Appendix A), satisfactory full blood count (FBC), with neutrophils > 1.5 x 10^ 
and platelets > 100 x 10^, and adequate renal and hepatic function (serum 
creatinine, < 1 2 5 pmol L' ' ; bilirubin < 17 mmol -L"'; and aspartate transaminase, 
< 35 |imol L"'). 
Ethics approval was obtained from the Hammersmith Hospital Research Ethics 
Committee and authorization for the use of radionuclides was given by 
Administration of Radioactive Substances Advisory Committee (UK). Patients 
were given information sheets (Appendix B) and a minimum of 24 hours to 
decide whether to enter the trial. Written consent for study participation was 
obtained. 
6.3.2 Study Design 
Patients underwent two PET scarming sessions coinciding with the start of two 
separate chemotherapy cycles (see Figure 13). Chemotherapy consisted of 5-FU 
plus FA given as either the de Gramont regime (FA 200 mg/m^ (maximum 
350mg) 2 hour infusion, 5-FU 400 mg/m^ bolus and 600 mg/m^ 22 hour 
continuous infusion, days 1 and 2, repeated every 2 weeks) or modified de 
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Gramont regime (FA 350 mg, 5-FU 400 mg/m^ bolus and 2,800 mg/m^ 46 hour 
continuous infusion, repeated every 2 weeks). Scanning was performed in the 
early afternoon to avoid diurnal variation in the metabolism of 5-FU (Harris BE. 
et ai, 1988). Prior to embarking on each scanning session, all patients had a FBC 
(as above) and clinical examination to ensure they were fit for chemotherapy. The 
first scanning session occurred on day 1 of the de Gramont regimen, and did not 
involve administration of nicotinamide and carbogen. The H2['^0] scan was 
followed by the 5-['^F]FU scan. 5-[^^F]FU was given concurrently with the 
administration of therapeutic 5-FU and injected as a 30 second bolus for the 90 
minute scan. The second scanning session occurred during a subsequent cycle of 
chemotherapy and patients were given 60 mg/kg nicotinamide orally 2-3 hours 
before scanning commenced. Carbogen (BOC Limited) inhalation began 5 
minutes before the start of both the H2['^0] and 5-['^F]FU scans and continued for 
a further 5 minutes during each scan. Patients breathed carbogen, comprising 95% 
oxygen and 5% carbon dioxide, delivered at 10 litres/minute through tightly 
fitting masks (Intersurgical UK cushion flex mask) which were strapped to the 
patients' faces using a two-tailed rubber harness (supplied by Mount Vernon 
Hospital, UK). The mask was attached to a two litre reservoir re-breathing bag 
and was connected to the gas cylinder via a one-way valve. 
['T15-FU + Day 1 5FU 
Session 1 
•Spssinn 1 
wmm 
Nicotinamide Carbogen 
% •• Start Stop Start Stop Start Stop 
Carbogen 
Figure 13: Study Design 
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6.3.3 Procedures 
Prior to the first scanning session patients had a pinprick tattoo appHed to their 
skin to ensure accurate and reproducible positioning on the ECAT 931 scanning 
couch. This was performed after simulation on a x-ray scaimer, using a recent CT 
scan for location of the metastasis. Patients were positioned in the scanner by 
matching skin marks with laser beams. 
On the patient's second visit to the scanner, they were aligned according to the 
tattoo, and a short transmission scan performed to ensure accuracy of position. 
For the duration of the scan, continuous arterial blood sampling and discrete 
samples were collected with an average total of 325 ml of blood taken per 
scanning session. Details of H2['^0] and 5-['^F]FU synthesis and scanning 
protocols are in Chapter 4. 
6.4 Data Analysis and Statistics 
Discrete blood samples were analysed using a blood gas machine to obtain pOi 
(mmHg), pCOi (mmHg), glucose (mmol/1) and pH. Cardiac output was calculated 
using the indicator dilution technique. This method has been adapted for use in 
dynamic PET H2['^0] scan (Yap JT. et al, 2000). The integral of the first pass 
arterial phase of the H2['^0] bolus was estimated by fitting the initial decline in 
the input function to a single exponential function. Cardiac output was calculated 
by dividing the integral of the 1st pass arterial phase by total radioactivity of 
injected dose. 
Regions of interest were drawn on each scan as previously described. 5-['^F]FU 
scans were analysed using a semi-quantitative technique in tumour, spleen, kidney 
and liver ROIs. Additional spectral and modified Patlak analyses were performed 
in tumour and spleen ROIs only. For spectral analysis, total plasma and parent 
plasma, to evaluate effect of metabolites, were used as input functions to calculate 
Ki, fracfional retention of 5- [ '¥]FU and permeability and surface area product. 
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H2[0^^] scans were analysed using the modified Kety-Schmidt equation (Wilson 
et al, 1992). Details of data analysis are given in Chapters 2 and 4. 
For statistical analysis, Wilcoxon signed rank test was used for matched pairs, and 
the Mann-Whitney test used for unmatched pairs. Data were also analysed using 
Pearson's correlation coefficient. All statistical tests were two sided and the 
significance level was set at <0.05. 
6.5 Results 
6.5.1 Patient characteristics 
8 patients entered the study (4 male and 4 female), with a mean age of 65 years 
(range 59-78 years). 5/8 patients presented with metastatic disease and had not 
previously received chemotherapy. Of the 3 patients who had been diagnosed 
previously, 2/3 had been given adjuvant treatment with a 5-FU based 
chemotherapy, but with a greater than 2 year gap elapsing before entering this 
study. 
2 patients did not complete the full study: 1 patient had disease progression and 
only had one cycle of chemotherapy; the other patient did not receive carbogen 
because of a high carboxyhaemoglobin level which is indicative of a being a 
heavy smoker and having sub-optimal respiratory function, although denying 
symptoms of COPD. 
6 patients underwent two PET scanning sessions, separated by a minimum of 2 
weeks and a maximum of two months. Clinical characteristics of these patients 
are given in Tables 6.1 and 6.2. 
All 6 patients tolerated breathing carbogen with only minimal discomfort 
experienced from tightness of the mask. A mean dose of 3530 mg of nicotinamide 
(range = 2820 to 4680 mg) was given with no side effects reported. 
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Table 6.1: Patient Characteristics 
Patient Patient Patient Primary Sex Age Body 
number scan scan site of (Years) surface 
number number disease area 
Pre C/N Post C/N 
1 p06479 p06490 colorectal M 74 1.7 
2 p06493 p06526 colorectal M 75 2 
3 p06538 p06550 colorectal F 59 1.43 
4 p06553 p06594 colorectal F 48 1.46 
5 p06588 p06606 colorectal M 52 1.68 
6 p06558 p06567 colorectal F 78 1.56 
Table 6.2: Regions of Interest Sampled 
Patient Metastases Size Regions sampled 
LK RK s L 
1 Liver: la 4cm V V V V 
Liver: lb 2cm 
2 Liver :2a 10cm V V V V 
Liver:2a 2cm 
3 Liver:3a 3 cm V V V V 
Liver: 3b 3 cm 
Liver:3c 3 cm 
Liver:3d 2cm 
4 Liver:4a 6cm V V V V 
Liver:4b 4cm 
5 Liver:5a 6cm V V V V 
Liver: 5b 3 cm 
Liver:5c 3 cm 
6 Lymph node:6a 2cm V V V V 
Lymph Node :6b 2cm 
kidney; S, spleen; L, liver; M, metastasis. 
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6.5.2 Scan Details 
Table 6.3 gives details of radionuclides and therapeutic 5-FU doses injected into 
individual patients. The mean injected activity of 5-[^^F]FU was 345 MBq (range 
1 3 6 ^ 0 3 MBq) and the mean injected dose of 5-FU was 380 mg/m^ (range 300-
400 mg/m^). In one patient (p06594) the injected dose of 5-['®F]FU was only 
135.6 MBq though this was deemed acceptable as her BSA was small at 1.46. 
Radiochemical purity was > 95.5% with the precursor uracil the only identified 
impurity. 
The mean injected dose of H2['^0] was 995.3 MBq (range = 880.6 - 1106.3 
MBq). 
There was a 36% (8/14 scans) failure rate in radiotracer production resulting from 
1/8 H2[^^0] and 7/8 5-['^F]FU production failures. 
Table 6.3: Scan Details for 5-'^F]FU and HifO'®] 
Patient Patient Bolus dose Injected 5-["F]FU H2[0"] 
scan number of 5-'*F]FU radiochemical activity 
number 5-FU activity purity (%) injected 
injected (MBq) (MBq) 
(mg) 
p06479 1 680 362.6 95^ 954.6 
p06490 1 680 380 9 9 j 999 
p06493 2 605 344 99.5 1006.4 
p06526 2 650 384.8 100 1043.4 
p06538 3 570 375 100 880.6 
p06550 3 570 403.5 100 939.8 
p06553 4 585 349^ 100 995.3 
p06594 4 585 135.6 100 1065.6 
p06588 5 670 373.7 100 976.8 
p06606 5 670 387.4 100 1106.3 
p06558 6 500 375^ 100 947.2 
p06567 6 500 395J 100 1028.6 
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6.5.3 Localisation of H2['^0] and 5-['®F]FU in Tumour and Normal Tissue 
Perfusion, uptake and localisation of 5-['^F]FU in different tissues were analysed 
by PET imaging. An axial CT scan and corresponding static images from H2['^0] 
and 5-['^F]FU scans pre C/N administration are shown in Figure 14. In the 5-
['^F]FU image, tissue radioactivity comprises fluorine-18-labelled parent 5-FU, 
anabolites and catabolites. As can be seen in both studies, hyperintense regions in 
normal liver and kidney probably represent the high blood flow to these organs as 
well as 5-['^F]FU metabolism (catabolism and excretion, respectively). On the 
other hand, liver metastases appear hypointense on both scans, indicative of poor 
tumour perfusion and inferior drug penetration. 
A) Typical transabdominal CT scan 
B) Perfusion scan and 
C) 5-['®F] FU drug scan, showing 
multiple liver metastases, liver, 
left kidney and spleen. 
Metastases 
Liver Spleen 
Metastases 
Left 
kidne\ 
Liver 
Figure 14: CT and PET Images 
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6.5.4 Physiological results 
The data show that in this study pOi increased 5 minutes after commencing 
carbogen inhalation (2-3 hours after nicotinamide) and after 10 minutes of 
carbogen inhalation blood pOi increased from 93 mmHg (range 77-117 mmHg) 
to 278 mmHg (range 213-319 mmHg), which was statistically significant (p = 
0.031). pOi levels decreased rapidly after cessation of carbogen breathing and 
were similar to pre-modulated levels within 5 minutes of stopping carbogen (see 
Figure 15). 
300 n 
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Data are mean ± SEM; C/N, carbogen and nicotinamide; number = 6 
Figure 15: Arterial p 0 2 before and after Carbogen and 
Nicotinamide 
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Though there was a slight increase in arterial pCO] in response to carbogen 
breathing this was not statistically significant (Table.6.5). 
In the 6 paired H2['^0] studies of cardiac output there was a non-significant 
reduction in values (p = 0.43) by 7 % after carbogen and nicotinamide (see Table 
6.4 below). 
Table 6.4: Values for Cardiac Output 
Patient Number 'Cardiac output pre C/N 'Cardiac output pre 
C/N 
1 Z79 2.69 
2 3.01 4 J 8 
3 128 2.41 
4 3.94 2.91 
5 3.66 Z73 
6 3jU 1 5 6 
, L/min; C/N, carbogen and nicotinamide 
The other physiological parameters measured showed minimal change with 
carbogen and nicotinamide (see Table 6.5). 
Table 6.5: Physiological Parameters 
Parameter Pre C/N Post C/N P value 
pOi (mmHg) 93.3 ±5 .7 
[79 to 108] 
278.2 ± 14.6 
[241-316] 
0.031 
pCOz (mmHg) 35.9 ± 1 
[33.3 to 38.4] 
3 6 J ± 3 
[30.6 to 42.4] 
^56 
Glucose (mmol/L) 6.2 ±0.58 
[4.3 to 8.0] 
6.2 ± 0.76 
[3.8 to 8.6] 
&86 
pH 7.45 ± 0.009 
[7.42 to 7.47] 
7.45 ± 0.02 
[7.40 to 7.50] 
1.00 
Cardiac output 
(L/min) 
3.42 ±0.18 
[2.93 to 3.90] 
3.11 ± 0.3 
[2.35 to 3.88] 
&43 
Data for p02, CO2, glucose and pH are for the 5 minute time point from scan start (i.e., after 10 
minutes of carbogen inhalation), the time at which the pOz values during the second scan were 
highest; C/N, carbogen and nicotinamide. Data are mean ± SEM [95% CI] 
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6.5.5 Perfusion and Volume of Distribution (Vj) 
Analysis of the H2[^^0] images yielded measurements of perfusion and the Va of 
water for ROIs drawn in tumour and normal tissues before and after 
administration of nicotinamide plus carbogen (see Figures 16 to 23 below). A 
summary of results is given in Table 6.6 
a) Tumour 
15 metastases were analysed: 13 liver and 2 lymph node metastases. One liver 
metastasis (lb) responded to treatment and became too small for analysis of 
perfusion and Vd after nicotinamide and carbogen. 
As expected, perfusion was lower in tumour than in normal tissues. Nicotinamide 
and carbogen administration led to an increase in tumour perfusion (Figure 16) in 
10/12 metastasis, with a mean increase of 56% (range -32% to +261%; f=.0024; 
n=12). There was no change in tumour perfusion in 1/12 liver metastasis. In 
contrast, perfusion decreased in the 2 lymph node metastases and 1/12 liver 
metastasis. 
Pre C/N 
Post C/N 
2b 3a 3d 4a 6a 6b 
LN LN 
l a 2a 
C/N; c a r b o g e n and nicotinamide 
Figure 16: Tumour Perfusion Before and After Carbogen 
and Nicotinamide 
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There was no statistical difference in tumour V j with pre carbogen and 
nicotinamide Vd of 0.78 ± 0.06 mlbiood/mltissue, and post carbogen and nicotinamide 
Vd of 0.73 ± 0.07 mlbiood/mltissue in the liver metastases. In the 2 lymph node 
metastases, Vd decreased after carbogen and nicotinamide. 
1.2 
1 
• | 0 .8 
0 . 6 -
& 0.4 
0.2 
0 
Pre C/N 
P o s t C/N 
1a 2a 2b 3a 3b 3c 3d 4a 4b 5a 5b 5c 6a 6b 
LN LN 
Metas tases 
C/N: c a r b o g e n and nicotinamide 
Figure 17: Tumour Vj Before and After Carbogen and Nicotinamide 
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b) Spleen 
Spleen had the highest organ perfusion pre and post carbogen and nicotinamide 
with values of 1.88 ± 0.41 mlbiood/min/mltissue and 1.78 ± 0.28 mlbiood/min/mltissue, 
respectively, with no significant difference. 
i j b f e r i • Pre C/N • Post C/N 
1 2 3 4 
Patient Number 
C/N: c a r b o g e n and nicotinamide 
Figure 18: Spleen Perfusion Before and After Carbogen and 
Nicotinamide 
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Spleen Vd was the same pre and post carbogen and nicotinamide, with values of 
0.94 ± 0.07 mlbiood/mltissue and 0.94 ± 0.41 mlbiood/mltissue respectively. 
& 
n Pre C/N 
• Post C/N 
3 4 
Patient Number 
C/N: c a r b o g e n and nicotinamide 
Figure 19: Spleen Vj Before and After Carbogen 
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c) Kidney 
In all 12/12 kidney ROIs sampled, perfusion decreased with a mean change of 
-43% (range -82% to -11%) post carbogen and nicotinamide. The result was 
statistically significant with jP=Q.0005. 
1 2.5 
E 2 
C 
% 1.5 
1 
E 1 
e o 0.5 
0 
0. 
• Pre C/N 
• Post C/N 
1 Rt 1 Lt 2 Rt 2 Lt 3 Rt 3 Lt 4 Rt 4 Lt 5 Rt 5 Lt 6 Rt 6 Lt 
Patient Number 
C/N: c a r b o g e n and nicotinamide Rt: right kidney; Lt: left Wdney 
Figure 20: Kidney Perfusion Before and After Carbogen and 
Nicotinamide 
Again, in all 12/12 kidneys sampled, Va decreased with a mean change of -17% 
(range -44% to 2%) and this was statistically significant with p = 0.001. 
E 
• Pre C/N 
• Post C/N 
1 Rt 1 Lt 2 Rt 2 Lt 3 Rt 3 Lt 4 Rt 4 Lt 5 Rt 5 Lt 6 Rt 6 Lt 
Patient Number 
C/N: ca rbogen and nicotinamide ^'Sht kidney; Lt: left kidney 
Figure 21: Kidney Vy Before and After Carbogen and 
Nicotinamide 
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d) Liver 
Hepatic perfusion index also decreased in all 6 patients with a mean change of 
-29% (range -42% to -8%). This was also significant with p = 0.031. 
E 
I 0.8 
• Pre C/N 
• Post C/N 
3 4 5 
Patient Number 
C / N : c a r b o g e n a n d n i c o t i n a m i d e Rt: right kidney; Lt, left kidney 
Figure 22: Liver Perfusion Index Before and After Carbogen and Nicotinamide 
Liver Vd index was not significantly altered after carbon and nicotinamide with p 
= 0.56. 
1 . 4 
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C/N: ca rbogen and nicotinamide 
Figure 23: Liver Vj Index Before and After Carbogen and Nicotinamide 
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Table 6.6: Summary of Results for perfusion and Vj for Regions 
Sampled 
Region Regional perfusion V j (mlbiood/tnltjssue) 
(mlbioo j)/min/mltissue) 
Pre C/N Post C/N P Pre C/N Post C/N P 
Liver 0.27 ± 0.03 0.36 ± 0.0024 0.78 ± 0.06 0.73 ± 0.52 
metastases [0.08 to 0.03 [0.53 to 0.07 
(n=12) 0.56] [0.13 to 
0.67] 
1.09] [0.41 to 
1.02] 
Lymph 0.87 ±0.06 0.35 ± N/A 1.04 ±0.01 0.7 ±0.01 N/A 
Node 
Metastases 
(n=2) 
[0.85-0.88] 0.002 
[0.35-
0.35] 
[1.04-1.06] [0.70-
0.71] 
Spleen 1.88 ±0.41 1.78 ± 1.00 0.94 ± 0.07 0.94 ± 1.00 
(n = 6) [0.82 to 0.28 [0.75 to 0.04 
2.94] [1.06 to 
2.50] 
1.14] [0.83 to 
1.04] 
Kidney 1.57 ±0.12 0.92 ± 0.0005 0.81 ±0.04 0.68 ± 0.001 
( n = 12) [1.30 to 0.12 [0.73 to 0.05 
1.80] [0.60 to 
1.20] 
0.90] [0.58 to 
0.79] 
* Liver 0.68 ± 0.09 0.46 ± 0.031 0.99 ±0.16 0.90 ± 0.22 
(n = 6) [0.40 to 0.09 [0.81 to 0.03 
0.96] [0.24 to 
0.67] 
1.81] [0.80 to 
0.99] 
Abbreviations; Vd, volume of distribution of water; n, number; C/N, carbogen and nicotinamide; N/A, not applicable 
*, index values for liver 
Data are mean ± SEM [95% CI]. 
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6.5.6 Semi-quantitative Analysis 
Figure 24 depicts characteristic time activity curves (TAC) for full dose 5-
[^^F]FU, corrected for injected activity and BSA, for the organs illustrated in 
Figure 14C, without carbogen and nicotinamide. Liver TAC showed a gradual rise 
and peak in 5-['^F]FU activity at around 30 minutes, attributed to the ability of the 
liver to convert intracellular fluorouracil to its catabolite a-fluoro-P-alanine 
(FBAL) as it is abundant in dihydropyrimidine dehydrogenase (DPD), the key 
enzyme in catabolism of 5-FU (Heggie G. et al, 1987). The decline in liver TAC 
reflects the slow release of ['^F]BAL back into the circulation. The early peak in 
kidney TAC indicates initial high delivery of 5-['^F]FU followed by a rapid 
decline probably representing saturation of metabolism of 5-['^F]FU by the 
kidney, which also possesses relatively high DPD levels (Heggie G. et ai, 1987). 
The curve is then followed by a gradual rise, as 5-['^F]FU is catabolised and 
excreted by this organ. The early peak in spleen TAC again indicates preliminary 
high delivery, followed by a reduction to a level sustained for the duration of the 
scan. This is consistent with both 5-['^F]FU and '^FBAL flowing freely through 
the spleen as the spleen does not participate in the metabolism of 5-FU. Finally, 
tumour TAC demonstrates a much smaller peak followed by constant levels 
suggesting trapping of 5-['^F]FU and anabolites. 
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Figure 24: Representative Tissue Activity Curves for (i) liver (ii) metastasis (iii) kidney and (iv) 
spleen 
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The early uptake of 5['^F]FU into tissues was measured at 3.75mins using 
SUVs jsmins to reflect predominantly delivery of the parent radiotracer (t,/2 = 5 to 
15 minutes (Presant C. et al, 1990) and has been calculated for tumour, spleen, 
kidney and liver. A summary of results is given in Table 6.7. 
a) Tumour 
A total of 14 metastases were analysed: 12 liver and 2 lymph node metastases. 
One liver metastases (3d) identified on CT imaging was poorly visualised on the 
5-['^F]FU scan and could not be analysed. As seen in the relevant TAG curves, 
pre carbogen and nicotinamide SUV3 ysmins was lower for tumour. SUV3 vsmins 
increased in 9/12 liver metastases after carbogen and nicotinamide with a mean 
1 2 1 
increase of 39%, which was not statistically significant at p = 0.064. In the 2 
lymph node metastases, there was no consistent change in SUVgjsmins after 
carbogen and nicotinamide. 
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C/N: c a r b o g e n and nicotinamide 
Figure 25: Tumour SUVa.ysmins Before and After Carbogen and Nicotinamide 
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b) Spleen 
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Figure 26: Spleen SUVa.-ysmins Before and After Carbogen and Nicotinamide 
There was no significant change in spleen SUVgjsmins post carbogen and 
nicotinamide in agreement with measurement of splenic perfusion. 
c) Kidney 
In 4/6 patients SUVsjgmins decreased after carbogen and nicotinamide in both 
kidneys. The mean reduction in kidney SUVa.ysmins was 45% and was statistically 
significant, p = 0.043. 
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Figure 27: Kidney SUVajsmin, Before and After Nicotinamide 
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d) Liver 
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Figure 28: Liver SUVa.YSmins Before and After Carbogen and Nicotinamide 
There was no significant change in hver SUVa.ysmins post carbogen and 
nicotinamide again in agreement with liver perfusion index. 
6.5.6.2 AUCgomins 
The area under the curve (AUG) over 90 minutes was calculated for each region, 
with and without the modulation of carbogen/nicotinamide .This represents tissue 
exposure to 5-['^F]FU for the period of the scan. A summary of results is given in 
Table 6.7. 
a) Tumour 
A total of 14 metastases were analysed: 12 liver and 2 lymph node metastases. As 
before, one liver metastases (3d) identified on CT imaging was poorly visualised 
on the 5-['^F]FU scan and could not be analysed As can be seen, there was no 
significant difference in the AUCgomins before or after administration of carbogen 
and nicotinamide. 
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Figure 29: Tumour AUCgomms Before and After Carbogen and Nicotinamide 
b) Spleen 
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Figure 30: Spleen AUCgomin: Before and After Carbogen and 
Nicotinamide 
AUCgomins for Spleen was the lowest, indicating poor retention of 5-['^F]FU. There 
was no change in AUCgomins in spleen after carbogen and nicotinamide. 
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c) Kidney 
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Figure 31: Kidney AUCgomins Before and After Carbogen and Nicotinamide 
Kidney had the second highest value for AUCgomins consistent with its role in the 
excretion of catabolites of 5-['^F]FU. There was no significant change in kidney 
AUCgomins after carbogen and nicotinamide. 
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Figure 32: Liver AUCgomins Before and After Carbogen and Nicotinamide 
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Liver had the highest AUCgomins, which is probably because of its role in 
catabolism of 5-['^F]FU. There was no change in liver AUCgomins after carbogen 
and nicotinamide. 
Table 6.7: Results for SUV3 ygmms and AUCgomin of 5-['®F]FU in Tumour, 
Spleen, Kidney and Liver Regions 
Region SUV3.75mins X 10"^  (m^/ml) AUCgomin (m /ml/sec) 
Pre C/N Post C/N P Pre C/N Post C/N P 
Liver 7.01 ± 8.32 ± 1.2 0.06 0.45 ± 0.41 + 0.32 
Metastases 1.3 [5.7 to 0.07 0.07 
(n - 12) [3.2 to 10.9] [0.28 to [0.25 to 
9.0] 0.60] 0.56] 
Lymph 9.02 ± 7.07 ± 1.2 0. 78 0.52+0.06 0.51+0.07 0.76 
Node 235 [5.6-6.3] [0.34- [0.32-
Metastases [10.6- 0.45] 0.47] 
(n = 2) 11.3] 
Spleen 12.3 ± 12.52 ± 0.84 0.25 ± 0.27 ± 0.84 
(n = 6) 0.83 0.95 0.014 0.04 
[10.2 to [10.1 to [0.21 to [0.17 to 
14.5] 15.0] 0.29] 0.37] 
Kidney 27.0 ± 17.7+1.4 0.04 1.29 + 0.2 1.21 ± 0.67 
(n = 12) 4.1 [15.0 to [0.86 to 0.14 
[18.0 to 21.0] 1.70] [0.89 to 
36.0] 1.50] 
Liver 15.89 ± 14.73 ± 0.44 1.62 + 0.1 1.62 + 0.56 
(n = 6) 1 0.8 [1.30 to 0.24 
[13.0 to [13.0 to 1.90] [1.00 to 
18.0] 17.0] 2.20] 
n, number; SUVs i^mms, standardised uptake value at 3.75 minutes; AUC,omm, area under the PET 
time activity curve; C/N, carbogen and nicotinamide. 
Data are mean ± SEM [95% CI]. 
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6.5.6.3 Relationship Between Tumour Perfusion and 5-['^F]FU Pharmacokinetics 
The relationship between tumour perfusion and 5-['^F]FU pharmacokinetics was 
studied in 11 Uver metastasis. 2 liver metastasis were not included as incomplete 
data had been obtained after carbogen and nicotinamide ( lb and 3d). 
Before intervention a significant correlation was found between SUV3jsmins 
(r=0.69, p=0.013) and AUCgomin (r=0.74, p=0.0167) and tumour perfusion. After 
carbogen and nicotinamide no correlation was seen with SUVsjsmins and tumour 
perfusion (r=0.09 p=0.53) or AUCgomin (r=0.18, p=0.38). 
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Figure 33: Correlation between perfusion and 
SUV3,75nim in Hvcr metastases (a) before and (b) 
after carbogen and nicotinamide 
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Figure 34: Correlation between perfusion and 
AUCwmins in liver metastases (a) before and (b) 
after carbogen and nicotinamide 
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6.5.7 Spectral Analysis 
Tissue fits and unit impulse response functions (IRF) were obtained from spectral 
analysis and are shown in Fig.35. IRF describes the time course of 5-['^F]FU in 
tissue that would be expected if it had been possible to deliver 5-['^F]FU 
instantaneously to the region of interest (Fig.35.c and f). The spectrum of kinetic 
results for a liver metastasis and spleen, shown in Figs.35.e and g reveal the 
number of kinetic components that adequately describe the data, and may 
correspond to the number of discrete tissue compartments that the PET technique 
can resolve, or reflect heterogeneity within the tissue. The speed of the dynamics 
increase from left to right and, in tumour and spleen spectrums, the right handed 
peak indicates the contribution of the delivery component. In tumour only is there 
a left handed peak, indicating trapping of 5-['^F]FU in tumour, as expected. The 
intermediate peak occurring in spleen may represent a discrete tissue compartment 
that exchanges reversibly with either plasma or other tissue compartments 
(Curmingham VJ. et al, 1993) or may simply reflect the heterogeneity within the 
spleen that is inherently detected using spectral analysis. 
In this study, spectral analysis was performed in metastases and spleen using two 
different input functions: (i) total plasma arterial input function and (ii) parent 
plasma arterial input function. As suggested in the nomenclature, the parent 
plasma has been corrected for radiolabelled metabolites of 5-['^F]FU, the major 
degradation product being ['^FJFBAL, whereas total plasma includes parent and 
metabolites. The reason for doing so was to establish whether the presence of 
metabolites in the input function would affect the parameters: Ki, FRF and PS, 
derived from spectral analysis. 
Kidney and liver could not be analysed by spectral analysis because the line of 
best fit of the time activity curve convolved with the arterial total or parent plasma 
input function was not robust enough, producing lines of best fit that were of poor 
quality. With liver this may be explained by the vasculature as the liver receives a 
dual blood supply from portal vein and hepatic artery and may therefore result in 
discrepancy between measured arterial input and actual hepatic input. Liver 
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metastases are principally supplied by the hepatic artery and hence satisfactory fits 
were obtained as shown below. 
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Figure 35: Results for Spectral Analysis Using 
Total Arterial Plasma Input 
a) arterial parent plasma input function for 5-[''F] FU b) arterial total plasma input function for 5-['®F] FU c & d) 
corresponding time activity curve for tumour and spleen, showing line of best fit e & f) impulse response function 
(IRF) for tumour and spleen, corrected for radioactive decay g & h) IRF for tumour and spleen displayed as kinetic 
components 
6.5.7.1 (i) Ki 
Ki values that were obtained from spectral analysis for tumour and spleen are 
shown in Figure 35. 10 liver metastases were analysed as 3 liver metastases (lb, 
2b and 3d) and both lymph node metastases were too small. Using either input 
function, in 8/10 metastases, Ki increased after carbogen and nicotinamide. The 
mean increase was 54% using parent plasma and was higher at 62% using total 
plasma input function, as would be expected as the latter has not been corrected 
for labelled metabolites. Ki was significantly increased after carbogen and 
nicotinamide in metastases with both input functions (see Table 6.8). There was 
no statistical difference seen after comparing Ki derived using the two input 
functions. 
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and Nicotinamide Using Total Plasma Input 
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Figure 37: Tumour Ki Before and After Carbogen 
and Nicotinamide Using Parent Plasma Input 
Function 
In the spleen, Ki was reduced in 4/6 patients with both input functions though the 
decrease was marginal and was not statistically significant (Table 6.8). Again, 
there was no statistical difference in Ki obtained form total or parent plasma input 
functions (Table 6.9). 
As seen in the summary Table.6.8, spleen Ki was greater than tumour K] by 
approximately five-fold, pre and post carbogen and nicotinamide, with an increase 
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seen in SUVs.ysmins as well, probably reflecting the higher perfusion measured in 
the spleen. 
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Figure 38: Spleen Ki Before and After Carbogen 
and Nicotinamide Using Total Plasma Input 
Function 
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Figure 39: Spleen Ki Before and After Carbogen 
and Nicotinamide Using Parent Plasma 
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Table 6.8: Table of K; for Tumour and Spleen Before and After Carbogen 
Region Ki X 10"' (mlbiood/min/mltissue) 
Using Total Plasma Arterial IF 
Ki X 10"' (mlbiood/min/mltissue) 
Using Parent Plasma Arterial IF 
Pre C/N Post C/N P Pre C/N Post C/N P 
Tumour 
(n=10) 
0.89 ±0.14 
[0.57 to 1.2] 
1.3 ±0.21 
[0.83 to 1.8] 
0.013 0.9 ±0.15 
[0.56 to 1.2] 
1.3 ±0.2 
[0.7 to 1.7] 
0.037 
Spleen 
(n = 6) 
6.3 ±0.81 
[4.2 to 8.4] 
6.0 ±0.7 
[4.2 to 7.8] 
1 7.1 ±0.7 
[5.1 to 8.9] 
6.2 ±0.7 
[4.4 to 8] 
0.441 
n, number; K] X 10 (mlbiood/riiin/mltissue); C/N, carbogen and nicotinamide. 
Data are mean ± SEM [95% CI]. 
Table 6.9: Comparison of Ki values obtained using total and parent plasma 
arterial input functions 
Region p value for Ki with no C/N p value for Ki with 
CW 
Tumour 0.56 0.94 
Spleen 0.19 0.7 
C/N, carbogen and nicotinamide 
6.5.7.2 FRF 
Fractional retention of 5-['^F]FU (FRF), was calculated from the IRF by dividing 
IRFimin/IRFeo min as explained in Chapter 2. This was to correct for the very 
earliest time points of the IRF that do not only represent delivery, but also have a 
blood volume component. 
Tumour FRF calculated using either total or parent plasma showed no consistent 
change after carbogen and nicotinamide with no change in 2/10 metastases, an 
increase in 5/5 metastases and a decrease in 3/10 metastases and there was no 
statistical difference in FRF, in agreement with resuks from tumour AUCgomins-
The most obvious difference was seen in the actual values obtained for tumour 
FRF using total or parent plasma for pre and post carbogen and nicotinamide. 
134 
Tumour FRF was higher pre and post carbogen and nicotinamide using parent 
plasma arterial input function and this was statistically significant. The reason for 
this finding may be because of the difference in the 2 input functions, where it can 
be seen that the plasma arterial concentration at 60 minutes is higher for total 
plasma. This results in a lower IRFeomins for total plasma than for parent plasma 
after convolution with tissue response and consequently lower FRF. 
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Figure 43: Spleen FRF Before and After Carbogen 
and Nicotinamide Using Parent Plasma Input 
Function 
In the spleen, FRF showed variable changes before and after carbogen and 
nicotinamide with both input arms in agreement with AUCgomins- There was no 
significant difference between spleen FRF derived using total or parent plasma 
input functions. 
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As can be seen from the summary Table 6.10, tumour FRF is higher than spleen 
FRF before and after carbogen and nicotinamide as expected from the results 
obtained from AUCgomins. 
Table 6.10: Table of FRF for Tumour and Spleen Before and After Carbogen 
and Nicotinamide Using Total and Parent Plasma Input Functions 
Region FRF x 10' 
Using Total Plasma Arterial IF 
FRF X 10' 
Using Parent Plasma Arterial IF 
Pre C/N Post C/N P Pre C/N Post C/N P 
Tumour 
(n= 10) 
1.6 ±0.49 
[0.48 to 2.7] 
1.1 ±0.29 
[0.45 to 1.8] 
&36 3.4 ±0.66 
[1.9 to 0.49] 
3.2 ±0.68 
[1.7 to 4.7] 
0.2 
Spleen 
(n = 6) 
0.10 ±0.031 
[0.22 to 
0.19] 
0.86 ±0.03 
[-0.007 to 
0.18] 
0.62 0.32 ±0.057 
[0.17 to 
0.47] 
0.28 ±0.059 
[0.13 to 0.43] 
0.8 
Data are mean ± SEM [95% CI]. 
Table 6.11: Comparison of FRF values obtained using total and parent 
plasma arterial input functions in Tumour and Spleen 
Region p value for FRF with no C/N p value for FRF with 
CW 
Tumour 0.039 0.002 
Spleen 0.62 0.06 
C/N, carbogen and nicotinamide 
6.5.7.3 Permeability Product Surface Area (PS) 
PS is calculated from the K, parameter (which is the product of regional flow and 
extraction) derived from spectral analysis, and from the corresponding perfusion 
values. See Chapter 2 for equations and further explanation of PS derivation. 
The PS for tumour increased in 8/10 liver metastases by a mean of 64% after 
carbogen and nicotinamide but did not achieve statistical significance with either 
1 3 7 
input functions. Interestingly, in the 2 metastases, (which were in the same 
patient), that had a reduction in PS, also had a reduction in SUVa.TSmins and K, with 
carbogen and nicotinamide. There was no statistical difference between input 
function arms and PS after carbogen and nicotinamide. 
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and Nicotinamide Using Parent Plasma Input 
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Values for PS product in the spleen were similar before and after 
carbogen/nicotinamide (Table 6.12) with both inputs suggesting that there was no 
modulation of transmembrane transport of 5-[^^F]FU by carbogen/ nicotinamide. 
There was no statistical difference between PS calculated for spleen for the two 
input functions either. 
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Table 6.12: Table of PS for Tumour and Spleen Before and After Carbogen 
and Nicotinamide Using Total and Parent Plasma Input Functions 
Region PS PS 
Using Total Plasma Arterial IF Using Parent Plasma Arterial IF 
Pre C/N Post C/N P Pre C/N Post C/N P 
Tumou 0.11 ± 0.18 ±0.037 0.052 0.12 ± 0.18 ±0.04 0.065 
r 0.016 [0.094 to 0.025 [0.088 to 
(n = [0.072 to 0.26] [0.063 to 0.27] 
10) 0.15] 0.18] 
Spleen 1.29 ± 0.77 ± 0.09 0.22 1.34± 0.82 ±0.097 0.16 
(n = 6) 0.46 
[0.11 to 
2.46] 
[0.53 to 1] 0.45 
[0.18 to 
2.5] 
[0.57 to 1.1] 
number 
Table 6.13: Comparison of PS values obtained using total and parent plasma 
arterial input functions in Tumour and Spleen 
Region p value for FRF with no C/N p value for FRF with C/N 
Tumour 0.^7 1 
Spleen 0.3/ 0 06 
C/N, carbogen and nicotinamide 
6.5.8 Patlak Analysis 
Ki was obtained using an extended model led graphical analysis for spleen and 
tumour (Mankoff e/ oA, 1996). As before, in 3 liver metastases (lb, 2b and 3d) 
and 2 lymph node metastases analysis was not possible due to poor fit of data. K| 
was unaffected by carbogen and nicotinamide modulation in the liver metastases 
and spleen. However, tumour K, was greater for tumour than spleen. (Table 6.14). 
The negative K, obtained in some patients for the spleen indicates that although 
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there is delivery and uptake of 5-['^F] FU by the spleen, there is greater washout 
of the radiotracer. 
Table 6.14: Summary of results for Ki in Tumour and Spleen 
N K | ^ ml/biood/min/mltjssue)x 10 
Pre C/N Post C/N P 
Tumour 
(n= 10) 
3.0 ±0.68 
[1.5 to 4.6] 
2.8 ±0.37 
[1.9 to 3.6] 
0.86 
Spleen 
(n = 6) 
-0.00255 ±0.017 
[-0.43 to 0.43] 
0.24 ± 0.02 
[-0.42 to 0.89] 
0.56 
C/N, carbogen and nicotinamide 
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Modified Patlak requires various assumptions to permit analysis and in kidney 
and liver these requirements are not fulfilled. One condition that is not satisfied is 
that both these tissues possess quantities of DPD and hence metabolise 5-['^F]FU 
which is one explanation why modified Patlak analysis was predicted to fail in 
them. 
6.6 Discussion 
Modification of the tumour microenvironment has potential to improve the 
efficacy of not only traditional cytotoxic treatments, but also novel anticancer 
therapies such as photodynamic, gene and biological therapies. Tumour blood 
flow and oxygenafion are critical determinants in the outcome of many such forms 
of cancer treatment including chemotherapy and radiotherapy (Vaupel el al., 
2001). Whilst the exploitation of methods to improve oxygenation is of primary 
concern in radiotherapy, the mechanisms involved are strongly linked to those 
affecting tissue blood flow and consequently have important implications for the 
delivery of systemically delivered chemotherapy. 
Conventionally, tumour hypoxia is divided into two distinct categories: chronic, 
diffusion limited hypoxia, occurring in tumour cells > 150 |im from blood vessels 
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as this is the approximate diffusion distance of oxygen (Thomlinson et al, 1955) 
and acute, perfusion-limited hypoxia (Chaplin et al., 1995; Kimura et al., 1996), 
resulting from transient, intermittent closure of small blood vessels. 
Early studies suggested that carbogen was more important in overcoming chronic 
hypoxia by overcoming vasoconstriction-induced hypoxia (Griffiths et al., 1997; 
Honess et al., 1995; Robinson et al., 1999), and nicotinamide thought to prevent 
acute hypoxia by stabilisation of tumour micro vasculature (Chaplin D. et al., 
1990). However, this explanation may well be considered an oversimplification as 
clarification is now sought relating to the observation that carbogen and 
nicotinamide may not only effect tissue perfusion but also tumour metabolism and 
physiology (Robinson et al., 2000). 
Inhaled carbogen increased the delivery of intravenous ifosfamide and 5-FU in 
experimental tumours in rat models (Rodrigues et al., 1997; Rodrigues et al., 
2002; Stubbs et al., 1998; Thews et al., 2002) using magnetic resonant 
spectroscopy (MRS). However, there is currently no data available on the effect of 
carbogen with or without nicotinamide on drug delivery in man. The purpose of 
this study was to demonstrate whether similar beneficial effects would occur in 
man following the administration of nicotinamide and carbogen to patients with 
metastatic colorectal cancer. The advantages of PET over MRS are its superior 
sensitivity, better spatial and temporal resolution and abihty to image deep-seated 
tumours and organs, though both are non-invasive modalities. AUhough MRS can 
distinguish parent compounds from radiolabelled metabolites, arterial blood 
sampling and the application of kinetic modelling analysis with PET allows 
quantification of relevant pharmacokinetic parameters. In addition it was possible 
to record effects of carbogen and nicotinamide in normal tissue and on human 
physiology. 
As expected there was a dramatic increase in pOj after carbogcn inhalation. This 
started within 7 minutes of carbogen inhalation and peaked at 10 minutes, though 
arterial pOi was not continually measured during this period. Arterial pOj 
returned to baseline values 5 minutes after discontinuation of carbogcn. These 
findings agree with results from non-clinical studies (Stubbs el al.. 1998; Thews et 
al., 2002). The rapid increase in arterial pO? in response to carbogen reflects intra-
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tumoural changes in O2 observed in human tumours detected by Eppendorf pOi 
probes (Falk S. et al, 1995; Powell et al, 1999). 
This study showed arterial pCOz was unaffected by carbogen although in animal 
models pCOz increased in response to inhalation of all gases containing differing 
proportions of CO2 (1% to 5%) with the maximum pCOi increase occurring with 
the largest CO2 component (Dunn et al., 1999; Thews et al., 2002). Furthermore, 
in a clinical study carbogen breathing induced a significant rise in arterial pCOi 
compared to breathing air or a combination of 98% O2 and 2% CO2 (Baddeley et 
al., 2000). However, in the latter study carbogen breathing was through a very 
tightly fitting mask which 29% of volunteers were unable to endure. In this study 
the mask was looser but all subjects tolerated carbogen for the required time 
interval, and as a consequence the carbogen may have been diluted with air 
resulting in no change in arterial pC02 measurements. 
Arterial pH was unaffected by carbogen in these patients, similar to findings from 
other clinical (Baddeley et al., 2000) and animal studies (Thews et al., 2002). 
Other animal studies have observed both increases (Dunn et al., 1999; Honess et 
al., 1995) and decreases (Stubbs et al., 1998) in pH in response to carbogen. Also, 
a significant rise in blood glucose levels in response to nicotinamide and carbogen 
was seen in mice, raising the issue of the approach inducing hyperglycaemia in 
man (Robinson et al., 2000). No such changes in arterial glucose were found in 
this study though. 
The lack of change in arterial pCOz, pH and glucose found in man suggests there 
may be species-related changes in pCOz and glucose in response to carbogen and. 
However, further work is needed to clarify the complex physiological changes 
that might occur in response to nicotinamide and carbogen administration in man. 
Using PET we were able to investigate concurrently a number of normal tissues, 
namely kidney, liver and spleen. Tissue-type dependent changes in perfusion were 
seen, consistent with a study in an experimental tumour model, where perfusion of 
the liver and kidney significantly decreased and an increase in perfusion in the 
spleen was noted after carbogen inhalation (Honess et al., 1995). In the animal 
study, the increase in splenic perfusion was further attenuated by the addition of 
nicotinamide and largest in treatment with nicotinamide only. We saw a dramatic 
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decrease in renal flow in response to nicotinamide and carbogen. This reduction in 
kidney perfusion, and corresponding decrease in water Vd, suggests that in man 
renal blood vessels shut down in response to carbogen and nicotinamide. A 
reduction in flow index was also seen in the liver where there was a tendency for 
Vd to decrease. As cardiac output was maintained, the effect on the kidney and 
liver perfusion indicate mechanisms of autoregulation in these organs, possibly 
resulting in the redistribution of blood flow from highly perfused organs (i.e., 
kidney and liver) to other tissues such as tumour. Acute local blood flow control 
is normally achieved by rapid changes in local constriction of arterioles to 
maintain a constant supply of oxygen to the tissue (Guyton et al., 1996). As there 
was no significant increase of pC02 in this study, the changes seen in normal 
tissue are likely to stem from hyperoxia. This suggestion is further supported by 
the lack of changes in liver or kidney perfusion with nicotinamide only in the 
animal model. In analogy with the animal study, the lack of change in perfusion in 
the spleen could be explained by suspension of any improvement in flow with 
nicotinamide by the vasoconstricting affect of the increased pOz. However, 
evaluation of the exact mechanism would have required separate studies with 
either nicotinamide or carbogen inhalation. The lack of significant change in 
cardiac output suggests systemic blood pressure could increase following 
nicotinamide and carbogen. Although blood pressure was not measured in our 
study due to positional constraints within the scanner, an increased blood pressure 
following carbogen was reported in experimental models (Braun R. et al., 2001; 
Dunn et al., 1999), while in normal human volunteers nicotinamide did not effect 
blood pressure (Stratford et al., 1992). 
Our study confirms the inferior blood flow in colorectal liver metastases 
compared with normal tissues such as spleen, kidney and liver and is of a similar 
magnitude to that reported in the literature using other measuring techniques 
(Vaupel P. et al., 1989). As noted in previous studies, the effects of nicotinamide 
and carbogen on tumour perfusion seem to be site dependent (Dunn et al., 1999). 
The 32% increase in tumour perfusion seen in response to nicotinamide and 
carbogen administration is in keeping with other studies, whereas perfusion of the 
two lymph node metastases decreased. A 22% increase was measured by Laser 
doppler probes in superficial, advanced human tumours (Powell MEB. et al.. 
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1997) and in experimental tumours a 75% increase in perfusion was documented 
following high-dose nicotinamide administration of 500 mg/kg (Braun R. et al, 
2001), a dose much higher than the maximum tolerated human dose. There is 
always concern that doppler measurements of tissue flow do not discriminate 
tissue perfusion from blood that flows through arterial-venous shunts (this can 
result in an overestimation of tissue perfusion). In this study with examination of 
liver metastases, consideration must be made of a dual blood supply to the liver 
and subsequently to the liver metastases, when using a technique that requires the 
assumption that the data are modelled using a one compartment model (Kety et 
al., 1948). A study by Ziegler et al in 1996 (Ziegler et al., 1996) used a dual input 
model to estimate liver blood flow compared with direct measurements of both 
inputs using microspheres in dogs. Flow values from the single input model were 
found to be closest to the microsphere values. Although the dual input in the liver 
may have introduced a source of inaccuracy the available data suggest that human 
tumour perfusion does increase in response to nicotinamide and carbogen. Also, 
any concern that the diverted blood flow might pass through vascular shunts in 
tumours can be negated because of the use of H2['^0] which is deposited in 
tissues by capillary exchange. 
The changes in perfusion in normal tissues and tumour in this study suggests an 
augmentation of blood flow in tissues less capable of local vascular control 
mechanisms, such as tumour. This finding is consistent with the theory that that 
the 'steal' phenomenon is the dominant mechanism for redistribution of host 
blood flow to tumour (Jirtle, 1988). The 'steal' effect originally describes the 
reduced tumour blood flow in response to drugs such as hydralazine, where 
normal tissue vasculature relaxes after administration of vasodilating agents 
thereby diverting blood flow from tumours which are not capable of further vessel 
dilatation. In this study, we have demonstrated a 'reverse steal' or 'gain' effect 
(Robinson et al., 1995) with apparent diversion of perfusion from normal tissue to 
the liver metastases, though not in lymph node metastases, suggesting differential 
tumour response. In this study however, the Vj of water in tumours did not alter in 
response to nicotinamide and carbogen administration, suggesting that there was 
no recruitment of previously non-functioning vessels in the liver metastases. In 
animal models vasoconstrictor-induced increases in the mean blood pressure has 
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led to increases in tumour blood flow but also interstitial fluid pressure (Zlotecki 
et al, 1995). High interstitial fluid pressure may also explain the lack of 
correlation between tumour blood flow and Ki. However, the tumour is likely to 
be responding in a heterogeneous manner. Parts of the tumour might be 
responding by an increase in flow with an increase in 5-FU extraction, whereas 
others might respond with an increase in Vd but no changes in flow. For example, 
in one tumour, (liver metastasis la), there was a large increase in Ki, no change in 
perfusion, but an increase in Vd and therefore more of tumour tissue being 
perfused. In another tumour, (liver metastasis 2a), there was a large increase in 
flow and Vd, but only a modest increase in Ki, which is likely to be due to a low 
single-pass extraction fraction (Crone, 1963) due to the high flow. 
The available data suggest that in humans, perfusion of liver metastases increases 
in response to nicotinamide and carbogen, but the underlying mechanisms remain 
complex. Whilst, the mode of action of carbogen and nicotinamide on tumour 
blood vessels is still unclear, it is likely to involve a complex interaction between 
tumour cells, tumour vasculature and the tumour microenvironment (Powell 
MEB. et al., 1997). Alteration in the concentration of vasodilators such as nitric 
oxide (NO) and its antagonist, endothelin, a peptide vasoconstrictor, have been 
speculated as other causes in the changes of tumour blood flow (Sibtain et al., 
2002). CO2 itself is a direct and powerful mediator of these substances and a local 
increase in CO2 leads to an increase in NO and a concomitant decrease in 
endothelin (Yoshimoto e/ a/., 1991); conversely, a high O2 reacts rapidly with NO 
by scavenging NO produced by endothelial cells (Ganong WF., 2001). 
Nicotinamide has also been found to independently affect the production of NO 
and endothelin and has been found to inhibit nitric acid synthase mRNA induction 
in activated macrophages (Pellat-Deceunynck et al., 1994). It would appear that a 
balance of NO and endothelin is of importance in manipulating tumour blood 
flow. 
The early uptake and delivery of 5-['^F]FU (measured as SUVsjsmins and K, 
respectively) was higher in the normal tissues studied than in the liver metastases, 
a finding that mirrored the higher normal tissue perfusion. This observation, 
together with a significant correlation between tumour perfusion and SUVa vsmins 
before intervention, suggests that 5-['^F]FU uptake is related to tissue perfusion in 
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liver metastases. The data show that nicotinamide and carbogen can increase 
tumour perfusion, although the effect on 5-['^F]FU uptake and delivery varied 
between individual metastases. These findings are similar to changes observed in 
mice, where only large tumours showed increased uptake of 5-FU in response to 
carbogen (McSheehy et al, 1998). In our study, all 5 liver metastases larger than 
4cm had increased SUVs.ysmins and Ki values (liver metastases: la, 2a, 4a, 4b and 
5a). In contrast, the effect of carbogen uptake and delivery in tumours less than 
4cm in size was variable and was not consistent with changes in regional 
perfusion. In normal tissue, changes in perfusion also reflected the uptake of 5-
['^F]FU with a significantly reduced perfusion and SUVa ysmins in kidneys after 
nicotinamide and carbogen, though no change in either parameter in the spleen. 
The tissue exposure measured as AUCgomin, retention of '^F-5FU measured as FRF 
and net clearance measured as Ki was higher in tumour than spleen, both before 
and after nicotinamide and carbogen. This indicates tumour trapping of 5-FU by 
the metastases, similar to the observation made using magnetic resonance 
spectroscopy (Presant C. et al., 1994). Differences in the retention of 5-FU in 
tumour and spleen might relate to differences in the gradients of extra- and 
intracellular pH between tissues (Ojugo ASE. et al., 1998), and/or differences in 
tissue proliferation (Wells et al., 2002a) with the formation of more 5-FU 
nucleosides in tumour than in normal tissue. In this study, tumour fractional 
retention and AUCgomin of 5-['^F]FU was unaffected by nicotinamide and 
carbogen. This finding contrasts with that of McSheehy et al who showed a 
carbogen-induced increase in 5-FU retention measured using MRS in murine RIF-
1 tumours (McSheehy et al., 1998). The group related the increase in 5-FU 
retention to a differential rise in extracellular versus intracellular pH, thus creating 
a proton pump gradient favouring intracellular retention of 5-FU in tumours 
(McSheehy et al., 2000). The lack of change in intratumoral retention of 5-
['^F]FU may be due to the 20-minute shorter duration of carbogen breathing in 
our study or a cancellation of the increased delivery because of an increased rate 
of washout. It remains to be seen whether a longer carbogen breathing time in 
humans might increase 5-['^F]FU retention, or a short breathing time to exploit 
the initial increase in delivery while minimizing the enhanced extraction. Future 
studies with MRS would also be of interest to identify any chemical species for 
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which there might be an increased exposure or retention. However, further study 
is required to examine the effects of nicotinamide and carbogen on 5-FU 
extraction from tissues. 
PermeabiUty and surface area product (PS) measures transport or diffusion across 
capillary endothelial cells and was higher in spleen than tumour before and after 
carbogen and nicotinamide administration implying either differences in tissue 
capillary permeability or capillary surface area. There was a non-significant 
increase in tumour in response to carbogen and nicotinamide. However, the 
increase does suggest that carbogen and nicotinamide may influence vascular 
permeability of 5-FU from plasma to tissue in tumours that has hitherto been 
undetectable in studies using MRS imaging, particularly as this study has shown 
that increased capillary surface area is unlikely as tumour Vd was unchanged. 
Comparing spectral analysis using total plasma and parent plasma arterial 
radioactivity as input functions showed that the only statistical difference was 
seen in FRF because of differences in the profile of the curves at later time points 
i.e. at 60 minutes. Ki and PS were unaffected by this and suggests that correction 
for labelled metabolites is not necessary to derive these parameters. Therefore, it 
may be possible to obtain Ki and PS for 5-['^F]FU without the use of arterial 
blood sampling, as the input function can be obtained directly from the PET 
image if a pool of arterial blood is within the field of view of the PET scanner 
during imaging . 
Other than discomfort in carbogen breathing, an important criterion to be 
considered is the potential effect of nicotinamide and carbogen on normal tissue 
toxicity. An earlier study in rats bearing GH3 prolactinomas found no carbogen-
induced enhancement of ifosfamide uptake, measured using MRS, in tissue 
extracts of liver, spleen, kidney, muscle and heart (Rodrigues el al, 1997). A 
more recent paper highlighted an unexpected MRS detection of 5-FU anabolites 
in the metastasis-free liver of a patient, raising the issue of increased 
hepatocellular toxicity with concurrent carbogen breathing (Griffiths JR. et al., 
2001). However, studies in rats did not find any carbogen-induced change in the 
liver or small intestine levels of 5-fluoro-2'-deoxyuridine-5'-monophosphate 
(FdUMP) measured using MRS. Our own study has corroborated the rat studies 
and indicates a lack of increased delivery and retention of '^F-5FU in kidney. 
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spleen and liver. The effects on renal perfusion suggest that angiotensin-
converting enzyme (ACE) inhibitors, which also affect renovascular function, 
should be avoided. 
This study has shown that carbogen and nicotinamide can alter perfusion and 5-
['^F]FU delivery in tumour and normal tissue. However, further studies are 
needed to assess whether varying the duration of carbogen breathing can enhance 
5-['^F]FU extraction and retention by metastases, and ultimately improve 
response and survival rates in patients undergoing 5-FU treatment for metastatic 
colorectal cancer. 
6.7 Summary 
1. Carbogen and nicotinamide can alter tumour and normal tissue perfusion 
in man resulting in tissue dependent effects. 
2. Carbogen and nicotinamide increase perfusion of colorectal cancer 
metastases in liver indirectly, by redistribution of blood from vascular 
tissues such as the kidney. 
3. The dramatic reduction of renal perfusion following carbogen and 
nicotinamide warrants further investigation into the possible mechanism(s) 
that may be involved. 
4. 5-[^^F]FU pharmacokinetic profile can also be modified by carbogen and 
nicotinamide with enhanced delivery to tumour reflecting the changes seen 
in perfusion. 
5. No deleterious effects were observed in 5-['^F]FU pharmacokinetics in 
normal tissue, an important consideration when evaluating 
chemotherapeutic agents. 
6. The methodology presented in this study will be helpful in appraising 
other agents postulated to improve the delivery and retention of 
systemically administered anti-cancer drugs in humans. 
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Chapter 7 5-FU and Interferon 
7.1 Introduction 
Interferons are pleiotropic cytokines, discovered almost 50 years ago, (Isaacs et 
al, 1957) and have been evaluated as potential therapeutic modalities as they 
exert antiproliferative and immunomodulatory effects on malignant cells (Jonasch 
et al., 2001) through cell surface receptor binding and signal transduction 
pathways (Wadler et al., 1997a). Two major subgroups are recognized depending 
on chromosomal location and receptor specificity; Type 1, to which interferon-a 
(IFN-a) and -(3 (IFN-P) subtypes belong and Type 2, which consists of 
interferon-y (Wadler et al., 1997b). 
Numerous in vitro studies have reported enhanced cytotoxicity of 5-FU in various 
cell lines by interferon although the actual mechanism of interaction is still 
unclear. An early study demonstrated growth inhibition in MC 38 
adenocarcinoma and HL-60 human leukaemic cells, most marked when 5-FU was 
preceded by IFN-a (Elias et al., 1988). However, a number of possible steps that 
may be responsible for interferon enhancing 5-FU cytotoxicity have been 
identified. 
Elias et al demonstrated an elevation in 5-fluoro-2'-deoxyuridine-5'-
monophosphate (FdUMP) in vitro following IFN-a and 5-FU compared to 5-FU 
alone (Elias et al, 1989). One possible explanation for the increase in FdUMP 
could be an IFN-a dose-dependent induction of thymidine phosphorylase (TP) 
(Schwartz et al, 1995; Schwartz et al, 1992). An in vivo study has shown a two 
fold elevation in TP in peripheral blood mononuclear cells following treatment 
with 5-FU and a single dose of IFN-a or IFN-P (given 1 to 2 hours before 5-FU), 
which persisted for 48 hours (Makower et al, 1997). 
Other studies have shown D N A damage in colon cancer cells, measured as single 
and double strand breaks induced by 5-FU, is increased by IFN-a modulation 
(Houghton et al, 1993; van der Wilt et al, 1997; Wadler et al, 1996). 
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Milano et al showed inhibition of dihydropyrimidine dehydrogenase catabolism of 
5-FU by interferon-a in vitro in various cell lines resulting in potentiation of 5-FU 
cytotoxicity (Milano et al, 1994). 
A study by Chu et al has shown that IFN-y can abrogate the 3-fold 5-FU induced 
expression of thymidylate synthase in vitro in the human colon cancer cell line 
H630, thereby enhancing the sensitivity of the cell to 5-FU in an otherwise 
relatively resistant 5-FU cell line (Chu et al., 1990). However, only minimal 5-FU 
induced TS over expression in human (Grem et al., 1995) and murine colon 
cancer cell lines was observed in other studies, with no effect on this by either 
IFN-y or IFN-a (van der Wilt et al., 1997). 
There is still no agreed consensus as to the mode of action of IFN-a on 5-FU 
despite the many studies and results in the literature. As response rates for the 
treatment of metastatic colorectal with 5-FU are dismally low, it is important to 
fully evaluate the enhanced efficacy that IFN-a potentially could bring. 
7.2 Study Aims 
7.2.1 Primary Aim 
1) To assess 5-['^F]FU pharmacokinetic changes following biomodulation by 
IFN-a in vivo in metastases and normal tissue, as the precise mode o f their 
interaction with 5-FU is still not fully understood. 
2) To relate any PET detected pharmacokinetic changes to known mechanisms of 
activity or to provide insight into novel modes of activity. 
7.2.2 Secondary Aims 
1) To establish whether the combination of 5-['^F]FU and IFN-a had any effect 
on normal tissue and tumour perfusion. 
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2) To establish whether dose of 5-FU had any effect on IFN-a biomodulation. 
7.3 Methods 
7.3.1 Patient Selection 
Patients with gastrointestinal (one patient) or colorectal cancer (five patients) with 
metastasis scheduled palliative chemotherapy with a 5-FU based treatment regime 
were enrolled in this study. All 6 patients had not had any previous treatment with 
chemotherapy and had metastases that were > 3 cm in size in at least 1 axis of 
dimension, as measured on CT scan. 
Eligibility criteria included a life expectancy of > 3 months, performance status > 
2, and adequate renal and hepatic function (serum creatinine, < 1 2 5 |imol-L''; 
bilirubin < 17 mmol -L"'; and aspartate transaminase, < 35 |.imol-L"'). 
Ethics approval was obtained from the Hammersmith Hospital Research Ethics 
Committee and authorization for the use of radionuclides was given by UK 
Administration of Radioactive Substances Advisory Committee (ARSAC). All 
patients gave written and informed consent for participation in the study. 
Dr Robert A Harte collected the data and the author analysed and interpreted the 
data. 
7.3.2 Study Design 
Patients underwent two 5-['^F]FU pharmacokinetics studies at the same time of 
day, one week apart: the first on day 1, while biomodulator-nai've and the second 
on day 8 after administration of IFNa (either lFNa-2a or -2b). IFNa (3 million 
units subcutaneously) was injected on days 1 , 4 , 7 , and 8. IFNa was given after 
the PET study on day 1 and 30 minutes before the 5-['^F]FU scan on day 8. 
Patients were assigned to either have tracer dose of 5-FU (4.8 to 8.4 mg/m ) or 
ftall dose 5-FU (375-400mg/m^) for both scans in the study. The radiotracer 5-
['^F]FU was administered intravenously either alone or co-injected with 5-FU in 
the ftill dose studies in all patients. The 5-['^F]FU radionuclide was injected as a 
bolus over 30 second to 1 minute and the scan duration was 60 minutes. 
153 
Tissue perfusion was obtained from C['^0]2 scans performed immediately before 
the 5-['^F]-FU scan on day 1 and day 8. Each patient received C['^0]2 via a face 
mask at a rate of 4MBq per milhUtre at 500mls/min for 5 minutes. The scan lasted 
10 minutes in total. 
7.4 Procedures 
Patients were positioned in the scanner on successive weeks using anatomical 
landmarks with a recent CT scan to locate metastasis and after insertion of a 
cannula. The patients' positioning was verified at the start of the second scan by a 
short transmission scan. 
Continual arterial blood sampling was performed during both scans with 
additional discrete samples obtained for metabolite analysis. 
7.5 Data Analysis and Statistics 
The data sets were transformed into analyzable formats. This involved 
reformatting the header folder of the dynamic image scans, converting well counts 
from ECAT counts into KBq using a conversion factor, and the application of a 
calibration factor for ['^O] and 5-['^F] decay. 
The perfusion scans were analysed using the modified Kety-Schmidt equation 
(Wilson e /a / . , 1992). 
Tracer and full dose 5-['^F]FU scans were both analysed using a semi-quantitative 
model to derive SUVa.ysmins and AUCeomins- Spectral analysis methods were used 
to obtain Ki and fractional retention of 5-FU (FRF) utilizing two input functions: 
(i) total plasma (parent and labelled metabolites) and (ii) parent plasma (parent 
alone). In addition, full dose 5-['^F]FU scans only were analysed using modified 
Patlak methodology to acquire Ki. 
Mann-Whitney for unmatched pairs or Wilcoxon signed rank test for matched 
pairs were used for statistical analysis. 
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7.6 Results 
7.6.1 Patient Characteristics 
6 patients were recruited into the study, three each to receive tracer (1 male; 2 
females) and full dose (2 males; 1 female). All 6 patients had liver metastases 
from their primary tumour. Mean age was 61 years (range 46 to 80 years). All 
patients had C['^0]2 and 5-['^F]FU scans before and after IFNa modulation. 
Patient characteristics are shown below in Tables 7.1. Table 7.2 gives details o f 
the number and size of liver metastasis and normal tissue regions that were 
sampled in each patient. 
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Table 7.1: Patient Details 
Patient 
number 
Patient scan 
number 
Pre ' iFN-a 
Patient scan 
number 
Pos t ' IFN-a 
Primary 
site of 
disease 
Sex Age 
(Years) 
Body 
surface 
area 
Tracer 
Dose 5-
FU 
1 p03185 p03195 colorectal F 54 1.64 
2 p03210 p03225 colorectal F 80 1.46 
3 p03239 p03251 colorectal M 59 1.75 
Full Dose 
5-FU 
4 p02696 p02711 colorectal M 67 2 
5 p02741 p02754 colorectal F 46 1.68 
6 p02784 p02795 gastric M 61 1.87 
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Table 7.2: Regions Sampled 
Patient 
'Number of liver 
metastases 
Maximum size of 
liver metastases (cm) 
'Spleen 'Liver 'Kidney 
.1 2 ( l a and lb) l a = 10; lb = 7 V X 
2 l(2a) 2a = 5 / y Rt. 
3 2 (3a and 3b) 3a = 5; 3b = 6 y V X 
4 2 (4a and 4b) 4a = 3; 4b = 3 y / X 
5 3 (5a, 5b and 5c) 5a = 7; 5b = 5; 5c = 3 y V Rt. 
6 1 ( & 0 6a = 3.5 y Rt. and Lt. 
7.6.2 Scan Details 
Table 7.3 gives details of the quantity of 5-FU administered and of the 5-['^F]FU 
activity injected. Mean 5-FU given in full dose studies was 724mg and in the 
tracer dose studies was 10.4mg. Mean injected activity of 5-['^F]FU was 347 
MBq (range 176 to 416 MBq). The patient with the lowest 5-['®F]FU activity of 
176 MBq also had a comparatively small BSA of 1.46 which meant that there was 
reasonable radiotracer uptake in the ROIs to permit quantitative analysis. Mean 
radiochemical purity was 97.6% (range 95.7 to 100%) with uracil identified as the 
only impurity. Blood sampling during C['^0]2 and 5-['®F]FU scans resulted in an 
estimated blood loss of 275 mis during each PET session. 
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Table 7.3: Scan Details 
Patient scan 
number 
Patient 
number 
Dose of 5-FU 
injected (mg/m^) 
Injected 5-['*F]FU 
activity (MBq) 
5-['*F]FU 
radiochemical 
purity % 
p03185 1 14 mg (8.4) ,349 95.7 
p03195 1 14 mg (8.4) 348 97.9 
p03210 2 7 mg (4.8) 176 90.8 
p03225 2 7 mg (4.8) 343 99.5 
p03239 3 10.3 mg (5.9) 348 98.6 
p03251 3 10.3 mg (5.9) 299 98.1 
p02696 4 800mg (400) 355 96.3 
p02711 4 800mg (400) 416 97.4 
p02741 5 672 mg (400) 359 98.9 
p02754 5 672 mg (400) 392 99.6 
p02784 6 701 mg (375) 375 98.9 
p02795 6 701 mg (375) 413 100 
7.6.3 5-[F"]FU Pharmacokinetic Results 
Semi-quantitative and spectral analyses were performed in full and tracer dose 
studies in tumours. Patlak analysis was performed only on full dose patient data in 
tumours. 
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7.6.4 Semi-Quantitative Analysis 
Using this methodology, SUVsjsmins as an indication o f 5-['^F]FU delivery and 
AUCeomins as a measure of tissue exposure to 5-['^F]FU, were derived. Similar 
tissue activity curve (TAG) shapes that were seen in tumours in chapter 6 were 
derived for tumours in this study. 
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Figure 50: Typical Tissue Activity Curves for 5-
[18F]FU in (i) Tracer Dose and (ii) Full Dose 
Studies 
159 
As can be seen from the TACs there was a difference in magnitude for tracer and 
full dose studies. This is reflected in the mean values for AUCeomins for full dose 
which are higher than for tracer dose (see Table 7.4). This shows that the tracer 
dose falls below saturation pharmacokinetics for 5-FU. At tracer dose, 4/5 
metastases had an increase in AUCeomins and at full dose, 4/6 had an increase. 
However, there was no statistical difference with the addition of IFN-a for 
AUCeomins at both dose levels. Mean AUCeomins before IFN-a was 0.17 ± 2.5 x 10"^  
and 0.27 ± 0 6 x 1 0 ' ^ m^/ml x sec for tracer and full dose respectively. After IFN-
a, AUCeomins was 0.19 
full dose respectively. 
± 3.2 x 10'^ and 0.27 ± 4.7 x 10"^  m^/ml/sec for tracer and 
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Figure 51: Tracer Dose: Tumour AUCeomins before 
and after Interferon 
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Figure 52: Full Dose: Tumour AUCeomins Before 
and After Interferon 
Mean SUVs.ysmins was similar for tracer and full dose. As mentioned, SUVa.ysmins 
gives an indication of delivery of radiotracer and consists of f low versus 
extraction parameters and is not affected by different doses. At neither dose level 
did IFN-a have an affect on SUVgjsmins. Mean SUVs.ysmins before IFN-a was 2.4 x 
ICT^  ± 1.9.x ICr^  and 9.5 x 10'^ ± 2.3 x lO'^m^/ml for tracer and full dose 
respectively. After IFN-a, mean SUVsjsmins was 7.9 x 10'^ ± 1.6 x 10 ^ and 7.9 x 
10"^  ± 2 X lO'^m^/mlfor tracer and full dose respectively. Individual results for 
SUV3.75mins before and after IFN-a for tracer and full dose studies are shown 
below in Figures 53 and 54. 
1 6 1 
1 . 4 x 1 0 -
1 1 x10"^  
\ a 
1 6 x 1 0 " ' -
3 
I/) . 
2x10^ 
l b 2a 3a 
Metas tases 
3b 
• Pre Interferon 
• Post Interferon 
Figure 53: Tracer Dose: Tumour SUVsjsmins before 
and after Interferon 
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Figure 54: Full Dose: Tumour SUVsysmins Before 
and After Interferon 
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Table 7.4: Semi-Quantitative Results for Tracer and Full Dose 5-P®F]FU 
Before and After Interferon 
Parameter Dose Before ^IFN-a After ^IFN-a p value 
'SUVsvsmins Tracer Dose 
n = 5 
2 . 4 x 10"^± 1.9 X 10"" 
[2.8 X 10"", 7.6 X 10-"] 
7.9 X 10-^ ± 2 . 0 X 10"' 
[2.1 X 10 \ 1.3 X 10""] 
0.63 
Full Dose 
n = 6 
9.5 X 10'^ ±2.3 X 10'^ 
[3.6 X 10 ^ 1 . 5 x 1 0 ^ ] 
8.7 X 10"'± 1.6 X 10"' 
[4 .6x 10-\ 1.3 X 10""] 
0.56 
AUCsOmins Tracer Dose 
n = 5 
0.17 ± 2 . 5 X 10"^  
[0.10, 0.24] 
0 . 1 9 ± 3 . 2 x 10'^ 
[0 .10,0.28] 
0.25 
Full Dose 
n = 6 
0.27 ± 0.6 X 10"^  
[0 .11,0.43] 
0.27 ± 0.047 
[0.15,0.39] 
&83 
mVsec/ml; \ Interferon- a 
Data are mean ± SEM; [95% CI] 
7 .6 .5 Spectra l Analys i s Resul ts 
As in Chapter 6, Ki and FRF were calculated for tumour to observe any affect of 
IFN-a on 5-['^F]FU pharmacokinetics in tracer and full dose studies. In addition, 
spectral analysis was performed by convolution of tissue radioactivity response 
and the two input functions, as described previously. This produced two data sets 
for Ki and FRF for tracer and full dose studies with good model fits obtained as in 
chapter 6. As can be seen below differences were observed in the input function 
curves for parent and total plasma in tracer and full dose studies, see Figure 54 
below. 
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Figure 55: Parent Plasma and Total Plasma Input 
Functions for (i) Tracer Dose and (ii) Full Dose 
Tracer Dose 5-P'F]FU Studies 
The initial part of the curve is similar for both input functions as is to be expected 
as there has not been a significant amount of 5-['^F]FU metabolism yet. The latter 
part of the curve reflects the subtraction of labelled metabolites in the parent 
plasma radiotracer curve which is apparent as the curve tends to fall to almost 
non-detectable levels at 2 000s, whereas in the corresponding total plasma input 
function, after 2 000s the curve is composed of radiolabeled parent and 
metabolites and hence levels remain higher. 
7.6.5.1 K, Results 
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7.6.5.1.1 Tracer Dose Results 
As can be seen from the table below, Ki was slightly higher after IFN-a when 
using either parent plasma or total plasma input ftonctions but suggesting no 
change in the delivery component as Mann-Witney statistics performed showed 
non-significant results obtained for parent plasma and total plasma before IFN-a 
(p = 0.31) and parent plasma and total plasma after IFN-a (p = 1). Mean values 
obtained for Ki for parent and total plasma before IFN-a and after IFN-a were 
also similar with no statistical difference. 
Table 7.5: Ki for Tracer Dose before and after Interferon-a, Using Parent 
and Total Plasma Input Functions 
Metastases 'Ki before 
^IFN-a parent 
plasma 
'Ki before ^IFN-a 
total plasma 
'Ki after 
^IFN-a 
parent plasma 
'Ki after 
^IFN-a 
total plasma 
la 0.24 0.25 0.4 0.27 
lb 0.3 0.29 0.48 0.52 
2a 0.57 0.75 0.2 0.085 
3a 0.075 0.87 0.094 0.054 
3b 0.088 0.06 0.052 0.29 
Mean ± 
SEM 
0.17 ± 0 . 0 6 6 0.15 ± 0 . 0 4 9 0.23 ± 0.076 0.24 ± 0.084 
Data are mean ± SEM 
7.6.5.1.2 Full Dose Results 
Again, results for Ki in both parent and total plasma analyses were not 
significantly different before and after IFN-a, p = 0.69 and 0.31 for parent and 
total plasma input functions respectively. 
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Table 7.6: Ki for Full Dose Before and After Interferon-a, Using Parent 
and Total Plasma Input Functions 
Metastases 'Kibefore 
^IFN-a 
parent 
plasma 
'Ki before 
'IFN-a 
total plasma 
'Ki after ^IFN-a 
parent plasma 
'Ki after 'IFN-a 
total plasma 
4a 0.250 0.220 0.30 0.220 
4b 0.300 0.290 0J5 0.300 
5a 0.025 0.038 0.14 0.140 
5b 0.500 0.500 0.16 0.160 
5c 0.320 0.370 0.27 0.240 
6a 0.530 0.410 0.30 0.300 
M e a n ± 
SEM 
0.32 ± 0.07 0.3 ± 0.07 0.25 ± 0.03 0.23 ± 0.028 
mlbiood/min/m tissue!Interferon- a 
Data are mean ± SEM. 
Table 7.7: Summary of Results for Ki 
Input 
Function 
Dose 'Ki Before TFN-a 'Ki After TFN-a p value 
Parent 
plasma 
Tracer Dose 0.17 ± 0 . 0 6 6 
[0.012, 0.53] 
0.23 ± 0.076 
[0.016, 0.44] 
0.19 
Full Dose 0.32 ± 0 . 0 8 
[0 .13,0 .51] 
0.25 ± 0.03 
[0.16, 0.34] 
0.69 
Total plasma Tracer Dose 0.15 ± 0 . 0 4 9 
[0.07, 0.29] 
0.24 ± 0.084 
[0 .011,0 .48] 
0.31 
Full Dose 0.3 ± 0.066 
[0 .13,0 .47] 
0.23 ± 0.028 
[0.16, 0.30] 
0.31 
, mlbiood/min/mlnssue; , Interferon- a 
Data are mean ± SEM [95% CI]. 
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7.6.5.2 Fractional Retention of 5-["F]FU 
7.6.5.2.1 Tracer Studies 
Fractional retention of 5-[^^F]FU (FRF') describes retention of radiotracer. As can 
be seen from individual values for tracer in Table 7.8 there was no change in 
mean FRP after IFN-a using either parent or total plasma input functions. 
Table 7.8: Fractional Retention of 5-P®F]FU for Tracer Dose before and 
after Interferon-a Using Parent and Total Plasma Input Functions 
Metastases 'FRF before 
^IFN-a 
parent plasma 
'FRF before 
^IFN-a 
total plasma 
'FRF after 
^IFN-a 
parent plasma 
'FRF after 
^IFN-a 
total plasma 
la 0.27 0.0027 0.27 0.0011 
l b &23 0.0049 &26 0.0076 
2a 0.26 0.064 0.56 0.085 
3a 0.42 0.04 0.29 0.03 
3b 0.45 0.14 &33 0.11 
M e a n ± 
SEM 
0.38 ± 0 . 0 5 6 0.05 ± 0.025 0.34 ± 0 . 0 5 6 0.047 ± 0.022 
' Fractional Retent ion o f 5 - [ F]FU; , Interferon- a 
The results also show that parent plasma FRF is higher than total plasma FRF 
before and after I F N - a . Mann-Witney statistics performed on these values showed 
a significant change obtained for parent plasma and total plasma before IFN -a (p 
= 0 . 0 0 7 9 ) and parent plasma and total plasma after I F N - a (p = 0 . 0 0 7 9 ) . As 
explained before, F R F is derived using the ratio, I R F e o m i n s / I R F i m i n - Looking at the 
two input functions for tracer, it can be seen that the plasma arterial 
concentrations at 60 minutes is higher for total plasma. This results in a lower 
I R F e o m i n s for total plasma than for parent plasma after convolution with tissue 
response and consequently a lower FRF. 
7.6.5.2.2 Full Dose Studies 
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In the full dose studies, again no change was seen on FRF of 5-['^F]FU and the 
addition of IFN-a with analysis using parent and total plasma input functions as 
shown in Table 7.9. 
Table 7.9: Fractional Retention of 5-[i®F]FU for Tracer Dose before and 
after Interferon-a Using Parent and Total Plasma Input Functions 
Metastases 'FRF before 'FRF before IFN- 'FRF after IFN- 'FRF after IFN-
IFN-a parent 
plasma 
a 
total plasma 
a 
parent plasma 
a 
total plasma 
4a 0.150 0.078 0.150 0.06 
4b 0.170 0.0605 0.560 0.0902 
5a 0.260 0.1 0.140 0.088 
5b 0.100 0.09 0.140 0.084 
5c 0.120 0.078 0.160 0.13 
6a 0.260 0.15 0.290 0.07 
Mean ± 0.18 ± 0 . 0 3 0.092 ± 0 . 0 1 3 0.24 ± 0.07 0.087 ± 0.01 
SEM 
T Fractional Retention of 5-[ F]FU; , Interferon- a 
FRF values using total plasma are lower than corresponding values calculated 
using parent plasma input functions. Mann-Witney statistical analysis comparing 
parent plasma and total plasma input functions for FRF was significant with p = 
0.015 and p= 0.002 before and after IFN-a respectively. As explained before, the 
reason postulated for this lies in the differing input function curves (Figure 50) 
and their affect on FRF calculation. 
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Table 7.10 Summary of Results for FRF 
Input 
Function 
Dose 'FRF 
Before ^IFN-a 
'FRF 
After ^IFN-a 
P 
value 
Parent 
plasma 
Tracer 
Dose 
n = 5 
0.38 ± 0 . 0 5 6 
[0.22, 0.54] 
0.34 ± 0 . 0 5 6 
[0.19, 0.50] 
0.65 
Full Dose 
n = 6 
0.18 ± 0 . 0 2 8 
[0.10, 0.25] 
0.24 ± 0.068 
[0.065 - 0.42] 
0.44 
Total plasma Tracer 
Dose 
n = 5 
5 x 1 0 - ^ ± 2 . 5 x 10"^  
[-0.02, 0.12] 
4.7 X 10"^  ± 2 . 2 x 10'^ 
[ -0 .013 ,0 .11] 
0.81 
Full Dose 9.2 X 10"^  ± 1.3 X 10"^  8.7 X 10'^ ± 9 . 8 X 10'^ 0.84 
n = 6 [6.0 X 10'^, 0.13] [6.2 X 10'^, 0.11] 
, Fractional Retention of 5-[ F]FU; , Interferon- a 
Data are mean ± SEM [95% CI]. 
7.6.6 Patlak Results 
Ki describes the net clearance of radiotracer from plasma to tissue and is derived 
from modified Patlak methodology. This was only possible in the full dose 
however and not in tracer dose studies. This is probably because the requirement 
that in Patlak that parent reaches equilibrium between plasma and tissue before 
irreversible trapping (Mankoff et al., 1996) is not achieved as there is insufficient 
parent drug initially or because the plasma curve goes to zero within a short time, 
in the tracer arm only Results for the full dose studies are shown in Figure 55. In 
all 6/6 metastasis Ki increased, giving a mean % change of +139%. Mean K, 
before IFN- a was 1.6 x 10'^ ± 3.1 x 10'^ and mean Ki after IFN- a was 3.4 x 10'^ 
± 7.5 X 10'^ mlbiood/min/mltissue- The p value was significant with p = 0.0313. 
169 
E 
c 
E 
E, 
• Pre Interferon 
• Post Interferon 
4a 4b 5a 5b 5c 
Metastases 
6a 
Figure 56: Tumour K| Before and After Interferon 
7.6.7 Tissue Perfusion and Volume of Distribution 
Tissue perfusion data from the tracer and full dose 5-[FU] arms have been 
combined as the €['^0%] scans were performed before the 5-['^F]FU scans and 
therefore will not be affected by the two different 5-[FU] dose schedules. 
Individual patient results for each region are shown below, and statistical results 
for all regions are summarized in Table 7.11. 
7.6.7.1 Tumour Perfusion and Volume of Distribution 
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Figure 57: Tumour Blood Flow Before and After 
Interferon 
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Figure 58: Tumour Vd Before and After Interferon 
In 4/11 metastasis perfusion increased, in 4/11 metastasis perfusion decreased and 
in 3/11 metastasis there was no change in perfusion after IFN-a. The mean value 
pre IFN-a was 0.31 ± 0.059 mlbiood/min/mltissue and post IFN-a was 0.27 ± 0.070 
mlbiood/niin/mltissue. However, there was considerable heterogeneity in individual 
tumour perfusion and the result was not significant. In 9/11 metastases Vj 
increased, and Vd decreased in 2/11 metastases after IFN-a. The volume of 
distribution pre IFN-a was 0.45 ± 0.084 mlbiood/mltissue and after IFN-a was 0.55 ± 
0.090 mlbiood/mltissue with a mean increase of 69% but the P value = 0.05 indicated 
marginal significance. 
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7.6.7.2 Splenic Perfusion and Volume of Distribution 
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Figure 59: Spleen Perfusion Before and After 
Interferon-a 
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Figure 60: Spleen Vd Before and After Interferon-
a 
Splenic perfusion and volume of distribution showed inconsistent changes after 
IFN-a (Table 7.5). Mean perfusion pre IFN-a was 1.7 ± 0.56mlbiood/min/mltjssue 
and mean perfusion post IFN-a was slightly less at 1.2 ± 0.27biood/rnin/mltjssue-
Mean Vd in the spleen pre IFN-a was 0.89 ± 0 . 0 1 2 mlblood/mltissue and post I FN 
was unaltered at 0.89 ± 0.022biood/min/mltjssue-
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7.6.7.3 Liver Perfusion and Volume of Distribution Index 
I 
1 £ 
E. 
c 
o 
o Q. 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0 
• Pre Interferon 
• Post Interferon 
Patient Number 
Figure 61: Liver Perfusion Index Before and After 
Interferon 
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Figure 62: Liver Vd Index Before and After 
Interferon 
As mentioned in Chapter 6, liver perfusion and volume of distribution are index 
values as this organ has a dual blood supply. In the 6 liver ROls analysed, both 
parameters were not significantly altered by modulation with IFN-a. Mean liver 
perfusion values of 0.45 ± 0.068 mlbiood/min/ml,issue and 0.39 ± 0.049 
mlbiood/min/mltissue were obtained pre and post IFN-a, respectively. Values for Vd 
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in the liver were similar before and after IFN-a , with values of 0.89 ± 0.019 
mlbiood/mltissue and 0.88 ± 0.033 mlbiood/mltissue, respectively. 
7.6.7.4 Kidney perfusion and Volume of Distribution 
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Figure 63: Kidney Perfusion Before and After 
Interferon 
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Figure 64: Kidney Vd Before and After Interferon 
In all 4 kidneys sampled, perfusion decreased with the administration of IFN-a 
with a mean reduction of 27%. Pre IFN-a was 2.44 ± 0.56 mlbiood/min/mltissue and 
post IFN-a was 1.72 ± 0.30 mlbiood/min/mltjssue though this was not significant (p = 
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0.13). Volume of distribution was unaltered with IFN-a, with pre IFN-a of 0.70 ± 
0.05 mlbiood/mltissue and post IFN-a of 0.73 ± 0.079 mlbiood/mltissue-
Table 7.11: Summary of Perfusion and Volume of Distribution statistics 
Pre and Post IFN 
Region Pre IFN-a 
'perfusion 
Post IFN-a 
'perfusion 
P 
value 
Post IFN-a 
'Vd 
Post IFN-a 
'Vd 
P 
value 
Metastases 
(n=10) 
0.31 ± 0 . 0 5 9 
[0 .18,0 .45] 
0.27 ± 0.070 
[0.12, 0.43] 
0.7 0.45 ± 0.084 
[0.26, 0.64] 
0.55 ± 0.090 
[0.34, 0.75] 
0.05 
Spleen 
(n = 6) 
1.7 + 0.56 
[0.29, 3.2] 
1.2 ± 0 . 2 7 
[0.49, 1.89] 
0.13 0.89 ± 0 . 0 1 2 
[0.86, 0.93] 
0.89 ± 0.022 
[0.84, 0.95] 
0.84 
Liver 
(n = 6) 
0.45 ± 0.068 
[0.28, 0.63] 
0.39 ± 0.049 
[0.27, 0.52] 
0.16 0.89 ± 0 . 0 1 9 
[0.84, 0.94] 
0.88 ± 0 . 0 3 3 
[0.80, 0.97] 
0.56 
Kidney 
(n = 4) 
2.44 ± 0.56 
[0.68, 4.2] 
1.72 ± 0 . 3 0 
[0.76, 2.7] 
0.13 0.70 ± 0.05 
[0.54, 0.87] 
0.73 ± 0.079 
[0.48, 0.98] 
1 
n, number; mlbiood/min/mlri 
[95% CI]. 
'Vd, volume of distribution, mlbiood/mlnssue; Data are mean + SEM 
7.7 Discussion 
Some early phase 2 studies of interferon modulation of 5-FU in metastatic 
colorectal cancer gave promising results (Patt et al, 1997; Pazdur et al, 1990; 
Wadler et al., 1989). Subsequent randomized phase 3 trials produced equivocal 
results and a recent meta-analysis comparing 5-FU ± IFN-a or 5-FU ± folinic acid 
+ IFN-a demonstrated no substantial benefit of the addition of IFN-a (Cancer, 
2001). Although the clinical application of interferon has decreased, there is still a 
potential subset of patients who may yet benefit from the addition of interferon. 
This study set out to evaluate the possible 5-FU pharmacokinetic parameters that 
may be affected by the biomodulation of IFN-a, as well as looking at effects of 
dose dependence. The potential effect of IFN-a on tumour and normal tissue 
perfusion was also examined. 
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The results from this study have shown that one pharmacokinetic parameter that 
I F N - a may modulate is retention o f 5-['^F]FU. This is suggested by the 
statistically significant increase in Ki that was seen in analysis of tumour in the 
full dose studies. represents the net unidirectional irreversible uptake o f parent 
into tissue, and is derived using extended Patlak methodology which takes into 
account the presence o f labelled 5-['^F]FU metabolites but which are not retained 
by the tissue being analysed (Mankoff et al, 1996). In the full dose study, there 
was an increase in all 6/6 tumour analysed, with a mean Ki before IFN-a of 1.6 x 
10'^ + 3.1 X 10"^  and post IFN-a of 3.4 x 10'^ ± 7.5 x 10'^ ml biood/min/ml tissue, p = 
0.03. This is consistent with a clinical study by Presant et al, in which 2/3 patients 
had an increase in intra-tumoural half-life after IFN-a modulation o f 5-FU 
measured in liver metastasis, indicating trapping of 5-FU (Presant et al., 2000), 
where 5 -FU pharmacokinetics were measured with '^F-MRS. The elevation in Ki 
post I F N - a corroborates the postulated mechanism of action in which there is an 
increase in thymidine phosphorylase and hence, FdUMP, fol lowing IFN-a 
(Schwartz et al., 1994; Schwartz et al, 1995), as there was no increase in 
radiotracer delivery in this study, which will be discussed later. Though the PET 
signal cannot distinguish between 5-['^F]FU and metabolites, the increased net 
clearance of parent 5-[^^F]FU (i.e. Ki) in tumour after IFN-a suggests that the 
IFN-a induced increase in thymidine phosphorylase leads to a subsequent 
increase and retention o f 5-['^F]FU as FdUMP, as it forms a stable complex with 
thymine synthase and a folate co-factor. 
In this study, another measure of retention, fractional retention o f 5-['^F]FU, was 
unaltered by IFN-a in tracer and full dose studies, using both parent and total 
plasma input functions. FRF is calculated using spectral analysis requiring 
relatively f e w assumptions to be upheld to allow analysis and differs from Kj. 
FRF gives a measure of tissue response relative to radiotracer concentration in 
plasma at 60 minutes after being normalized for variability in the delivery 
component (i.e. IRFimin)- One explanation for there being no change in FRF is that 
IFN-a may inhibit dihydropyrimidine dehydrogenase metabolism of 5-FU, which 
will decrease 5-FU clearance from plasma (Milano et al., 1994). This will 
manifest as no change in IRFeomins post IFN-a as any rise in tissue signal (possibly 
from enhanced 5-['^F]FU anabolism) will correspond with a rise in plasma 5-
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[^^F]FU levels. Another reason for a lack o f difference in FRF after IFN-a could 
be because o f the rapid loss of parent 5-['^F]FU from plasma. 
AUCeomins was another parameter calculated in full dose and tracer studies and 
gives an indication of tissue exposure to 5-['^F]FU over 60 minutes. There was no 
change in AUCeomins after IFN-a in tracer or ftill dose tumour analysis. AUCeomins, 
whilst normalised for injected radiotracer activity and decay, and body surface 
area, does not take into account radiotracer delivery to the tissue which can be 
highly variable, as seen by values for SUVs s^mms and Ki, and may effect the final 
estimate o f AUCeomins. 
A s expected however, both AUCeomins and FRF were greater in the ftall dose 5-
studies pre and post IFN-a than the tracer dose 5-['^F]FU studies, but this 
did not attain a significant value. This reflects that in the tracer dose studies, the 
injected levels of 5-['^F]FU were be low saturation kinetics for 5-FU metabolism. 
•However, this study was limited by the use o f only two dose levels o f 5-FU. 
Both FRF and Ki were calculated using parent and total plasma input functions. 
A s in the carbogen and nicotinamide modulation studies, Ki was the same 
regardless of which input function was used before and after IFN-a but, FRF was 
significantly different. A s stated previously, the accepted input function for 
spectral analysis is using parent plasma. The same argument applies as to why 
total plasma input function will not give an accurate measure o f IRFeomins as the 
radioactivity will predominantly consist of 5-['^F]FU metabolites and not parent, 
which does not affect K, as this is derived from an earlier time point. 
The results here show that there was no difference in 5-['^F]FU delivery to 
tumours as represented by SUVa.ysmins and Ki in either tracer or ftill dose 5-
['^F]FU studies with IFN-a. This may be related to results from tissue perfusion 
observed in this study. 
Perfusion and volume of distribution measured using inhaled C['^0]2 and 
calculated in tumour, spleen, kidney and liver (as an index). The results 
demonstrated that IFN-a did not modulate perfusion or V j in any o f these tissues. 
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However, IFN-a does exhibit anti-angiogenic properties in rodent tumour models 
alone (Wang et al, 2003) or in conjunction with other anti-angiogenic agents and 
cytoctoxic agents (Wadler et al., 1997a). IFN-a exerts its anti-angiogenic effect 
probably by inhibition of production of an angiogenic promoter, the basic 
fibroblast growth factor. IFN-a has been used successfully in children in the 
treatment of life threatening haemangiomas who received daily doses of IFN-a 
for several months (Folkman et al., 1992; Greinwald et al., 1999). Further studies 
are needed to establish the effect of IFN-a on normal tissue or tumour perfusion 
in humans. The reason no change was seen in perfusion here may be due to more 
complex reasons. Thymidine phosphorylase has been reported to be identical to 
platelet derived endothelial cell growth factor (PD-ECGF) an enzyme closely 
associated with tumour angiogenesis (Miyadera et al., 1995; Moghaddam et al., 
1992). Thymidine phosphorylase (PD-ECGF) promotes tumour angiogenesis by 
inducing endothelial cell migration, particularly in the initial stages of tumour 
growth (Focher et al., 2001; Marchetti et al., 2001). There are many other tumour 
cytokines and growth factors involved in angiogenesis and subsequently tissue 
perfusion and the underlying mechanisms have not been fully elucidated. 
Further discussion regarding thymidine phosphorylase (TP) is warranted as it 
appears to be one important step by which IFN-a modulates 5-FU. In addition to 
its essential role in converting 5-FU to FdUMP (via thymidine kinase), TP 
catalyses the reversible phosphorolytic cleavage of thymidine and analogues to 
their respective bases and deoxyribose-1-phosphate and maybe play a role in 
thymidine haemostasis (Fox et al., 1995). It has been proposed that one role of TP 
is to control the intracellular levels of thymidine, which at higher concentrations 
become toxic to cells and cause replication errors in DNA (O'Brien et al., 1996). 
TP, whilst present in a wide range of normal tissue, has elevated expression in 
many tumours and higher levels of TP are associated with a worse prognosis in 
some malignancies, colorectal cancer amongst them (Takebayashi et al., 1996). 
The effect of TP on angiogenesis, as mentioned above, is one factor involved in 
the development of a more aggressive phenotype and subsequent increased 
resistance to cytotoxic agents. Indeed, a recent study looking at colorectal cancer 
biopsies has shown that tumours with a higher gene expression of TP are more 
likely to be non-responders to 5-FU chemotherapy (Metzger et al., 1998). This 
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conflicts with previous studies where induction of TP has been associated with 
enhanced 5-FU activity in vitro (Schwartz et al, 1994; Schwartz et al, 1995). In 
contrast, Salonga et al found that colorectal tumours responding to 5-FU have low 
gene expression of TP (Salonga et al., 2000). The same group found other factors 
that independently predict response to 5-FU are low gene expressions of both 
thymidylate synthase and dihydropyrimidine dehydrogenase (Salonga et al., 2000) 
confirmed in studies by Soong (Soong et al., 2008). Within this cohort though are 
a group of patients who despite having a low TP, are still non-responders to 5-FU 
based chemotherapy (Metzger et al., 1998), which infers that TP expression does 
not uniformly identify responding tumours. It is in this group of patients who are 
of interest as they may benefit from IFN-a combined with 5-FU. Identification of 
these individuals may now be possible using a blood test. Braybrooke et al found 
that following a single dose of IFN-a, there was a rapid and sustained induction of 
TP in peripheral blood mononuclear cells in 64% of patients (Braybrooke J. et al., 
2000). However, it remains to be seen whether stratifying treatment in this 
specific cohort of patients for modulation of 5-FU with IFN-a is clinically 
beneficial. 
7.8 Summary 
1. In vivo analysis of IFN-a modulation of 5-FU normal tissue and tumour 
pharmacokinetics can be performed using PET. 
2. In this study, a single dose of 3 million units of IFN-a did not have any 
effect on blood f low or volume of distribution in normal tissue or tumour. 
3. IFN-a increases net clearance (Ki) of 5-FU from plasma to tumour. This 
substantiates one postulated mechanism where IFN-a induces thymidine 
phosphorylase resulting in elevated levels of FdUMP. 
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Chapter 8 2-["C]thymidine To Measure the Pharmacodynamic 
Endpoint of Anti-cancer Drugs 
8.1 Introduction 
A pivotal aspect of cancer treatment is determining tumour response as a 
measurement of the pharmacodynamic endpoint to cancer treatment. The standard 
technique to assess tumour response to anti cancer treatment in addition to cUnical 
examination is with conventional imaging modalities such as x-ray, ultrasound, 
computed tomography, or MRI. These methods rely principally on changes in 
anatomical criteria such as tumour dimensions (unilateral or bilateral) or volume 
to determine whether therapy has been a success or failure. However, the 
dependence on changes in tumour size alone is unlikely to be the most accurate 
measure of response for several reasons. A negative radiological scan may not 
necessarily be indicative of a 'cure' as a radiological complete response may still 
be compatible with the survival of approximately 10^ cells including replicating 
stem cell that could jeopardise an apparently successful treatment (Collins et al, 
1956). Alternatively, any residual tumour mass may be partially or completely 
composed of necrotic, apoptotic or inflammatory tissue as well as viable tumour 
cells, which can confound interpretation of results. After the instigation of 
chemotherapy or radiotherapy regimes, there may often be a delay of 2-3 months 
before any obvious signs of tumour response are apparent, which impedes 
decisions on rapid treatment modification when there has been no response. The 
new opportunities being offered in cancer medicine such as antiangiogenic agents 
or gene therapy may be cytostatic and treatment will not invariably lead to a 
reduction in tumour size. There is a clinical need for an alternative strategy of 
response assessment and with an emphasis on earlier prediction and detection of 
pharmacodynamic endpoints to facilitate faster screening of novel drugs. 
Change in tumour size is preceded by important biochemical changes, including a 
decrease in cellular proliferation and/or an increase in cellular death rate and 
subsequent decline in the number of viable tumour cells (Krohn, 2001). One of 
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the most accurate measures of tumour growth remains serial biopsy (Chang et al., 
1999; Feldman et al., 1986), but this is obviously impractical and has limitations 
in itself including potential sampling errors particularly in tumours, which are 
intrinsically heterogeneous. 
Measurement of tumour growth and DNA synthesis are attractive targets for PET 
imaging. 2-["C]thymidine is a novel PET radiotracer that is being explored as a 
method to measure cellular proliferation in vivo. 
8.2 Thymidine Background 
The use of thymidine in cell growth studies represents the gold standard measure 
of DNA synthesis and cellular proliferation. DNA is synthesised from four 
nucleotides: cytosine, guanine, adenine and thymidine. Thymidine is of great 
importance as it is the native pyrimidine base used in DNA synthesis and is not 
incorporated into RNA as are the others, making it a logical choice to act as a 
labelled marker to image DNA proliferation. 
Thymidine utilised by the cell is either synthesised by the de novo (endogenous) 
or salvage (exogenous) pathway (Figure 65) both of which are tightly regulated. 
In the mammalian cell most of the thymidine used is produced from uridylate via 
the de novo pathway (Mankoff et al., 2000). Thymidine is produced from 
deoxyuridine monophosphate which is methylated to form thymidine 
monophosphate (TMP) by thymidylate synthase (TS). Labelling thymidine to 
image cellular kinetics exploits the salvage pathway. In this pathway, extracellular 
thymidine is rapidly transported into the cell using a facilitated, non-energy 
dependent transporter (Wohlhueter et al., 1979), where it is converted to TMP by 
thymidine kinase (TK). Within the cell, TMP produced by the exogenous and 
endogenous pathways undergoes sequential phosphorylation before incorporation 
into DNA. Unless there is a shortage of the precursor, thymidine, the rate of DNA 
synthesis depends on the 'proliferative state' of the tissue and not on the 
concentration of the precursor. The flux of nucleotides through the precursor pool 
and into DNA is called the rate of synthesis (Cleaver JE., 1967). Levels of the 
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enzymes TK and TS are under strict control (Cleaver JE., 1967). TK exists in two 
forms: TKl, found in the cytoplasm but only in dividing cells, and TK2, found in 
mitochondria and is not cell-cycle regulated (Munch-Petersen et al, 1991). The 
levels of both TKl and TS are increased 5- to 10- fold prior to and during the S 
(synthesis) phase of the cell cycle (Cleaver JE., 1967; Tannock, 1992). 
Uridine phosphate (dUMP) 
Endogenous pathway 
Thymidylate synthetase 
Thymidine kinase r / 
Thymidine • Thymidine phosphate — • dTDP — • dTTP ; 
~ ^ ^ (dTMP) / 
DNA polymerase / 
Exogenous pathway 1 r ! 
DNA 
Key: dUMP, deoxyuridine monophosphate: dTMP, deoxythymidine monophosphate: dTDP, deoxythymidine 
diphosphate, dTTP, deoxythymidine triphosphate. 
Figure 65: Diagram S h o w i n g Incorporation of 
Thymid ine into D N A via Exogenous and 
Endogenous Pathways 
Tritiated thymidine ([ H]-thymidine) has been used for over 50 years in this 
capacity to measure cell growth and elucidate the cell cycle using autoradiography 
after injection of [^H]-thymidine into animals and subsequent excision of a tissue 
sample. 
8.3 Development of Thymidine in PET 
PET obviously offers the advantage of in vivo measurement of cell proliferation 
using positron emitting radiolabelled thymidine. Preliminary feasibility studies by 
Larson et al investigated the use of [^HJthymidine, [^HJuridine, ['''C]-2-
deoxyglucose, and [^^Ga]citrate which were injected intravenously into mice with 
solid subcutaneous EMT-6 sarcoma. High uptake of the radiotracers in tumour 
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demonstrated their potential for tumour imaging in PET (Larson SM. et ai, 1981). 
A further study by the same group examined [^HJthymidine in mice, rats and 
canine tumours, either transplanted or spontaneous. They again observed a high 
tumour to tissue uptake ratio, with prolonged retention in tumours (Larson SM. et 
al, 1981). For PET imaging, thymidine has been labelled with ["C] in either the 
5-methyl (Sundoro-Wu et al., 1984) or 2-carbonyl position (Vander Borght et al., 
1991) and have both been used in pre-clinical studies and for in vivo imaging of 
tumours in man. The principle difference between the two radiotracers is in their 
in vivo labelled metabolite profiles (see Figure 66). 
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Figure 66: Diagram showing catabolism of 
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Thymidine is rapidly metabolised by thymidine phosphorylase which is found in 
many tissues including tumours and platelets (Cleaver JE., 1967). The labelled 
metabolites produced by this process are thymine, dihydrothymine, P-
ureidoisobutyric acid and finally, carbon dioxide ( C O 2 ) . Tumours generate a small 
amount of these labelled metabolites, but the major source is the blood as a result 
of the degradation of thymidine by the liver and platelets. Methyl-["C]thymidine 
generates more radiolabelled metabolites that accumulate in the tissues that have 
already taken up thymidine, and therefore they may not contribute to the image 
background to the same extent as more freely distributed labelled metabolites. In 
contrast the principle metabolite of 2-["C]thymidine is ["C]02, which is rapidly 
transported into tissues and is fairly ubiquitous. Initial investigators assumed, over 
simplistically, that was rapidly cleared from the body by exhalation. 
However, a study by Shields et al has shown that ["C]02 is relatively slowly 
cleared from the body. They found that whilst approximately 50% of the 
radiolabelled metabolite, is exhaled after 60 minutes of scanning, a 
substantial amount of is retained in tissue, with a smaller quantity (5-
10%) present as intermediate labelled metabolites (Shields AF. et al, 1992). 
is reversibly transported between tissue and blood with which it 
equilibrates according to tissue pH, with the majority of trapped in tissue 
as bicarbonate. 
8.4 Pre-Clinical Studies 
The rapid clearance of radiolabelled thymidine from the circulation as observed 
by Larson (Larson SM. et al., 1980) led to concern that the distribution of 
thymidine might primarily reflect tissue blood flow rather than cellular 
proliferation. A study by Shields et al measured the uptake of methyl-
thymidine in mice and dogs and showed that between one and sixty minutes 
there was no correlation with blood flow as measured using ['"'CJiodoantipyrine. 
The results were not affected by the type of radioisotope used or route of 
administration as comparable results were obtained using methyl-[^H]thymidine 
and methyl-[''^C]thymidine, administered intravenously or by intraperitoneal 
injection (Shields et al., 1984). 
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Studies by Goethal et al showed that in spite of intense in vivo metabohsm of 
methyl- ["C]thymidine, major radioactivity was found in rapidly dividing tissue 
of both the normal Wistar rat, and in rats with chemically induced tumours 
(Goethals et al., 1999). In the duodenum and tumour, at least 55% of ["C] was 
precipitated in the DNA fraction and about 60% as DNA precursors in the 
supernatant. However, despite theses findings the contribution of radiolabelled 
metabolites to the tissue signal is still important. 
The need to evaluate the in vivo metabolism of thymidine was further emphasised 
in a study where the incorporation of exogenous hydrogen-3 - thymidine into 
DNA in human cell lines was found to vary enormously from 18-100%; the rest 
being metabolised (Taheri et al., 1982). 
Shields et al performed studies to examine the distribution and metabolism of 
methyl labelled thymidine in [^H], ['^C] and [''^C] positions in normal mice and in 
dogs with and without lymphoma. They found that in rapidly proliferating tissue 
in mice, most of the radioactivity by sixty minutes was present in DNA with 
smaller amounts present in metabolites. Studies in dogs however, revealed more 
activity in metabolites rather than in the DNA of tumour and splenic tissues 
Significant differences were also observed in retention in mice of [^H] labelled 
thymidine compared to carbon labelled thymidine. This was attributed to 
reutilisation of the radiolabelled carbon from the methyl group from metabolites 
prior to incorporation into proteins, whilst with [^H]thymidine, tritium is lost, 
presumably in the form of tritiated water (Shields et al., 1990). 
After first describing the synthesis of 2-[''^C]thymidine (Vander Borght et al., 
1991), Vander-Borght performed a study to compare the in vivo distribution of 2-
[^'^CJthymidine with methyl-[^H]thymidine in liver regeneration in partially 
hepatectamised Wister rats. A significantly higher accumulation of 2-
[''^CJthymidine was seen in regenerating rather non-regenerating liver, with the 
amount of radioactivity in DNA giving a good correlation with the total tissue 
radioactivity. In contrast, no such correlation was evident with methyl-
thymidine. Further analysis of radioactive tissue showed that 72% of 2-
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[''^CJthymidine accounted for DNA radioactivity compared to only 39% with 
methyl-[^H]thymidine (Vander Borght et al, 1990). 
8.5 Clinical Studies 
A wide variety of tumours have been imaged in clinical studies utilising either 
methyl- or 2-ring- [''CJthymidine. One of the earliest studies by Martiat in 1988 
investigated the uptake of methyl-["CJthymidine in Non-Hodgkins lymphoma 
(NHL). In this preliminary trial, methyl-[^ ^ C]thymidine uptake was higher in 
patients with high grade (HG) NHL (Martiat et al., 1988). A similar study was 
performed by Jamar et al in patients with primary or recurrent NHL, but using 2-
["C]thymidine instead. Again increased uptake of 2-["C]thymidine was 
demonstrated in all 18 patients within ten minutes of administration with higher 
uptake observed in HG compared to low grade (LG) tumours, but no clear 
difference was seen between LG and intermediate grade tumours (Jamar F. et al., 
1992). 
Several studies have imaged cerebral lesions with labelled thymidine. In a study 
comprising 20 patients; 10 patients with a malignant lesion and 10 patients with a 
benign tumour, methyl-["CJthymidine uptake was increased in 8/10 patients with 
malignancy, but in none of the 10 patents with benign tumours (Eary et al., 1999). 
Pomper et al investigated the differentiating potential of methyl-["C]thymidine to 
distinguish primary central nervous system lymphomas from benign lesions in 10 
patients with AIDS compared to magnetic resonance imaging (MRI) (Pomper et 
al., 2002). All patients with lymphoma had a positive PET image and PET had a 
higher accuracy than MRI. 2-["C]thymidine has also been used in cerebral 
imaging studies. In one study, 2-["C]thymidine identified 11/14 untreated brain 
tumours with an average uptake twice that of normal brain. However, no 
correlation was seen between tumour grade and thymidine uptake. This was 
primarily affected by the high uptake in 4 patients with low grade meningioma 
(Vander Borght et al., 1994). 
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Radiolabelled thymidine PET imaging has also been conducted in bronchial 
carcinomas. Lonneux et al found disappointing results when using methyl-
['^CJthymidine. Images obtained were uninterpretable because of accumulation of 
the radiolabelled metabolites (Lormeux M. et al., 1996). A study by Shields et al 
in 4 patients with small cell lung cancer found that the tumours were easily 
identified with 2-["C]thymidine (Shields AF. et al., 1998b). On the whole, these 
clinical results have led the way for the development of analytical models from 
which quantative information on cellular proliferation can be derived. 
8.6 Analysis of ["C]thymidine images 
Analysis of PET thymidine images can provide quantative regional estimates of 
cellular proliferation. The least complex approach to ["Cjthymidine image 
analysis is the static uptake measures such as standardised uptake value (SUV). 
However, though this is simple to calculate, it leads to significant bias in 
estimating thymidine flux into DNA because it does not take into account the time 
course of imaging and does not consider the influence of labelled metabolites. 
The production of radiolabelled metabolites that are not involved in DNA 
synthesis and are present in the region of interest confounds interpretation of the 
thymidine scan images as it is not possible to distinguish between different 
radiolabelled chemical species using PET. To overcome the problem of labelled 
metabolites, development of analytical models for quantitative measurement have 
favoured the use of 2-["C]thymidine rather than methyl-["C]thymidine. The pre-
clinical (Vander Borght et al., 1991) and clinical (Lonneux M. et al., 1996) 
studies described above highlight the problems inherent with the radiolabelled 
metabolites produced by methyl-["C]thymidine leading to accumulation in 
tumour and poor resolution on clinical images. Though the principle metabolite of 
2-[*^C]thymidine, labelled CO2, has considerable retention in tissue (Shields AF. 
et al., 1992), various strategies have evolved to correct for this metabolite. 
Mankoff et al proposed a graphical model to determine thymidine flux from blood 
into DNA as a measure of cellular proliferation based on the assumption that 
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thymidine flux (FIUXTCIR) can be described by the product of native thymidine 
blood concentration ([TDR]b) and a flux constant (Ktcir) (Mankoff et al, 1998): 
FluXTdR = [TDR]b K-TdR 
The exogenous pathway provides only a fraction of the thymidine used in DNA 
synthesis, with the remainder provided by the endogenous pathway. Previous 
studies have shown that the fraction of thymidine incorporated into DNA from the 
endogenous pathway (fext) is a function of thymidine in the extracellular fluid. As 
thymidine is readily permeable through tissue capillaries, then the extracellular 
concentration of thymidine should closely follow blood concentration. Therefore 
if thymidine blood concentration is known, then synthetic rate of DNA (SRDNA) 
can be calculated from measurements of flux of thymidine firom the external 
pathway. Assuming that half the nucleotides base pair contain thymidine (Cleaver 
JE., 1967), then: 
^^DNA —2- • Flux^j^ 
e^xt 
The five compartment model devised by Mankoff requires on-line blood 
measurements to analyse metabolites from which three separate input functions 
(thymidine, intermediate metabolites and CO2) are obtained, which are used to 
estimate eight rate constants (Mankoff et al., 1998). Animal studies have validated 
this model's ability to predict the time course of 2-["C]thymidine incorporation 
into DNA, and stimulations in mice have shown that this analysis does provide 
reliable values of thymidine flux (Mankoff et al., 1999). A modification was 
introduced by performing a sequential [ "CjOi scan in a clinical study with 20 
patients with cerebral lesions to identify the transfer of metabolite across the 
blood brain barrier and provide an input function (Eary et al., 1999). However, 
these approaches can potentially lead to a problem identifying parameters 
accurately due to the similarity in time course for each input function and the 
inherent noise in the data. Furthermore, the compartment model requires some a 
priori of the biological fate of the compounds in vivo in order to construct the 
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number of compartments and the relationship between them, and hence, is highly 
constrained. If the assumptions are incorrect then the model will be inaccurate. 
An alternative approach was developed using spectral analysis which requires no 
a priori decision about the most appropriate compartmental structure 
(Cunningham VJ. et al, 1993) which produces an impulse response function 
(IRF) from the plasma input function and tissue activity time curve (see Chapter 
2). In a study by Wells et al, 2-[''C]thymidine in regions of interest in tumours 
was described using the fractional retention of thymidine (FRT). This parameter is 
defined as the ratio of IRF at 60 minutes (IFRaomins), which reflects retention, to 
that at one minute (IRFimin), which reflects delivery. FRT is therefore normalised 
for tracer delivery to allow comparison between regions which have different 
clearances of tracer. In this study, Wells found a significant correlation between 
FRT and Ki-67 index, an ex-vivo histopathological marker of DNA proliferation, 
in 17 chemotherapy naive patients with advanced intra-abdominal malignancy 
(Wells et al., 2002b). Another study by Wells has shown good reproducibility of 
data in intra-patient 2-["C]thymidine scans performed 1 week apart (Wells et al., 
2005). Though the plasma input function was corrected for metabolites, no 
attempt was made to adjust for contribution of labelled metabolites in the 2-
[^'CJthymidine PET image in either study. However, the same group have 
developed a dual- scan approach to correct for radiolabelled CO2 to refine the 
analysis described above. In this dual-scan procedure, in addition to the 2-
["CJthymidine scan, a supplementary metabolite scan is also performed which 
allows correction of the parent scan for the presence of systematically derived 
radiolabelled metabolites that are delivered to tissue (Gunn R. et al., 2000). 
8.7 2-["C]thyinidine to Assess Pharmacodynamic End-Points 
Shields et al studied response to treatment in four patients with small cell lung 
cancer (SCLC) and two patients with high grade sarcoma. All patients had a PET 
scan with 2-["C]thymidine before treatment and one week after chemotherapy. In 
3 patients with a complete response (two patients with SCLC and one with 
sarcoma), all had a substantial reduction of 55-89% in 2-["C]thymidine uptake. In 
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one patient with SCLC who had a partial response, a smaller reduction of 48% 
was seen. Two patients with progressive disease, one patient each with SCLC and 
sarcoma had a minor reduction in 2-["C]thymidine uptake of 8% and 3%, 
respectively. However, these scans were analysed using limited modelling 
methods (Shields AF. et al, 1998b). 
In this study, the feasibility of using the dual scan approach and spectral analysis 
modelling to determine the pharmacodynamic end-point after chemotherapy using 
2-[''C]thymidine will be examined. 
8.8 Study Aims 
The primary aim is to assess the change in 2-['^C]thymidine uptake in tumour 
before and after chemotherapy and to correlate this with conventional imaging in 
tumour. 
A secondary aim is to assess the feasibility of using a dual scan approach in a 
clinical study. 
Also, this study aims to assess cellular proliferation in normal tissue and to assess 
the effect of chemotherapy on these tissues. 
8.9 Methods 
8.9.1 Patient Selection 
Any patient with histologically proven primary or metastatic (excluding cerebral 
metastases) lung cancer who was due radical or palliative treatment with a 
conventional intravenous chemotherapy regime was eligible for the study. The 
patient had to have had a recent CT scan of their thorax prior to commencement of 
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treatment with a lesion of greater than 3 cm in at least one dimension and that 
could be evaluated using the RECIST classification system (Appendix B). 
Other eligibility criteria included a WHO performance status of greater than 2 
(Appendix A), and adequate full blood count, renal and hepatic function to be able 
to tolerate chemotherapy. 
Ethics approval was obtained from the Hammersmith Hospital Research Ethics 
Committee and authorisation for the use of radionuclides was given by the 
Administration of the Radioactive Substances Advisory Committee (ARSAC 
UK). Fully informed and written consent was given by the patient for 
participation in the study. 
8.9.2 Study Design 
The patient underwent two PET scanning sessions using 2-[''C]thymidine and 
[^'CJHCOs (for metabolite correction) one week before commencing 
chemotherapy and one week after the third cycle of chemotherapy. In each 
scanning session, the 60 minute 2-[^'C]thymidine was performed first, following a 
30 second intravenous bolus injection. After a twenty minute interval, the 62 
minute ["CJHCOs scan was performed, again after a 30 second intravenous bolus 
administration of the radiotracer. 
Prior to the first PET scanning session and after one week after the third course of 
chemotherapy, the patient had conventional imaging i.e. CT or MRI, of the site of 
the disease and a blood test for ftill blood count. 
8.10 Procedures 
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The patient was positioned on the PET scanner couch using the recent CT scan to 
locate the tumour to be imaged. Anatomical landmarks were noted and utilised to 
position the patient accurately for the subsequent PET scanning session. 
Continuous arterial blood sampling was obtained during both scans via an arterial 
cannula which was also used to obtain discrete blood samples. 
8.11 Data Analysis 
PET image scans were analysed after drawing a region of interest (ROI) on 
tumour, normal lung and bone marrow manually, using the CT scan to help with 
organ identification and delineation. 
2-["C]thymidine scans were analysed using semi-quantative methodology to 
obtain SUVgrnins 3Jld AUCfiOmins-
Spectral analysis was also performed to obtain Ki and fractional retention of 
thymidine (FRT), after metabolite correction. A number of steps are required in 
order to perform metabolite correction. Plasma arterial input functions for the 2-
[''CJthymidine and ["CJHCOa scan from continuous and discrete blood samples, 
are generated. In the 2-["C]thymidine scan, two input functions are generated: (i) 
combined parent and intermediate metabolite input function (Plasmaxhy) and (ii) 
input function for the metabolite CO2 that is measured in the discrete samples 
during the 2-["C]thymidine scan, (PlasmaThycoz). The Plasmaihy input function is 
created as a dying exponential. It was necessary to use combined parent and 
intermediate metabolite for Plasmajhy input function as after 20 minutes, (due to 
rapid metabolism) no parent 2-["C]thymidine is detected in the plasma, which 
limits analysis of data. A combined parent and intermediate metabolite Plasmajhy 
input function permits use of a non-zero input function and also intermediate 
metabolite levels are very small compared to the main metabolite, ["C]02, at later 
time points, though we must assume that both parent and intermediate metabolite 
have similar phosphorylation. From the ["CJHCOa scan, the a single input 
function is obtained from measurement of ["C]02 in arterial plasma (PlasmaCOz). 
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From the bicarbonate scan, the following is derived using spectral analysis and 
deconvolution: 
TISSHC03 = Plasmaco2 ® IRFHCO3 
Where, TISSHCOS IS the region of interest in the [ " C J H C O s scan, and IRFHCOS is the 
impulse response function that is generated from the tissue and blood data and ® 
represents the deconvolution operator. 
In the 2-[''C]thymidine scan, the following derived using spectral analysis and 
deconvolution: 
TisSThyC02 = PlaSmaThyCOZ ® IRFHC03 
Where, the IRFHCOB from the bicarbonate scan is deconvolved with the 
PlasmaThyC02 from the 2-['^C]thymidine scan, to generate the CO2 component in 
the region of interest in the 2-[''C]thymidine scan, Tissxhycoi-
Tissue thymidine and intermediate metabolite is calculated by subtraction: 
Tissihy - Tisstotallhy " TisSThyC02 
Where, Tisstotaiihy is the total thymidine tissue activity from the ROI in the 2-
[^'CJthymidine scan and TissThyco2 is derived as outlined above. Tissniy represents 
the thymidine and intermediate metabolite content for the ROI from the 2-
[^'C]thymidine scan after metabolite corrected tissue. 
Finally, spectral analysis was used to generate the IRF (IRFyhy) and Ki for each 
ROI from the 2-["C]thymidine scan: 
Tissxhy = Plasmaxhy® IRFxhy 
From the IRFimin and IRFeomin, the fractional retention of thymidine (FRF) is 
calculated by: 
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F R F = IRFeOmin/ I R F l m i n 
8.12 Results 
8.12.1 Patient Characteristics 
A 49 year old female, ex-smoker, entered the study. She had presented with a one 
week history of left shoulder pain and was found to have a mass on chest x-ray. A 
CT guided biopsy gave histology of non-small cell lung cancer. She had not had 
any previous treatment. After a staging CT scan, she was commenced on three 
courses of chemotherapy, given every 3 weeks and consisting of: Gemcitabine at 
Igm/m^ (dose 1 900 mg administered) given on day 1 and day 8, and Carboplatin 
at 5 (Glomerular Filtration Rate + 25) (dose administered 750 mg) given on day 1 
only. 
PET scanning sessions were performed one week prior to commencement of 
chemotherapy, and one week after the third chemotherapy cycle. Total blood loss 
during each PET session was approximately 355 mis and she tolerated the 
scanning sessions well, without any adverse effects. A follow-up CT scan was 
also performed one week after the third cycle of chemotherapy. 
8.12.2 PET Scan Details 
The following table gives details of 2-["C]thymidine and ["C]HC03 that were 
administered on each PET session. 
Table 8.1: Scan Details 
Scan Injected 2-[''C]thymidine Injected 
number 2-["C]thymidine radiochemical ["C]HC03 
activity (MBq) purity % Activity 
(MBq) 
Pre 'CT t00057 288.6 100 407 
Post 'CT t00075 3293 100 355.2 
, Chemotherapy 
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8.12.3 Conventional Radiology 
The patient had a CT one week before and after three courses of chemotherapy. 
The initial CT scan showed two masses in the left lung. The larger mass was a 
5cm X 4 cm lobulated tumour situated in the left apical region, invading the left 
brachiocephalic vein. The smaller mass, within the left side of the mediastinum, 
was greater than 3 cm. and irregular in outline. After chemotherapy, the largest 
mass had decreased to 3 cm x 3 cm and the smaller mass had decreased to 2 cm, 
giving a partial response. 
8.12.4 Haematological Results 
The patient had a full blood count prior to commencing, and one week after 
chemotherapy and the results are shown below in Table 8.2. 
Table 8.2: Full Blood Count Before and After Chemotherapy 
Haematological Indices pre chemotherapy 1 week post 
chemotherapy 
Haemoglobin 13.8 8.7 
White Cell Count 8.1 3.7 
Platelets 495 523 
8.13 2-[''C]thymidine Analysis 
Three regions were analysed in the 2-["C]thymidine scans: lung tumour, normal 
lung and bone marrow, using the recent CT scan to help with organ delineation 
and drawing of regions of interest. An example of the lung cavity from summated 
2-[''C]thymidine PET images is shown in Figure 67. 
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Normal lung Lung tumour 
Figure 67: Coronal View of Thorax Using 2-
piC]thymidine Imaging 
The regions of interest from the 2-["C]thymidine scans were analysed using 
semi-quantitative analysis to derive SUVsmins and AUCeomins- Analysis was also 
performed using spectral analysis after metabolite correction using the ["C]HC03 
scan data to derive Ki and FRT 
8.13.1 Semi-Quantitative Analysis 
Tissue radioactivity versus time curves for lung tumour, normal lung and bone 
marrow were plotted pre and post chemotherapy. The curves looked similar for 
each region before and after treatment. Curves of the regions before chemotherapy 
are shown below. 
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SUVsmins and AUCeomins were derived for each region and corrected for decay and 
body surface area (BSA) and the percentage change was calculated before and 
after chemotherapy (Table 8.3). SUVsmins gives an indication of early uptake of 2-
[^'C]thymidine, though is not corrected for labelled metabolites in the tissue. As 
can be seen, lung tumour > bone marrow > normal lung SUVgmms, before and after 
chemotherapy. SUVgmins post chemotherapy marginally increased in lung tumour 
by 2.1% and in normal lung by 8.8%. In bone marrow, there was an increase in 
delivery of 2-[''C]thymidine of 30.4% after chemotherapy. 
Table 8.3 SUVsminsfor 2-[''C]thymidine Before and After Chemotherapy 
'SUVsmins pre ^CT 
t00057 
SUVsmins pOSt 
^CT 
t00075 
% change after 
chemotherapy 
Lung tumour 3.065 X 10"^  1 7 2 8 x 10^ + 2.1 
Normal lung 1.224 X 10"' 1.3311 X 10"' + 8.8 
Bone marrow 2.061 X 10"' :L687xlO^ + 30.4 
, Standard uptake value at 3 minutes, m /ml; , Chemotherapy 
AUCeomins gives an indication of 2-["C]thymidine retention in regions of interest, 
though again there is no tissue correction for radiolabelled metabolites. Looking at 
Table 8.4, AUCeomins it can be seen that lung tumour > bone marrow > normal lung 
before and after chemotherapy. Post chemotherapy, the largest reduction in 
AUCeomins was seen in the bone marrow, with a decrease of 13.5%. Lung tumour 
retention of 2-["C]thymidine decreased by 6.8%, in keeping with the reduction in 
size of the tumour as observed on the CT image obtained post treatment. Normal 
lung AUCeomins increased marginally by 2.5% post chemotherapy. 
Table 8.4 AUCeomins for 2-["C]thyinidine Before and After Chemotherapy 
'AUCeomins pre ^CT 
t00057 
'AUCeomins post ^CT 
t00075 
% change after 
chemotherapy 
Lung tumour 0.15 0.14 -6 .8 
Normal lung 0.060 0.062 + :L5 
Bone marrow 0.13 0.11 - 13.5 
, Area under curve over 60 minutes, m /ml x sec; , Chemotherapy 
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8.13.2 Spectral Analysis 
As described in methodology, spectral analysis was performed on the 2-
['^CJthymidine image data after radiolabelled metabolite correction, and 
using a metabolite corrected 2-[''C]thymidine arterial plasma input function. For 
each region of interest the tissue data was convolved with the arterial input 
function to produce a data fit as shown in Figure 69, which as can be seen was 
satisfactory for the organs analysed, and similar post chemotherapy. From this an 
impulse response function was derived, which is used to describe the tissue 
response of 2-['^C]thymidine if it had been possible to deliver 2-["C]thymidine to 
the tissue instantaneously. The spectrum of kinetic results for lung tumour and 
normal lung and bone marrow, are also shown in Figure 69. Using a log scale, the 
number of kinetic components that adequately describe the data are revealed, and 
this corresponds to the number of discrete tissue compartments that the PET 
technique can resolve. The speed of the dynamics increase from left to right and, 
in all tissue regions, a right handed peak is present, indicating the contribution of 
the delivery component. In lung tumour and bone marrow regions, but not in 
normal lung, a left handed peak is seen, indicating trapping of 2-["C]thymidine in 
these regions. This was expected as both these tissues should have a high rate of 
DNA proliferative activity. 
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Figure 69: Spectral Analysis Curve for 2-
[iiC]thymidine 
a) arterial plasma input function for 2-["C]thymidine 
b, e, h) corresponding time activity curve for tumour, normal lung and bone 
marrow, showing line of best fit 
c, f, i) impulse response function (IRF) for tumour , normal lung and bone marrow 
corrected for radioactive decay, 
d, g, j) IRF for tumour, normal lung and bone marrow displayed as kinetic 
components 
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For all regions, Ki was calculated from spectral analysis, reflecting delivery of 2-
['^C]thymidine pre and post chemotherapy. As can be seen from Table 8.5, Ki in 
lung tumour > bone marrow > normal lung before and after chemotherapy. In all 
tissue regions, Ki increased following treatment, with a 33.3% increase in lung 
tumour, 18.6% increase in normal tissue and a modest 5.9% increase in bone 
marrow. These changes also reflect the effect seen on SUVsmins after 
chemotherapy, but of a different magnitude. 
Table 8.5 Ki for 2-["C]thymidine Before and After Chemotherapy 
'Ki pre ^CT 
t00057 
'Ki post ^CT 
t00075 
% change after 
chemotherapy 
Lung tumour 9 x 1 0 ^ 1.2 X 10"' + 3 1 3 
Normal lung 7 x 1 0 ^ 8.3 X lO"" + 18.6 
Bone marrow 1.7 X 10"^  1.8 X 10"' + 5.9 
J ""blood/"""/:'"tissue, , I^ieillUlIlcrdpy 
Fractional retention of 2-["C]thymidine (FRT) has been calculated for the regions 
before and after chemotherapy. As expected, FRT in lung tumour > bone marrow 
> normal lung reflecting again the increase proliferative nature of tumour and 
bone marrow. After chemotherapy, FRT in the lung tumour still had the highest 
value, but FRT in normal lung was greater than in bone marrow. After 
chemotherapy, FRT decreased by 20.7% in lung tumour, in keeping with the 
changes observed in AUCeomins and CT radiology. In bone marrow, FRT also 
decreased by 10.5%, similar to the decline in AUCeomins, which is probably related 
to the known impact anti-cancer chemotherapy has on normal cellular 
myeloproliferation. 
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Table 8.6 Fractional Retention of 2-["C]thymidine Before and After 
Chemotherapy 
'FRT pre ^CT 
t00057 
'FRT post ^CT 
t00075 
% change after 
chemotherapy 
Lung tumour 2.9 X 10"^ 2.3x10"^ -20.7 
Normal lung 1.6 X 10"^  1.8 X 10 '^ + 13.2 
Bone marrow 1.9 X 10"^  1.7 X 10'^  -10.5 
, Fractional Retention of 2-[ CJthymidine; , Chemotherapy 
8.14 Discussion 
Functional imaging using PET can supplement information derived from clinical 
and radiological examinations that in themselves have limitations in assessing 
tumour response to anti-cancer treatment as outlined previously. 
By far the commonest radiotracer used in PET to determine tumour response is 
['^F]fluoro-2-deoxy-D-glucose ([^^F]FDG.) (Young et al, 1999). The increased 
demands of glycolysis in neoplastic cells compared to benign cells and 
consequent higher uptake of ['^F]FDG has been used to infer information on 
tumour growth and proliferation. Numerous in vitro and in vivo studies in humans 
have demonstrated that the uptake of ['^F]FDG is related to tumour grade in a 
range of malignancies. In general, low grade, slowly proliferating tumours have 
less ['^F]FDG uptake than is seen in poorly differentiated, rapidly growing 
tumours (Avril et al., 2001; Buck et al., 2002; Vesselle et al., 2002). However, 
non-cell division related tumour cell activities require a supply of energy as do 
inflammatory cells such as macrophages and neutrophils (Kubota et al., 1992). 
Other factors reported to influence [ ' ¥ ]FDG uptake include upregulation of 
glucose transporter 1 receptors, number of viable tumour cells present, 
microvessel density and hexokinase expression, making glucose metabolism an 
ambiguous measure of tumour proliferation (van de Wiele et al., 2003b). 
Direct imaging of tumour proliferation with 2-["C]thymidine is being explored as 
a radiotracer that may circumvent the potential discrepancies associated with 
FDG-PET image interpretation. This study has demonstrated the feasibility of 
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clinical imaging to assess tumour response with 2-["C]thymidine using a dual 
scan approach with spectral analysis to correct for the radiolabelled metabolite, 
["C]02. 
The most important parameters which were derived from analysis of the 
successive 2-["C]thymidine PET scans in this study to give an indication of 
thymidine utilisation and hence DNA synthesis and tissue proliferation are 
retention of thymidine or FRT and tissue exposure to thymidine, or AUCeomins-
From the results presented here, there was a reduction in both AUCeomins and FRT 
in lung tumour following chemotherapy, consistent with results obtained from 
conventional imaging where according to the RECIST criteria a partial response 
i.e. a reduction in tumour size of 30%, was achieved on visual inspection of the 
post treatment CT scan. The reduction in FRT of 20% was greater than the 
reduction seen in AUCeomins after chemotherapy, FRT is a quantitative parameter 
and more likely to give an accurate indication of decline in DNA synthesis in the 
lung tumour, as suggested in the study by P. Wells, where a significant correlation 
between Ki-67 and FRT was demonstrated (Wells et al., 2002a). Furthermore, the 
FRT derived in this study is probably a more robust measure of DNA proliferation 
as the tissue sampled has been corrected for the metabolite ["C]02. 
In bone marrow, a reduction in FRT of 10.5% and in AUCeomins of 13.5% was 
observed after chemotherapy corresponding with the changes in the peripheral 
blood profile indices, haemoglobin and white cell, whose values also decreased 
post therapy. The chemotherapeutic drugs, carboplatin and gemcitabine, are 
known to be myelosuppressive agents with cumulative reduction in haemoglobin 
levels but particularly affecting white cell and platelet counts, with the nadir seen 
within three weeks post carboplatin and seven to ten days post gemcitabine 
chemotherapy, which coincides with the second PET scanning session. 
In normal lung, a small increase in FRT of 13.2% and AUCeomins of 2.5% was 
seen after chemotherapy. Gemcitabine has been rarely reported to cause 
parenchymal lung toxicity resulting in interstitial pneumonitis, pulmonary fibrosis 
and oedema but there are no reports of adverse side effects on lung tissue 
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attributed to by carboplatin, so a predicted change in DNA proliferation and cell 
growth was not expected in normal lung. 
The parameters Ki and SUVgmins calculated from the 2-['^C]thymidine PET 
images give an indication of delivery of thymidine to the regions of interest. Ki 
and SUVsmins increased in the lung tumour, normal lung and bone marrow after 
chemotherapy The increase in Ki may simply be a reflection of perfiision to the 
region, though blood flow was not measured in this study. However, after one 
minute, thymidine delivery is independent of blood flow (Shields et al, 1984) so 
it is unclear why SUV at three minutes increased in lung tumour and bone marrow 
as there was decreased retention of 2-["C]thymidine after chemotherapy. In the 
study by Wells et al no correlation was found between delivery of 2-
["CJthymidine and Ki-67, an in vitro marker of DNA proliferation (Wells et al., 
2002a) and indeed the relationship between delivery and retention of thymidine in 
tissue has not been fully elucidated. 
This study has demonstrated the feasibility of imaging pharmacodynamic 
endpoints using 2-['^C]thymidine using a dual scan approach to correct for tissue 
metabolites. In addition to assessing tumour response to chemotherapy, it was 
possible to measure the effect of treatment on the proliferation of normal tissue 
such as bone marrow and lung which is an essential consideration when 
determining the toxicity profiles of anti-neoplastic drugs. A study by Shields et al 
has shown that changes in uptake of 2-["C]thymidine in tumours only one week 
after treatment can give an indication of tumour response to chemotherapy shortly 
after treatment initiation (Shields AF. et al., 1998b). Using the dual scan 
technique as performed in this study, an actual measure of change in proliferative 
rate is achievable in normal tissue and tumour. This could potentially enable a 
physician to alter treatment earlier than is currently possible in non-responding 
tumour and spare excessive normal tissue toxicity in patients, if present. 
Another use of imaging with 2-["C]thymidine that is being explored is to monitor 
thymidine salvage kinetics after treatment with Thymitaq™, a non-classical 
thymidine synthetase (TS) inhibitor. As previously mentioned, TS is a critical 
enzyme in DNA synthesis, and cells can overcome this cytotoxic effect by 
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incorporating thymidine from the extracellular or salvage pathway. Measurement 
of this salvage pathway was devised using 2-["C]thymidine imaging in patients 
with gastro-intestinal malignancies 1 hour after treatment with Thymitaq^'^ who 
had an increase in intra-tumoural uptake compared to controls. This uptake 
coincided with the peak plasma concentrations of the drug in treated patients 
(Wells et al., 2003). 
A newer thymidine analogue, 3'-deoxy-3'-flurothymidine (FLT) has been 
developed as another promising radiotracer with which to measure cellular 
proliferation non-invasively using PET and was first studied in dogs for this 
purpose (Shields AF. et al., 1998a). Labelled with ['^F], FLT has the advantages 
of a longer half-life than 2-["C]thymidine and therefore does not have to be 
manufactured on site for clinical use and is resistant to catabolism so it produces 
fewer radiolabelled metabolites that interfere with analysis. However, ['^F]FLT is 
not directly incorporated into DNA but rather its uptake and intracellular 
phosphorylation has been shown to correlate with thymidine kinase 1 (TKl) 
activity, an enzyme closely linked to cellular proliferation, as observed in A549 
ling cancer cells in vitro (Rasey et al., 2002). There have been several clinical 
studies using ['^F]FLT (Buck et al., 2002; Shields AF. et al., 1998a; Smyczek-
Gargya et al., 2004; Vesselle et al., 2002) in a wide range of cancers. In a series of 
twenty-six patients with untreated solitary pulmonary nodules, the uptake of 
[^^F]FLT measured by SUV correlated significantly with Ki-67 (r = 0.87), with 
100% specificity and 86% sensitivity. The lower sensitivity was attributed to 
false-negative scans in three patients with malignant lung lesions which all had a 
low rate of cellular proliferation (Buck et al., 2002). In another study ten patients 
with biopsy or clinically suspected NSCLC underwent dynamic scanning with 2-
["C] thymidine and correlated uptake of ['^F]FLT with Ki-67 
immunohistochemistry. Using both SUV and Patlak analysis, to determine FLT 
flux, a strong correlation was found between ['^F]FLT uptake and Ki-67 (Vesselle 
et al., 2002). In a more recent study twelve patients with primary breast cancer 
had static ['^F]FLT scans of 80 to 120 minutes duration. SUV was calculated and 
compared to Ki-67 labelling index, but no correlation was found between the two 
parameters. The absence of correlation between ['^F]FLT uptake and Ki-67 in 
breast compared to a positive association in lung tumours was assumed to be 
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because of differences in growth patterns in the two tumour types (Smyczek-
Gargya et al, 2004). Another study has demonstrated a correlation between Ki 
and fractional retention of ['^F]FLT and Ki-67 in breast tumours, suggesting 
superiority of quantative analysis when using ['^F]FLT PET to image cellular 
proliferation in breast cancer (Kenny et ah, 2005). There is also some literature 
available on ['^F]FLT uptake and tumour response assessment. A pre-clinical 
study investigating the response of tumours to 5-FU in mice with radiation-
induced fibrosarcoma found a reduction of ['^F]FLT uptake after treatment and an 
association with proliferating cell nuclear antigen in tumours (Barthel et al, 
2005). A clinical study by Kenny et al has shown that ['^F]FLT PET can be used 
to distinguish between clinical response and stable disease in patients with breast 
cancer 1 week after chemotherapy (Kenny et al., 2007). 
FMAU or [l-(2'-fluoro-2'-deoxy-P-D-ribofuransonyl) thymine] is another 
thymidine analogue originally developed as an antiviral and anti-leukaemic drug 
that has been shown to be rapidly taken up by cells, phosphorylated by TK and 
variably incorporated into DNA, with little catabolism (Philips et al., 1983). 
2[^'^C]FMAU uptake was high in tumour xenografts compared to normal tissue in 
pre-clinical studies (Conti et al, 1995). Studies are on going to evaluate its ftill 
potential in human studies after it has been radiolabelled with fluorine-18 (Sun et 
fl/.,2005). 
lodo- and bromodeoxyuridine (lUdR, BUdR) are formed after replacement of the 
methyl group in thymidine with iodine and bromine, respectively, and are 
incorporated into cells synthesising DNA. lUdR and BUdR have been used to 
measure cell cycle in biopsy specimens with flow cytometry after labelling with 
monoclonal antibodies or fluorescent dyes. lUdR and BUdR have been labelled 
with radioisotopes which have a long half-life: (half-life = 4.2 days) 
(Guenther et al, 1998) and ^^Br (half-life = 16 hours) (Bergstrom et al., 1998) for 
PET imaging studies. Though taken up in tumour, image analysis is complicated 
by rapid dehalogenation and liberation of the labelled halogen molecule. Imaging 
24 to 48 hours after injection may allow for clearance of the free halogen, 
although this time lapse has led to a reduction in tumour activity. Clinical studies 
with [^^B]UdR have revealed conflicting results in brain tumours and melanoma, 
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with little radioactivity in brain tumour DNA, but in the melanoma group, uptake 
of [^^BUdR] correlated significantly with MIB-1 staining (Boni et al, 1999; 
Gudjonssona et al., 2001). Blasberg et al performed delayed imaging of 24 hours 
with lUdR in meningiomas and gliomas. There were variable correlations 
between Kj, SUV, and tumour to brain activity ratios (Tm:Br) and other measures 
of tumour proliferation (tumour type and grade, labelling index, and patient 
survival) observed. However, greater image specificity and significance of the 
SUV and Tm:Br values would be obtained by achieving greater washout and 
clearance of the exchangeable fraction of residual (background) radioactivity in 
the tumours, i.e., by increased hydration and urinary clearance and possibly by 
imaging later than 24 h after ['^'^IJIUdR administration (Blasberg et al., 2000). 
The study presented here provides encouraging results for the application of 2-
[''C]thymidine PET imaging of pharmacodynamic endpoints. Accurate and early 
in vivo response assessment to chemotherapy can avoid prolonged treatment with 
chemotherapy in unresponsive tumours and identify tumour response to cytostatic 
and molecular targeted drugs. Further studies may allow the construction of 
guidelines correlating early tumour response measured by 2-["C]thymidine with 
conventional methods as the EORTC has devised for FDG-PET. In normal tissue, 
changes in cellular proliferation may help determine toxicity profiles of 
conventional anti-proliferative drugs and novel drugs, as cytotoxicity is a major 
pharmacodynamic endpoint in phase 1 drug trials. 
Imaging of cellular proliferation either directly using thymidine, such as 2-
[''C]thymidine or indirectly with an analogue, such as ['^F]FLT, could be of huge 
importance in cancer treatment and drug development. 
8.15 Summary 
• Dual scanning with 2-["C]thymidine and ["C]bicarbonate is feasible in a 
clinical setting. 
208 
Changes in 2-[^'C]thyniidine uptake in tumour and normal tissue can 
provide a non-invasive measurement of DNA synthesis and cellular 
proliferation in response to chemotherapy. 
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Appendix A 
WHO PERFORMANCE STATUS 
Activity Performance Description Score 
Fully active, able to carry out all pre-disease performance without any 0 
restriction. 
Restricted in physically strenuous activity by ambulatory and able 1 
to carry out work of a light or sedentary nature, such as light house work 
or office work. 
Ambulatory and capable of all self-care, but unable to carry out any 2 
work activities. Up and about for more than 50% of waking hours. 
Capable of only limited self-care. 
Confined to bed or chair for more than 50% of waking hours. 
Completely disabled and cannot carry out any self-care. 4 
Totally confined to bed or chair. 
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Appendix B 
Response to Treatment of Solid Tumours (RECIST) Guidelines 
Definitions 
At baseline, all tumours are measurable, non-measurable or truly non-measurable. 
Measurable Lesions 
Measurable lesions are lesions that can be accurately measured in at least one 
dimension and are > 20mm on conventional imaging techniques or > 10mm using 
spiral CT. 
Non-measurable 
Non-measurable lesions are lesions that can be accurately measured in at least one 
dimension and are < 20mm on conventional imaging techniques or < 10mm using 
spiral CT. 
Truly Non-measurable lesions 
Immeasurable lesions are bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusions and inflammatory breast disease. 
Methods of Measurement 
Clinical examination 
Clinically detected lesions are only considered measurable if they are superficial 
(e.g. skin nodules and palpable lymph nodes. 
Chest x-ray 
Lesions on chest x-ray are accepted as measurable lesions when they are clearly 
defined and surrounded by aerated lung. 
CT and MRI 
CT and MRI are best currently available and the most reproducible methods for 
measuring target lesions selected for response assessment. 
Ultrasound 
When the primary end point of the study is objective response evaluation, 
ultrasound should not be used to measure tumour lesions that are clinically not 
easily accessible. 
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Endoscopy and laparoscopy 
The utilisation of these for objective tumour evaluation has not yet been fully 
validated. 
Tumour markers 
Tumour markers alone cannot be used to assess response. However, if tumour 
markers are initially above the upper normal limit, they must return to normal 
levels for a patient to be considered in complete clinical response. 
Cytology and histology 
Cytological and histological techniques can be used to differentiate between 
partial and complete response in rare cases. Cytological confirmation of the 
neoplastic nature of any effusion that appears or worsens during treatment is 
required when the measurable tumour has met criteria for response or stable 
disease. Under such circumstances, the cytological examination of the fluid 
collected will permit differentiation between response or stable disease. 
Tumour Response Evaluation 
Baseline evaluation 
All measurable lesions up to a maximum of 5 lesions per organ and 10 lesions in 
total, representative of all involved organs, should be recorded as target lesions 
and measured and recorded at baseline. Target lesions with the longest diameter 
should be selected. A sum of the longest diameter for all target lesions will be 
calculated and reported as sum of longest baseline diameter. 
All other lesions are reported as non-target lesions and should be recorded but not 
measured. 
Response Criteria 
Evaluation of Target Lesions 
Complete Response: the disappearance of all target lesions 
Partial Response; at least a 30% decrease in sum of longest baseline diameter of 
target lesions, taking as reference the baseline sum longest diameter. 
Progressive Disease: at least a 20% increase in the sum of the longest diameter of 
baseline lesion taking as reference the smallest sum longest diameter recorded 
since the treatment started or the appearance of one or more lesions. 
Stable Disease: neither sufficient shrinkage to qualify for partial response or 
sufficient increase to qualify for progressive disease, taking as reference the 
smallest sum longest diameter recorded since the treatment started. 
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Evaluation of non-target lesions 
Complete Response: the disappearance of all non-target lesions and the 
normalisation of tumour markers. 
Incomplete response/stable disease: the persistence of one or more non-target 
lesion (s) and/or the maintenance of tumour marker level above normal limits 
Progressive disease: the appearance of one or more new lesions and/or 
unequivocal progression of non-target lesions. 
Evaluation of best overall response 
The best overall response is the best response recorded until disease progression 
or recurrence. Table 1 provides overall response for all possible combinations of 
tumour response in target and non-target lesions with or without the appearance of 
new lesions. 
Table 1 Overall response for all possible combination of tumour responses* 
Target lesion Non-target lesion New lesion Overall response 
CR CR No CR 
CR Incomplete response/SD No CR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or no PD 
Any PD Yes or no PD 
Any Any Yes PD 
*CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease 
Frequency of tumour re-evaluation 
Frequency of tumour re-evaluation while on treatment should be protocol specific 
and adapted to the type and schedule of treatment. 
Confirmation 
Partial/Complete response: to be assigned this status, changes in tumour 
measurement must be confirmed by repeat assessment that should be made not 
less than 4 weeks after the criteria for response are first met. 
Stable disease: measurements must have met the stable disease criteria at least 
once after start of treatment at a minimum interval in general, not less than 6 to 8 
weeks. 
Duration of Overall response 
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The duration of overall response is taken from the time that measurement criteria 
are met for complete or partial response (which ever status is recorded first) until 
the first date that progressive or recurrent disease is objectively documented. 
Duration of stable disease 
Stable disease is measured from the start of treatment until the criteria for disease 
progression is met. 
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Awards and Publications 
Awards 
2002 FECS/ASCO/AACR study award, Flims, Switzerland. 
2002 ASCO Merit Award, Orlando, USA. 
Publications 
Book Chapter 
N Gupta and PM Price. Molecular Imaging in Cancer Treatment: PET 
Imaging in Oncology Ed. 2: New Horizons in Oncology 
Original Papers and Reviews 
N Gupta, PM Price, EO Aboagye. PET for in vivo pharmacokinetic and 
pharmacodynamic measurements Eur J Cancer 2002 38 2094-2107 
Nishi Gupta, Azeem Saleem, Safiye Osman, Eric O. Aboagye, Robert Philips, 
Claire Vernon, Harpreet Wasson, Terry Jones, Peter J. Hoskin, Patricia P. Price. 
Carbogen and Nicotinamide Selectively Increase Blood Flow and 5-Fluorouracil 
Delivery in Colorectal Cancer Metastases Clin Cancer Res 12 3115-3123 
Oral Presentation 
N Gupta, A Saleem, S Osman, P Hoskin, P Price and E Aboagye. Carbogen and 
nicotinamide selectively increase blood flow to liver metastasis. BACR 2002 
Posters and Abstracts 
N Gupta, E Aboagye, A Saleem, R Harte, S Osman, B Phillips, C Vernon, H 
Wasan and P Price. Delivery and Retention of 5-FU can be Modulated and 
Measured Independently in Vivo in Man. Proc Am Soc Clin Onco 2003 22 p212, 
850a 
EO Aboagye, A Saleem, N Gupta, C Brock, P Price. What new pharmacokinetic 
information can molecular imaging provide us? Eur J Cancer 2002 38 Supp 7 S12 
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N Gupta, A Saleem, S Osman, P Hoskin, P Price and E Aboagye. Carbogen and 
nicotinamide selectively increase blood flow index (BFI) and 5-fluorouracil (5-FU) 
delivery in human tumours. Proc Am Soc Clin One 2002 21 p i24 ,493a 
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